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Outline of this thesis

Outline of this thesis
I
n oncology, residual disease is like a surgeons red poppy. The red poppy, also known as 
Papaver rhoeas or "red weed" grows on sandy grounds. Its seeds stay below the surface 
during surprisingly long periods of time and only germinate once they get exposed to 
light. One day, a farmer might discover a small group of red poppies on his field. When he 
ploughs his field, he can also plough the red poppy flowers, without even noticing the seeds.
When he ploughs the same field again, even years later, the bright red flowers will appear 
again. Not only do they reappear, this time the red flowers are spread throughout his entire 
field. The initial small group of red poppies represents the malignant tumour the surgeon 
has to deal with. Removing the flowers alone is not enough, because dormant seeds might 
be present. Additional strategies to radically eliminate the red weed are needed to improve 
the prognosis of the patient.
Colorectal cancer (CRC) is the third m ost common cancer affecting both men and women in 
the Western world and prognosis mainly depends on the presence of local or distant meta­
stases.1,2 The disease is widely studied and the pathophysiology is quite well understood. For 
example, 90% of patients who die from CRC have liver metastases. There are few cancers in 
which the metastatic pattern displays such a high degree of predictability. Presently, surgical 
techniques have developed in such a way that both patients with a primary tumour as well 
as patients with liver metastases qualify for, by intention, curative surgery. However, local 
recurrences at the site of the anastomosis (also known as anastomotic recurrences, loco-re­
gional recurrences or anastomotic relapse) and in the liver are frequently encountered and 
result in poor prognosis. 2,3 In general, two hypotheses on the aetiology of these recurrences
are believed to have merit. First, microscopic disease might be left behind as the result of --------
either irradical resection of the tumour or the presence of micrometastases (in the liver). 11 
Secondly, intraoperative tumour shedding could be a potential source of recurrent tumour 
growth. The surgical wound plays a key role in the etiology of local recurrences. Several 
preclinical studies have shown that surgical trauma and subsequent angiogenesis during 
wound healing lead to enhanced tumour cell adhesion and promote tumour growth.4-8 
In the battle against recurrent tumour growth in curative CRC treatment, the main focus cur­
rently is on adjuvant (5-fluorouracil-based) chemotherapy. Up till now, only patients with 
stage III and high risk stage II colon carcinoma have convincingly shown to benefit from 
these strategies.9,10 However, this systemic treatment with multiple cycles is quite stressful 
for patients and has some important side effects. Moreover, the mechanism of action of che­
motherapy requires an interaction with every tumour cell while the sensitivity of tumour 
cells for chemotherapy varies. More localised treatment strategies, like intra-abdominal 
lavage with cytotoxic agents, have not shown a therapeutic effect so far.11 As for patients 
who undergo curative surgery for colorectal liver metastases, the rationale for adjuvant che­
motherapy remains a matter of debate. Adjuvant hepatic arterial infusion of chemotherapy 
has shown beneficial results, but constitutes a complex and risky intervention.12 Systemic 
adjuvant chemotherapy might improve disease-free and overall survival, but the available 
clinical studies lack statistical power.13 Moreover, the same drawbacks for patients treated 
with adjuvant chemotherapy after colectomy also apply to those treated for liver metastases.
Patients with unresectable colorectal liver metastases can qualify for local ablation techni­
ques such as radio frequency ablation (RFA). Although this technique has been developed 
and improved over the last years, local recurrences are frequently encountered and no adju­
vant treatment strategy has been successful so far.14,15
Radioimmunotherapy (RIT) uses monoclonal antibodies (mAbs) directed against tumour- 
associated antigens, which are expressed at higher levels in tumours than in normal tissues. 
These mAbs can be labelled with radionuclides, like I-131, Y-90 and Lu-177. RIT offers the 
opportunity to selectively irradiate tumour cells, while sparing normal tissues. Another ad­
vantage of RIT is that the p-particles emitted by most radionuclides used in RIT have a range 
exceeding multiple cell diameters. As a consequence, tumour cells not expressing the target 
antigen may be killed by radiation emitted by radiolabelled antibodies targeting adjacent 
tumour cells, the so-called crossfire effect (see Fig 1).
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Figure 1
Principle of radioimmunotherapy. (1) Tumour-specific monoclonal antibody (mAb) labelled with radio­
nuclide. (2) Binding of mAbs to antigens on the cell mem brane of a tum our cell. (3) The crossfire effect: 
irradiation of non-antigen expressing tum our cells (dark) by mAb binding to surrounding cells.
The principle behind RIT has a history of more than a century. It was Bence Jones who, in 
1847, was the first to observe a tumour-associated substance in human urine. The disco­
very of the carcinoembryonic antigen (CEA) by Gold and Freeman in 1965 was crucial for 
research on RIT in CRC. About 10 years later the group of Goldenberg was the first to use 
I-131 labelled polyclonal antibodies against CEA to target CRC in vivo. Over the past years, 
strong evidence has been found that the uptake of radiolabelled antibodies in small tumours 
is found to be higher and more homogenous than uptake in larger tumours, due to a better 
perfusion of the tumour and a low interstitial pressure.16 Thus, RIT appears potentially 
more suitable as a way to treat small tumour lesions. Using RIT in the treatment of CRC is 
also attractive since it is known that these tumours are relatively radiosensitive. Moreover, 
mAbs against CRC-associated antigens have been developed and optimized and they are now  
available for preclinical studies as well as clinical applications.
Outline of this thesis
The studies described in this thesis are based on the hypothesis that RIT might be an ef­
fective treatment modality for microscopic or minimal residual disease after intentionally 
curative surgery in CRC patients and can prevent or delay growth of local recurrences. The 
aim of the studies was to investigate the following hypotheses:
1. Adjuvant RIT prevents loco-regional recurrences after intestinal resection for CRC
2. Adjuvant RIT prevents local recurrent tumour growth after surgical resection of liver 
metastases of CRC
3. Adjuvant RIT prevents local recurrent tumour growth after RFA of liver metastases of 
CRC
To test these hypotheses, rat models for anastomotic recurrences and for situations repre­
senting treatment of liver metastases were developed. In addition, a study was performed 
on the best way to visualize small liver tumours in an animal model. Finally, a chapter was 
dedicated to the potential clinical implications and complications of introducing adjuvant 
RIT in the postoperative setting.
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A b str a c t
Background
Radioimmunotherapy (RIT) is suitable for the treatment of microscopic residual disease and 
might therefore have an adjuvant role after colonic cancer surgery.
Methods
An anastomosis was constructed in male Wag/Rij rats after intraluminal injection of 2 x 106 
CC531 tumour cells. The biodistribution of m In-labelled MG1 monoclonal antibody was as­
sessed after intraperitoneal administration. The therapeutic efficacy of 177Lu-labelled MG1 
(74 MBq per rat), administered on the day of surgery (D0, n = 13) or 5 days later (D5, n = 13), 
was compared with that of carrier only (n = 13). The primary endpoint was perianastomotic 
tumour growth 28 days after surgery.
Results
m In-labelled MG1 preferentially accumulated in perianastomotic CC531 tumours. RIT resul­
ted in a transient reduction in bodyweight in both treatment groups compared with controls, 
but there were no other signs of clinical discomfort. No macroscopic or microscopic peria­
nastomotic tumour growth was found in eight of 11 animals in the D0 group and 11 of 13 in 
the D5 group, whereas 11 of 13 controls had macroscopic tumour (P = 0.011 and P = 0.001 
respectively).
Conclusion
This study suggests that RIT may be an effective adjuvant treatment for preventing local 
recurrence after resection of colonic cancer.
Radioim m unotherapy prevents local recurrence
Colorectal cancer is the third com m onest cancer among both men and women in the Western world.1,2 It is associated with a worldwide 5-year survival rate of 4 0 -6 0  % and prognosis is mainly determined by the presence of local or distant m etastases.3 
Locoregional recurrence is a frequent complication after surgery with curative intent. These 
local relapses are defined as tumour recurrences in the initial tumour bed, operative field, 
anastomosis (either sutured or stapled), or in peritoneal structures contiguous or adherent 
to the primary tumour.4 The reported 5-year incidence varies between 4 and 28 %5-8, de­
pending mainly on tumour stage.5,6,9,10 Surgical treatment of the recurrent tumour may im­
prove 5-year survival (from the date of diagnosis of recurrence) to 9-43  %, but total surgical 
clearance is difficult, resulting in a median survival of 14 months for those with incomplete 
resection of the recurrence.5
Two theories for the development of local recurrence after potentially curative resection of 
colorectal cancer have been put forward: non-radical resection of the tumour and corres­
ponding lymph nodes and spillage with subsequent implantation of tumour cells after sur­
gery. Data from clinical studies suggest that local recurrence is related to the tumour node 
metastasis stage at diagnosis and tumour clearance at surgery.11-14 According to the second 
theory, tumour cells may be present in the abdomen as a result of seeding from the primary 
tumour or spillage during surgery. Several preclinical studies have shown that surgical trau­
ma and subsequent angiogenesis during wound healing lead to enhanced peritoneal tumour 
cell adhesion and tumour growth.15-18
Radioimmunotherapy (RIT) using radiolabelled monoclonal antibodies (mAbs) directed
against tumour-associated antigen offers the opportunity to irradiate tumour cells selec- --------
tively, while sparing normal tissues. Several preclinical and clinical studies have indicated 17 
that RIT can be effective for cancer treatment19-24 Because tumour targeting with radiolabel- 
ledmAbs is more efficient in small tumour lesions, RIT is considered suitable for minimal 
or microscopic residual disease.21 The aim of the present study was to test the hypothesis 
that RIT might be an effective way of preventing local recurrence after colonic resection for 
cancer in an experimental model using MG1, a mAb directed against a tumour-associated 
antigen expressed on the syngeneic colonic carcinoma cell line CC531.25
M e th o d s
Cell line and monoclonal antibody
The syngeneic rat colonic carcinoma cell line CC531 is derived from colonic tumours of 
Wag/Rij rats exposed to 1,2-dimethylhydrazine.26 CC531 was cultured and suspended as 
described previously.27 MG1 mAb was purchased from Antibodies for Research Applications 
(Gouda, the Netherlands). It is a murine IgG2a antibody, raised by immunization of mice with 
CC531 colonic carcinoma cells. It recognizes a cell antigen of about 80 kDa, localizes prefe­
rentially in CC531 tumours when injected into rats, and has minimal cross-reactivity with 
other cell types.25,28
Chapter 1
Antibody labelling
m In and 177Lu were purchased from Covidien (Petten, The Netherlands) and IDB Holland 
(Baarle Nassau, The Netherlands) respectively. The MG1 antibody was labelled with m In 
and 177Lu, and purified as described previously.27 The specific activity of the m In-labelled 
diethylenetriamine penta-acetic acid (DTPA)-MG1 preparation (hereafter referred to as 
m In-MG1) was 700 kBq/^g. The mean specific activity of the 177Lu-labelled DTPA-MG1 pre­
parations (177Lu-MG1) was 500 (range 300-633) kBq/^g. Radiochemical purity, determined 
by instant thin-layer chromatography on silica gel strips (Gelman Sciences, Ann Arbor, Mi­
chigan, USA) using 0.10 m ol/l citrate buffer (pH6.0) as themobile phase, exceeded 95% for 
all m In-MG1 and 177Lu-MG1 preparations.
Affinity analysis
CC531 cells were cultured to confluency in six-well plates. To determine the concentration 
required to inhibit binding by 50 % (IC50), cells were incubated for 4 h at 4 °C in 2 ml binding 
buffer (RPMI 1640 containing 0.5 % bovine serum albumin (BSA)) with 1.1 kBq m In-MG1 
and increasing concentrations of unlabelled MG1 (0 .01-30 nm ol/l). Scatchard analysis was 
performed to determine the dissociation constant (Kd) and maximum binding (Bmax). Cells 
were incubated for 4 h at 4 °C in 2 ml binding buffer with increasing concentrations of m In­
--------  MG1 (0 .05-25 nmol/l; 0 .04-22 kBq). Non-specific binding was determined by co-incubation
18 with an excess of 13 nm ol/l unlabelled MG1. In both assays, cell-associated activity after 
incubation was measured in a y counter
Surgical procedure
Fifty-four 10-12-week-old male Wag/Rij rats, with a mean weight of 250 g, were used 
(Charles River Laboratories, Sulzfeld, Germany). They were accustomed to laboratory con­
ditions for 1 week before use and housed under non-sterile, standard laboratory conditions 
(temperature 20 -2 4  °C, relative humidity 50 -60  %, 12-h light-dark cycle), with free access 
to animal chow and water. All experiments were conducted in accordance with the princi­
ples laid out by the revised Dutch Act on Animal Experimentation (1997) and approved by 
the institutional Animal Welfare Committee of Radboud University Nijmegen.
All surgical procedures were carried out under clean conditions. Immediately after the onset 
of general anaesthesia (isoflurane, oxygen and nitrous oxide), the abdomen was shaved and 
disinfected with 70 % ethanol. During the operation, rats were placed on a warmed mattress 
to limit heat loss, and eye drops containing 20 m g/g chloramphenicol were administered to 
prevent dehydration of the eyes. The abdomen was opened via a 4-cm midline laparotomy 
The descending colon was lifted gently out of the abdomen and any faecal content was shif­
ted to the proximal or distal colon. At approximately 2 -3  cm from the peritoneal reflection 
the mesenteric veins near the colon were fulgurated over 1 cm using an electrocoagulation 
device. Two atraumatic bulldog clamps were then placed on the colon, isolating 1 cm of lu­
men. Using a 29-G needle and a 1-ml syringe, 2 x 106 CC531 tumour cells, suspended in 0.1 
ml phosphate-buffered saline (PBS), were injected intraluminally between the two clamps.
Radioim m unotherapy prevents local recurrence
After 30 s, which was considered a realistic and practical interval for tumour cells to adhere 
to the wall of the colon, 5 mm of colonic tissue containing the puncture area was resected. 
Continuity was restored by construction of an inverted anastomosis with eight interrupted 
absorbable monofilament 8 /0  sutures. The clamps were removed after placement of the first 
stitch and all sutures were placed at an equal distance. The muscular layer of the abdomen 
was closed with continuous absorbable braided 3 /0  sutures and the skin with iron wound 
clips. Warmed saline (10 ml) was injected subcutaneously for rehydration. Rat cages were 
kept on a warm mattress for the first 24 h after operation. Before and 12 h after surgery, and 
twice daily on the first and second day thereafter, analgesia was given in the form of subcu­
taneous injections of buprenorphine, 2 ^g per 100 g bodyweight.
Biodistribution
To determine the uptake of 177Lu-MG1 in different organs and perianastomotic tumours, the 
biodistribution of m In-MG1, as surrogate radionuclide for 177Lu, was determined. Fifteen 
Wag/Rij rats had the surgical procedure and tumour inoculation as described above. On 
each of days 21, 25 and 27, five rats received a single intraperitoneal injection of 370 kBq 
m In-MG1 (MG1 protein dose 0.6 ^g per rat) in 0.2 ml PBS containing 0.5 % BSA. On day 28 
the animals were killed using oxygen-carbon dioxide asphyxiation and dissected. Tumour, 
blood, liver, spleen, kidney, lung, muscle, small intestine and large intestine were sampled,
blotted dry and weighed. Activity was measured in a y counter. The results were expressed --------
as a percentage of the injected dose (ID) per gram of tissue. 19
Radioimmunotherapy study
The therapeutic efficacy of RIT was determined after random assignment of 39 rats to re­
ceive an intraperitoneal injection of either RIT (n = 26) or PBS carrier (n = 13) after the 
surgical procedure and tumour cell inoculation. RIT consisted of 74 MBq 177Lu-MG1 in 0.5 ml 
PBS administered in a single dose on either the day of surgery (D0 group, n = 13) or 5 days 
later (D5 group, n = 13). RIT was administered on the day of surgery in order to assess its 
ability to prevent implantation of free intraabdominal tumour cells after colorectal cancer 
surgery; it was administered after 5 days to evaluate whether it could treat microscopic local 
recurrence of colorectal cancer. The carrier was administered in the control group on the day 
of surgery. The primary endpoint was local recurrence, defined as the presence of tumour 
nodules within 1 cm of the anastomosis 28 days after tumour inoculation. Toxicity was mo­
nitored by bodyweight measurement and assessm ent of general condition. Bodyweight was 
measured daily during the first week and twice weekly thereafter. All rats were killed and 
dissected 28 days after surgery. The abdominal cavity was carefully inspected, with special 
attention to the perianastomotic area. All macroscopic tumour deposits were resected and 
weighed. The anastomosis, including 1 cm of tissue on both sides, was removed for routine 
histopathological staining with haematoxylin and eosin. Microscopic tumour growth was 
scored as either present or absent.
Chapter 1
Statistical analysis
Statistical analysis was performed using SPSS software (SPSS, Chicago, Illinois, USA) and 
GraphPad Prism 4.00 (GraphPad Software, San Diego, California, USA) software. Sample size 
was determined by a power calculation based on observations from a pilot study with the 
animal model, and an estimated effect of RIT in 65 % of treated animals (G. M. de Jong and 
B. de Man, unpublished data). Dichotomous values were compared using Fisher's exact test. 
Comparison of continuous variables was done by ANOVA post hoc testing followed by Dun­
nett t procedures. All tests were two sided; P < 0.050 was considered statistically significant.
R e su lts
Affinity analysis
MG1 exhibited a mean (s.d.) IC50 for CC531 cells of 1.2 (0.2) nm ol/l (Fig. 1a). Scatchard ana­
lysis revealed that MG1 had a mean (s.d.) Kd of 1.5 (0.4) nm ol/l and bound maximally to 
120.000 (20.000) epitopes per cell (Fig. 1b).
Figure 1
Analysis o f  binding between labelled antibody  
and tum our cells.
(a) Typical binding p lo t o f  ln ln-labelled diethy- 
lenetriamine penta-acetic acid-M Gl (111ln- 
MG1) w ith CC531 cells. The mean (s.d.) con­
centration required to inhibit binding by 50 % 
( IC J  was 1.2 (0.2) nmol/l.
(b) Scatchard p lo t o f  111In-MGl and CC531 cells. 
The mean (s.d.) dissociation constant (KJ was
1.5 (0.4) nm ol/l and m aximum binding (Bma)  
was 120 000 (20 000) epitopes/cell
Surgery
One of the 54 rats died shortly after the operation, probably from hypothermia. All other 
surgical procedures went uneventfully
c o n ce n tra tio n  un labe lled  MG1 (log(pM ))
bound  (pm ol)
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B iodistribution  of MG1
The biodistribution of m In-MG1 is summarized in Fig. 2. There was preferential uptake in 
the tumour, exceeding 2 %ID/g, at all time points. After 3 days, uptake in normal tissues 
did not exceed 1 %ID/g. The radiolabelled antibody was retained in the tumour and the 
mean(s.d.) tumour to blood ratio increased from 1.34(0.30) on day 1 to 6.42(2.58) by 7 days 
after injection.
Figure 2
Biodistribution. Animals underw ent tu ­
mour cell inoculation and surgery and 
were killed 28 days later. One (black 
bars), three (white bars) or seven (gray 
bars) days preceding sacrifice rats were 
injected intraperitoneally with 111ln- 
DTPA-MG1. Bars represent mean values 
wi th SD.
21 
Efficacy of radioimmunotherapy
One rat was excluded from the experiment because RIT had been administered intraluminal­
ly. The relative bodyweight of all rats, expressed as a percentage of the preoperative weight 
on the day of surgery, decreased in the postoperative period (Fig. 3). The minimum mean 
weight of rats treated with 177Lu-MG1 on the day of surgery (D0 group) was significantly lo­
wer than that of the control group (P = 0.001). This difference disappeared towards the end 
of the experiment. RIT induced a delay in regaining normal growth rate when administered 
on the fifth day after surgery (D5 group), resulting in a lower bodyweight compared with the 
control group at the end of the experiment (P = 0.016). All 37 rats survived the experimental 
period and none showed clinical signs of discomfort.
Table 1. Macroscopic and microscopic tum our recurrence
Group (n)
M acroscopic tum our  
grow th
M icroscopic tum our  
growth
M acroscopic
periton eal
carcinom atosis
Control (13) 11 11 8
RIT D0 (11) 0 (P<0.001) 3 (P=0.011) 0 (P=0.002)
RIT D5 (13) 0 (P<0.001) 2 (P=0.001) 0 (P=0.002)
P-values refer to differences w ith the control group.
Chapter 1
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10 15 
days after surgery
20 25
Figure 3
Course o f  body weight. Depicted is the mean re­
lative body weight, w ith respect to preoperative 
weight, in the DO-group (triangles), D5-group 
(circles) and the control group (squares).
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Figure 4
Individual values fo r  tum our w eight in the peri­
anastomotic area 28 days after surgery in rats 
receiving radioimmunotherapy (RIT) on the day 
o f  surgery (DO -group) or 5  days later (D5-group) 
and in the control group. Horizontal line repre­
sents median value in control group.
None of the rats from the therapy groups had 
macroscopic tumour growth in the periana­
stomotic area or elsewhere in the abdomen 
(Table 1), whereas 11 of 13 control rats had 
macroscopic tumour growth at the site of the 
anastomosis (P < 0.001). Median weight of 
this tumour was 0.04 (range 0.02-2.5) g (Fig. 
4). Eight of 13 rats in the untreated group 
developed peritoneal carcinomatosis, with 
tumour nodules at the liver hilum, m esen­
tery and gonadal fat pads as well as in the 
laparotomy wound (P = 0.002 versus treated 
groups). None of the animals had any signs of 
wound healing disorders, such as anastomotic 
leakage or abdominal wall closure defects. 
Histopathological staining revealed the pres­
ence of microscopic tumour nodules in three 
of 11 rats in the D0 group and two of 13 in 
the D5 group. The rate of local recurrence 
remained signficantly higher than in the con­
trol group (P = 0.011 and P = 0.001 respec­
tively). Specimens from the anastomotic area 
contained tumour nodules either in lymph no­
des or in blood vessels (Fig. 5).
D is c u s s io n
RIT effectively prevented local recurrence and 
peritoneal carcinomatosis after partial colo­
nic resection in rats with a high intraluminal 
concentration of syngeneic colonic carcinoma 
cells. RIT was equally effective whether admi­
nistered on the day of the operation or 5 days 
later. These results suggest that RIT could pre­
vent local recurrence resulting from both im­
plantation of intraabdominal tumour cells and 
the presence of (microscopic) tumour residue 
after colorectal cancer surgery. Although rats 
treated with RIT had a significantly lower bo- 
dyweight several days after the procedure, no 
adverse event such as infection or impaired 
wound healing was observed, as noted previ­
ously.29
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Figure 5
Typical histological specimens showing CC531 tumour cells (a) in a lymph node and (b) in a blood vessel 
near the anastomosis (haematoxylin and eosin stain, 25x original magnification)
The syngeneic rat colonic carcinoma cell line CC531 was used in this study because of its 
reproducible growth pattern in Wag/Rij rats.30 With a protocol of intraluminal inoculation 
before intestinal resection and anastomosis, perianastomotic tumour growth occurred in 
more than 80 % of the animals. Comparable results were achieved in other studies in which 
similar procedures were used.31,32 The potential of the MG1 mAb to target CC531 tumours in 
vivo has been studied previously.25,30 The present study demonstrated that MG1 had a nano­
molar affinity for the antigen expressed on CC531 cells. In line with the present data, Koppe 
and colleagues27 found that tumour uptake of MG1 labelled with both 111In and 177Lu was 
about 4 %ID/g for intraperitoneal CC531 tumours and that the antibody accumulated pre­
ferentially in tumour tissue. Thus, intraluminal injection of CC531 tumour cells in syngeneic 
rats is considered a reproducible animal model for studying local recurrence after colonic 
cancer surgery, and RIT using 177Lu-MG1 has good targeting capacity in this model.
Adjuvant 5-fluorouracil-based chemotherapy after resection of stage III and high-risk stage II 
colonic carcinoma is currently the recommended strategy to prevent distant metastasis and 
improve disease-free survival.33 Apart from abdominal lavage with normal saline, no perope­
rative therapy is being used to prevent implantation of tumour cells spilt at the time of sur­
gery. Furthermore, lavage would not be expected to prevent relapse from residual disease. 
Theoretically, adjuvant intraperitoneal administration of chemical agents could prevent re­
current tumour growth from both residual tumour after non-radical resection and seeding 
of tumour cells. Intraperitoneal administration of 5-fluorouracil to prevent local recurrence 
and peritoneal carcinomatosis has been tested in experimental and clinical settings, with no 
clear evidence of superiority over intravenous administration.34-36 Other substances, such as 
chlorhexidine-cetrimide preparations and povidone-iodine, have shown promising results 
in vitro, but were unsuccessful in vivo.37,38 The weak cytotoxic effect in vivo may be the result 
of chemical inactivation by organic molecules in peritoneal fluid and blood.38-40 The antian- 
giogenic agent suramin appeared to enhance tumour growth in an animal model, possibly 
owing to an unexpected immunosuppressive effect.31 Peritoneal lavage with distilled water 
after colorectal cancer surgery was effective only after sequential lavages and more than 
half an hour of incubation, and is thus an impractical method.41 An advantage of RIT is that it 
can be administered intraperitoneally in a single dose and does not have major side-effects. 
The timing of administration of RIT in the clinical setting requires consideration. Immediate
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postoperative administration of RIT had a transient effect on bodyweight, so delayed adju­
vant treatment might be preferable as it would allow the patient to recover from the opera­
tion first. It might also be necessary to delay treatment when surgery-related complications 
warrant intensive care, to ensure minimal exposure of medical personnel to radiation. In 
this study, RIT was equally effective when administered on the day of surgery or several days 
later, when small tumour nodules might be present, confirming the feasibility of a delayed 
approach.
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A b str a c t
Background
Adjuvant radioimmunotherapy (RIT) has previously shown to reduce the incidence of local­
regional recurrences of colorectal cancer (CRC) in an experimental model. The aim of the 
present study was to investigate the survival benefit of adjuvant RIT and compare with ad­
juvant chemotherapy.
Methods
In male Wag/Rij rats an anastomosis was constructed after intraluminal injection of CC531 
tumour cells. The therapeutic efficacy of 177Lu-labelled MG1 (single dose, 300 MBq/kg, iv, 
n=20) was compared with that of (5-fluorouracil based) chemotherapy (6 weekly cycles, ip, 
n=20) and no treatment (n=20). Primary endpoint was survival. Toxicity was monitored by 
body weight measurement.
Results
Both adjuvant chemotherapy and RIT affected body weight, but the body weight of the RIT 
group remained significantly higher than that of the chemotherapy group (P<0.001). Kap­
lan-Meier survival analysis showed that the overall survival of both treated groups was sig- 
30 nificantly better than that of the control group (P=0.024 and P=0.029 for the RIT and chemo­
therapy group, respectively). Survival after treatment with RIT did not differ from survival 
after treatment with chemotherapy (P=0.911).
Conclusion
This study provides proof of principle that adjuvant RIT can improve survival after intenti­
onally curative CRC surgery. Moreover, RIT seem s to be equally effective as adjuvant chemo­
therapy, with less toxicity and fewer interventions required.
Adjuvant radioim m unotherapy and adjuvant chem otherapy
The diagnosis of local-regional recurrence after potentially curative colorectal cancer (CRC) surgery is devastating and has a major impact on the prognosis.1 These local­regional recurrences are defined as tumour recurrences in the initial tumour bed, 
operative field, anastomosis (either sutured or stapled), or in peritoneal structures conti­
guous or adherent to the primary tumour.2 The reported 5-year incidence of local-regional 
recurrences, also known as anastomotic relapse, varies between 4% and 28%, mainly de­
pending on tumour stage and surgical technique.3-6 Two theories for the development of 
local-regional recurrence after potentially curative resection of colorectal cancer have been 
put forward: (1) non-radical resection of the tumour and corresponding lymph nodes or (2) 
spillage with subsequent implantation of tumour cells after surgery. Data from clinical stu­
dies suggest that local-regional recurrence is related to the tumour-node-metastasis (TNM) 
stage at diagnosis and tumour clearance at surgery.3,4,7,8 According to the second theory, tu­
mour cells may be present in the abdomen as a result of seeding from the primary tumour 
or spillage during surgery. Several preclinical studies have shown that surgical trauma and 
subsequent angiogenesis during wound healing lead to enhanced local peritoneal tumour 
cell adhesion and tumour growth and therefore play a crucial role in the etiology of local­
regional recurrences.9-12 As such, most (surgical) oncologists consider local-regional recur­
rence and peritoneal carcinomatosis (PC) to be two different disease stages. PC can also be 
the result of preoperative full-thickness invasion of the bowel wall by an invasive cancer or 
a rupture or a structure of a tumour. Moreover, PC manifests as a diffuse spread of multiple 
metastatic nodules on the peritoneal surface.13 Currently, adjuvant chemotherapy to prevent
dissemination is only routinely advised in stage III and high risk stage II patients, but has --------
serious side-effects and requires multiple treatment cycles.14 31
Radioimmunotherapy (RIT) using radiolabelled monoclonal antibodies (mAbs) directed 
against tumour-associated antigen offers the opportunity to irradiate tumour cells selec­
tively, while sparing normal tissues. Several preclinical and clinical studies have indicated 
that RIT can be effective for cancer treatment.15-19 Because tumour targeting with radiolabel­
led mAbs is more efficient in small tumour lesions, RIT is considered suited for minimal or 
microscopic residual disease.21 In a previous study in rats it was demonstrated that adjuvant 
RIT, using MG1 mAb directed against a tumour-associated antigen expressed on the syngen­
eic colon carcinoma cell line (CC531), prevents peri-anastomotic tumour growth after colo­
nic resection, as determined one month after tumour inoculation.20 The aim of the present 
study was to test the hypothesis that both adjuvant RIT and adjuvant chemotherapy could 
improve survival and to investigate the toxicity both treatment strategies.
M e th o d s
Cell line and monoclonal antibody
The syngeneic rat colonic carcinoma cell line CC531 is derived from colonic tumours of 
Wag/Rij rats exposed to 1,2-dimethylhydrazine.21 CC531 was cultured and suspended as 
described previously.17 MG1 mAb was purchased from Antibodies for Research Applications 
(Gouda, the Netherlands). It is a murine IgG2a antibody, raised by immunization of mice with
Chapter 2
CC531 colonic carcinoma cells. It recognizes a cell surface antigen of about 80 kDa, localizes 
preferentially in CC531 tumours when injected into rats, and has minimal cross-reactivity 
with other cell types.22,23 In our previous study we demonstrated that MG1 has a high affinity 
(1.0 nM), preferentially localizes in perianastomotic tumours and retained in the tumour for 
more than 7 days after injection.20
Antibody labelling
177Lu was purchased from IDB Holland (Baarle Nassau, the Netherlands). The MG1 antibody 
was labelled with 177Lu and purified as described previously.27 The mean specific activity of 
the 177Lu-labelled diethylenetriamine penta-acetic acid (DTPA)-MG1 preparation (hereafter 
referred to as 177Lu-MG1) was 154 (range 146-162) kBq/^g. Radiochemical purity, deter­
mined by instant thin-layer chromatography on silica gel strips (Gelman Sciences, Ann Ar­
bor, Michigan, USA) using 0.10 m ol/l citrate buffer, pH 6.0, as the mobile phase, exceeded 95 
% for all 177Lu-MG1 preparations.
Surgical procedure
Sixty ten-to-twelve-week-old male Wag/Rij rats, with a mean weight of 240 g, were used
--------  (Charles River Laboratories, Sulzfeld, Germany). They were acclimatized to laboratory con-
32 ditions for one week before use and housed under non-sterile, standard laboratory condi­
tions (temperature 20 -2 4  °C, relative humidity 50-60  %, 12-h light-dark cycle), with free 
access to animal chow and water. All experiments were conducted in accordance with the 
principles laid out by the revised Dutch Act on Animal Experimentation (1997) and appro­
ved by the institutional Animal Welfare Committee of Radboud University Nijmegen. An 
anastomosis was constructed after intraluminal injection of 2 x 106 CC531 tumour cells as 
described previously.20 In summary, via a laparotomy 1 cm of lumen of the descending colon 
was isolated by placing two atraumatic bulldog clamps, where after the CC531 tumour cells 
were injected intraluminally. After 30 s, 5 mm of colonic tissue containing the puncture area 
was resected. Continuity was restored by construction of an inverted anastomosis with eight 
interrupted absorbable monofilament 8 /0  sutures, which were placed at an equal distance. 
Warmed saline (10 ml) was injected subcutaneously for rehydration. Postoperatively, rats 
were allowed access to tap water immediately and to food ad libitum 24 h later. Rat cages 
were kept on a warm mattress for the first 24 h after operation. Before, 24 hours and 48 
hours after the surgical procedure, analgesia was given in the form of subcutaneous injecti­
ons of 5^g per 100 g body weight of a selective COX-2-inhibitor.
Radioimmunotherapy and chemotherapy
The therapeutic efficacy of RIT and chemotherapy was determined after random assignment 
of the rats to receive adjuvant RIT (n = 20) or chemotherapy (n = 20) or no adjuvant treat­
ment (n = 20) after the surgical procedure and tumour cell inoculation. RIT consisted of an 
intravenous injection of 300 MBq/kg 177Lu-MG1 in 0.25 ml PBS administered in a single dose.
Adjuvant radioim m unotherapy and adjuvant chem otherapy
Since a previous study had shown that RIT was equally effective if administered at the day 
of operation or five days later, RIT was given on day 5.20 The chemotherapy regime consisted  
of intraperitoneal injections of 5-fluorouracil (25 m g/kg/cycle), leucovorin (2 m g/kg/cycle) 
and oxaliplatin (4 m g/kg/cycle) in 2.5 ml 5% dextrose. Chemotherapy was given once every 
week for 6 weeks, starting on postoperative day 7.
The primary endpoint was survival. Toxicity was monitored by body weight measurement 
and assessm ent of general condition. Body weight was measured daily during the first three 
postoperative days and twice weekly thereafter. When the humane endpoint (one of the fol­
lowing signs present: >20% body weight loss, abdominal distension and ascites, signs of 
physical discomfort like breathing problems) was reached, rats were euthanized using oxy­
gen/carbon dioxide asphyxiation and dissected.
When the median survival was reached in all groups, all remaining rats were euthanized and 
dissected. At dissection the abdominal cavity was carefully inspected, with special attention 
to the perianastomotic area. The peritoneal cancer index (PCI) was scored as described by 
Koppe et al.17 The PCI is the sum of tumour scores (0=no macroscopic tumour growth, 1=lit- 
tle tumour growth, 2=moderate tumour growth, 3=abundant tumour growth) at nine spe­
cific sites in the adbomen. All macroscopic tumour deposits present in the abdomen were 
resected and weighed. The anastomosis, including 1 cm of tissue on both sides, was remo­
ved for routine histopathological staining with haematoxylin and eosin. Microscopic tumour 
growth was evaluated by an experienced pathologist, blinded for the therapeutic regime 
given, at four levels in each slice and scored as either present or absent.
days after surgery
Figure 1
Course o f  body w eight during the f ir s t  two months after surgery. The mean (± SD) relative body weight, 
with respect to preoperative weight, is given fo r  the RIT group (black circles), chemotherapy group (white 
triangles) and the control group (white squares). The black arrow indicates the administration o f  RIT and 
the interrupted arrows indicate the administration o f  chemotherapy.
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Statistical analysis
Statistical analysis was performed using the SPSS software (Chicago, IL) and GraphPad 
Prism version 4.00 for Windows (GraphPad Software, San Diego USA). The power calcula­
tion, which led to a group size of 20 animals each, was based on the hypothesis that adju­
vant treatment (either RIT or chemotherapy) could improve survival to the same extent as 
observed in a previous study.24 Kaplan-Meier survival curves for overall survival were gene­
rated. The Log-rank test was used to identify the difference between the groups for overall 
survival. The level of statistical significance was set at a P-value of <0.05. The slopes of the 
individual body weight-curves were determined by linear regression analysis. Means and 
standard deviations were used to describe continuous data and differences were calculated 
using one-way ANOVA and independent-samples t-tests.
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Figure 2
Survival curves. Lines represent groups receiving adjuvant radioimmunotherapy (black circles), adjuvant 
chemotherapy (white triangles) and no adjuvant treatm ent (controlgroup, white squares).
R e su lts
All surgical procedures w ent uneventfully. The relative body weight of all rats during the first 
two months after surgery, expressed as a percentage of the preoperative weight on the day 
of surgery, is summarized in Figure 1. The course of the body weight, expressed as the mean 
slope of the curves, of the animals was affected by the administration of adjuvant therapy 
(P<0.001). The mean slope of the body weight of the animals in the control group was 0.53 ± 
0.08 g /  day. The mean slope of the body weight of the animals in the RIT and chemotherapy
Adjuvant radioim m unotherapy and adjuvant chem otherapy
groups was 0.46 ± 0.08 and 0.30 ± 0.08 g/day respectively (P<0.009 and P<0.001 as compa­
red to the control group). The weight gain in the chemotherapy group was also significantly 
lower than that in the RIT group (P<0.001). With regard to the general condition of the ani­
mals, diarrhoea was the most prominent finding. Forty eight percent of all rats suffered from 
episodes of mild diarrhoea, not correlated with the treatment given (Pearson's correlation
0.04, P=0.757).
One hundred and seventy days after tumour cell inoculation, all three groups had reached 
the median survival. The survival curves are shown in Figure 2. Kaplan-Meier survival analy­
sis showed that the overall survival curves of both treated groups differed significantly from 
the control group (P=0.024 and P=0.029 for the RIT and chemotherapy group respectively). 
Overall survival after treatment with RIT did not differ significantly from survival after tre­
atment with chemotherapy (P=0.911). Median survival was 157,170 and 97 days in the RIT,
Figure 3
Histological specimen from  the 
anastomosis o f a ra t from  the con­
trol group (H&E staining, 12.5x 
enhanced). CC531 tumour cells in 
a lymph node near the anastomosis 
(red arrow) and in a blood vessel 
near the anastomosis (red arrow  
head). The green arrow indicates 
sutures a t the side o f  the anasto­
mosis.
chemotherapy and control group, respectively. Although 8 out of 10, 7 out of 10 and 15 out 
of 15 of the euthanized animals of the RIT group, chemotherapy group and control group 
respectively, had tumour growth at the anastomotic area at the time of euthanasia, the deci­
sive humane endpoint criterion to euthanize a rat differed between the rats in each group. 
For example, ascites was present in all rats in the chemotherapy group, but only in half of 
the animals from the two other groups. With respect to the secondary endpoints, the mean 
PCI at dissection was 6.8 ± 5.8, 2.1 ± 2.6 and 4.8 ± 4.1 and the average weight of all intra­
abdominal tumours was 8.2 ± 6.3 g, 1.7 ± 2.2 g and 5.1 ± 3.5 g in the RIT, chemotherapy and 
control groups, respectively.
At the end of the experiment, 10 rats in the RIT group, 10 rats in the chemotherapy group 
and 5 rats in the control group were still alive. Histopathological staining revealed the pre­
sence of microscopic tumour nodules in only one of the remaining rats from both the RIT 
group and the control group. Specimens from the anastomotic area contained tumour nodu­
les either in lymph nodes or in blood vessels (Fig. 3).
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D is c u s s io n
In an animal model for anastomotic recurrences of CRC, adjuvant RIT improved survival. 
Moreover, the survival benefit of adjuvant RIT was similar to the survival benefit of adjuvant 
chemotherapy, but with less signs of toxicity and less interventions. The syngeneic rat colo­
nic carcinoma cell line CC531 was used in this study because of its reproducible growth pat­
tern in Wag/Rij rats.30 With a protocol of intraluminal inoculation before intestinal resection 
and anastomosis, perianastomotic tumour growth occurred in 16 out of 20 of the untreated 
animals. The maximum tolerated dose (MTD) of intravenous 300 MBq/kg 177Lu-MG1 in rats 
was determined previously.24 Studies on the biodistribution of radiolabelled antibodies in 
models of peritoneal carcinomatosis (PC) show that 24 hours post-injection the uptake in 
intraperitoneal tumours after intravenous injection does not differ from the uptake after 
intraperitoneal injection of the mAbs.25 Moreover, loco-regional metastases have a different 
pathophysiology than PC, which is illustrated in the model currently used by the presence of 
tumour deposits either in vessels or in lymph nodes near the anastomosis and not peritoneal 
implants. A study by Schlom et al. suggests that uptake in these haematogenic or lymph node 
metastases is not influenced by the route of administration.26
The therapeutic effect of adjuvant RIT in colorectal cancer has been demonstrated in pre­
vious preclinical and clinical studies on adjuvant RIT after hepatectomy and peritoneal de- 
bulking for CRC.17,27 These positive results illustrate the advantages of RIT. RIT is a targeted
--------  therapy that will result in specific irradiation of tumour cells. Moreover, tumour cells not
36  expressing the target antigen may be killed by radiation emitted by radiolabelled antibodies 
targeting adjacent tumour cells. Because of this so called bystander effect, the therapeutic 
response of RIT is less dependent on direct interaction between the mAb and individual cells 
than many other systemic therapies. This feature also distinguishes RIT from immunothe­
rapy. The superiority of RIT over unlabelled antibody treatment has been demonstrated by 
Koppe et al. in an previous experiment in an animal model for peritoneal carcinomatosis17 
and might be explained by the fact that not all mAbs activate the complement system or in­
duce antibody-dependent cell-mediated cytotoxicity.28 Finally, radionuclides are not subject 
to multidrug resistance. Extrapolating the efficacy of RIT in animal models to that in patients 
is difficult. However, the differences between animal models and the actual patient situation 
with respect to activity concentrations in the tumours and tissues are rather small. Because 
the activity concentration over time determines the radiation absorbed dose, and thus bio­
logical effects, it is reasonable to assume that animal models should be able to predict actual 
clinical scenarios fairly well.19
In the current study the effect of adjuvant RIT was compared to the effect of adjuvant chemo­
therapy. Based on current clinical protocols for adjuvant chemotherapy in stage III and high­
risk stage II CRC patients, in this study a chemotherapeutic regime consisting of 6 weekly 
cycles with 5-fluorouracil, leucovorin and oxaliplatin was used.29 No data exist on the exact 
effectiveness of this chemotherapy regime on the CC531 cell line, however, using the MTD in 
preclinical studies is a generally accepted strategy to study the therapeutic effect of cytotoxic 
agents in rodents. Dosages were chosen based on available literature on the MTD of this 
regime in rodents.30-32 No separate MTD-study was performed by us because of the simila­
rity between the model used and the models described in the literature (which also poses 
an ethical dilemma). Therefore, we cannot exclude the possibility that in the model used in
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this study the MTD would be slightly different from the one used. Intraperitoneal deposition  
of chemotherapy in rats is accepted as a slow release route (or protocol) resulting in conti­
nuous drug exposure for prolonged periods of time and could therefore mimic the human si­
tuation.33 In the current study, toxicity was monitored by body weight and general condition, 
but was also reflected in the secondary end points. Although the number of rats was small 
and a high variation in the data was noted, the PCI at dissection and intra-abdominal tumour 
weight of the euthanized rats in the chemotherapy group seemed lower than in the RIT and 
control group. These differences can be explained by the observation that all rats in the che­
motherapy group developed ascites, while only half of the animals in both other groups did.
Adjuvant 5-fluorouracil-based chemotherapy after resection of stage III and high-risk stage
II colonic carcinoma is currently the recommended strategy to prevent (local-regional) re­
lapse and improve disease-free survival.34,35 However, this systemic treatment with multiple 
cycles is a major burden for patients and has some severe side effects.29 Moreover, the me­
chanism of action of chemotherapy requires an interaction with every tumour cell and sen­
sitivity of tumour cells for chemotherapy varies. The individual responses to chemotherapy 
are hard to predict and no good prognostic markers for chemotherapy response in colorectal 
cancer are available yet.36 In stage II CRC patients high risk features, indicating a higher risk 
on dissemination, have been defined. These include obstruction, perforation, inadequate 
lymph node sampling or T4 disease.34 Presence of one of these features constitutes a rea­
son to recommend adjuvant chemotherapy. However, such reasoning does not account for
possible tumour spillage during surgery, which can always occur and not only in patients at --------
high risk. If the implementation of adjuvant strategies in lower stage CRC patients should be 37 
considered, one should always be aware of the fact that these patients already have a good 
survival when treated with surgery only (75% to 80% at 5 years). This excellent prognosis 
without adjuvant treatment strategies thus justifies only interventions with high effective­
ness, low toxicity and short duration.14 The results of the current study show that adjuvant 
RIT might m eet these criteria. While achieving a similar survival benefit, the toxicity and the 
administration schedule might favour RIT over chemotherapy. Previous studies have also 
shown that adjuvant RIT does not influence wound healing.37
The therapeutic efficacy of RIT is dependent on the biodistribution of the mAb. Different 
strategies have been pursued to improve this.38-40 One important factor determining biodis­
tribution is the known inverse correlation between the uptake of radiolabelled antibodies 
and tumour size.41 This correlation forms the basis for using RIT as an adjuvant after surgical 
removal of bulky tumour. Aarts et al. proposed to use galactosylated antibodies for the tre­
atment of intraperitoneal lesions because these can improve the tumour-non-tumour ratios, 
since carbohydrated antitumour antibodies clear very rapidly from the blood.42 The fact that 
RIT is considered to be particularly suited for small volume disease determines choice of the 
radionuclide. Using 177Lu for RIT has several advantages over the use other ^-emitting ra­
dionuclides like 90Y and 186Re with respect to physical half-life, the presence of gamma-rays, 
the energy of the beta-particles and consequently the range of the beta-particles in tissue.25 
In this respect RIT using alpha-emitting radionuclides could also be interesting, because 
alpha-particles have a high linear energy transfer and a short path length in biological tissue, 
although availability is limited.43
Myelotoxicity is dose-limiting in RIT and since the uptake of radiolabelled mAbs in bone mar­
row is correlated to the uptake in blood, the outcome of RIT can also be improved by fracti-
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onating or repeating the administered dose.44 However, an important potential disadvantage 
of fractionated RIT in clinical application as well as in animal models is the development of 
human antimouse mAb (HAMA), and rat antimouse mAb (RAMA), respectively. Development 
of HAMA's of RAMA's will lead to treatment interruption and thus a decreased therapeutic ef­
ficacy. Finally, outcome of RIT can be improved by using pretargeted RIT (PRIT). In PRIT, the 
tumour is pretargeted with an antibody construct that has affinity for the tumour-associated 
antigen on one hand and for a radiolabelled hapten on the other. The radiolabelled hapten is 
administered in a later phase, preferably after the antibody construct has cleared from the 
circulation. PRIT could thus enhance the radiation dose that could be guided to the tumour.45 
Since this study provides the proof of principle that the effectiveness of adjuvant RIT can be 
similar to the effectiveness of this particular combination of adjuvant chemotherapy, future 
studies are certainly warranted. For instance, it might be interesting to study the effect of a 
combination therapy in this animal model, since the therapeutic effect of chemotherapy and 
RIT might be additive or even synergistic.46 Such preclinical data could certainly constitute 
a basis for new clinical trials on adjuvant treatment, including RIT, after potentially curative 
surgery of CRC patients.
38
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A b str a c t
Liver metastases of colorectal carcinoma occur in about 50-60%  of patients. To improve 
survival of these patients, there is an urgent need for new treatment strategies. For this pur­
pose, the availability of a preclinical model to develop and test such treatments is mandatory. 
An ideal animal model for studying liver metastases of colorectal origin should mimic all 
aspects of the metastatic development in humans and be practical, predictable, and optimal 
in terms of ethical considerations. Thus far, no model has been developed which satisfies all 
these conditions. As a consequence, choosing an animal model for the study of liver metasta­
ses requires compromises and choices about the necessary characteristics that depend on 
the purpose of the intended experiments. This overview addresses the advantages and dis­
advantages of different animal models used for research on experimental liver metastases 
of colorectal origin. Based on data available in literature, we conclude that heterotopic in­
jection of undifferentiated syngeneic tumor cells in immunocompetent rodents covers most 
of the desired characteristics. Both subcapsular as well as intraportal injection will yield 
suitable models and the eventual choice will depend on the aim of the study.
Animal m odels for liver m etastases
I
n 50 to 60 % of all patients with colorectal carcinoma (CRC), liver metastases will deve­
lop at some point in the course of the disease.1,2 In 25 % of the patients, these metastases 
are already present at the time of diagnosis of the primary tumour.3,4 Another 50 % of the 
patients will develop metachronous liver metastases within 5 years.5 Surgical resection of 
metastatic liver tumours, which is possible in 20-50 % of patients at first presentation, is the 
only chance for cure with a reported 5-year survival rate ranging from 10 % to 58 %.5-12 Still,
90 % of these patients eventually die due to recurrent disease, which again involves the liver 
in 45-75 % of cases.4,5;13-17 Therefore, there is an urgent need for new treatment strategies to 
improve the prognosis of CRC patients with liver metastases. For this purpose, the availabi­
lity of a preclinical model to develop and test such treatments is mandatory. In 1959 Leduc 
was the first to describe the successful formation of liver tumours in mice after injection of 
tumour cells in the spleen.18 After this report numerous other animal models have been des­
cribed for liver metastases of colorectal carcinoma. The ideal animal model should mimic all 
aspects of the metastatic development in humans. For an animal model for liver metastases 
of colorectal origin we defined the following criteria:
1. Tumour cells need to be vital and have metastatic potential.
2. Tumour cells need to reach and invade the liver parenchyma, and subsequently settle 
and grow out into tumour nodules.
3. The model should be efficient (a high proportion of the animals used should exhibit the 
required characteristics).
4. The model should be reproducible.
5. The model should be practical. 45
Ethical considerations are not subject of this review. So far, no model has been developed 
which satisfies all these conditions. As a consequence, choosing an animal model for the stu­
dy of liver metastases requires compromises and choices about the necessary characteristics 
that depend on the purpose of the intended experiments. This overview addresses the (dis) 
advantages of different animal models used for research on experimental liver metastases 
of colorectal origin.
Human versus rodents
Rodents are the most frequently used animals to study carcinomas of colorectal origin. The 
first rats used for studies were domesticated Rattus Norvegicus. These rats were used in 
research already before 1828.19 Based on this strain, various strains of genetically slightly 
different rats have been developed and are used nowadays. Mice are used for animal studies 
since 1900 and originate from the house mouse (Mus musculus). Due to their long history in 
animal science and easy accessibility the use of rodents has many advantages. For example, 
the known <1% incidence of the spontaneous development of CRC in both mice and rats 
limits the occurrence of non-iatrogenic tumours and guarantees a very low risk of violation 
of the experiment.20 Still, the use of rodent models for cancer research is not universally 
accepted, since they might not truly represent the development of tumours in humans. For 
example, although the murine immune system shares many features with the human im­
mune system, they differ on several aspects. Holsapple and co-workers compared the deve-
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lopment of the immune system in rodents and humans. When adjusted for gestation period 
and duration of life some phases of development are delayed in rodents relative to humans.21 
This could influence the mechanisms of carcinogenesis in rodents. However, the fact remains 
that multiple characteristics in human and rodent carcinogenesis are remarkably similar. 
These concern, for instance, overall cancer incidence, mortality rates and age-patterns. Alt­
hough this does not exclude the existence of pathological differences on a molecular level, it 
does suggest that rodents and humans share pathways that are important for cancer deve-
lopment.22,23
In order to review the animal models used for research on liver metastases of colorectal ori­
gin, we will discuss the advantages and disadvantages of the procedures for tumour inocula­
tion. In general, there are two options: transplantation of xenografts in immunodeficient ani­
mals and transplantation of allografts in immunocompetent rodents. This review is focused 
on models using immunocompetent rodents since immunocompetent animals better reflect 
the normal immune status in patients with colorectal carcinomas that develop metastases. 
Also, such animals generally exhibit a more stable health status while their intact immune 
system allows examination of the effects of immunotherapy, which is increasingly investi­
gated as a treatment option for cancer.20,24 For both immunodeficient as immunocompetent 
rodents we will discuss five principal routes to inoculate CRC cells to generate liver metasta­
ses: subcutaneous, intrasplenic, intraportal, intrahepatic and into the colonic wall.
46  L iver m e t a s ta s e s  in  im m u n o d e f ic ie n t  r o d e n ts  ( ta b le  1)
The ability to alter the mouse genome in order to optimize the carcinogenesis of human 
xenografts offers a wide range of possibilities in cancer research.23 The nude mouse is the 
prototype of an experimental rodent that bears congenital thymic aplasia resulting in T- 
lymphocyte-related immune deficiency. Despite the relative fragile health of these animals, 
they are widely used in cancer research.25-27 The major advantage of the possibility to use 
human CRC cell lines in immunodeficient rodents, is the plausible similarity in pathologic 
behaviour to the human situation. Human colon carcinoma (HCC) cells used for implantation 
are derived from either the primary colon- or rectum tumour or from a metastasis. Hypothe­
sizing that the latter possesses a proven metastatic capability, some researchers have used 
cells obtained from a liver metastasis of a CRC patient to induce liver tumours.28-31 
Early studies in immunodeficient mice demonstrated that subcutaneous injection of tumour 
cells does not give rise to liver m etastases.32-34 Subsequently, many researchers have focused 
on intrasplenic injection. Garofalo and co-workers studied the metastatic potential of a liver 
metastasis from the HCC cell line HT-29 in both nude, beige/nude/xid  and SCID mice and 
found liver metastases in respectively 78 %, 100 % and 25 % of the animals, 6 weeks after 
intrasplenic injection. Though this might indicate a higher metastatic potential of nude and 
beige/nude/xid  mice, one should be reluctant to draw this conclusion because these data 
originate from different experiments, reporting also a wide variation in development of lung 
metastases found in animals from different strains. Only 8 % of the SCID mice developed 
lung metastases, in contrast to 100 % of the beige/nude/xid  mice.35 In four separate studies 
in BALB/c nude mice, intrasplenic injection of HCC cell lines, e.g. HT-29-M (cancer cells from
Animal m odels for liver m etastases
a lung metastasis of HT-29), P4733, P10055 and P8589 resulted in approximately 70-80 % 
liver metastases. All animals inoculated with HT-29-M cells developed lung metastases as 
well.31,33,36,37 A similar incidence of liver metastases was reported by Morikawa after intrasp­
lenic injection of another HCC cell line (KM-20). By performing several selection cycles of 
the tumour cells, they reduced the time between inoculation and metastatic development 
from 98 to 50 days.34,38 In none of the studies a splenectomy was performed after tumour 
cell injection.
Cai and co-workers injected tumour cells (HCC HT-29LMM and HCC HCT116) in the portal 
vein of Crl: NU/NU-nuBR nude mice and found liver metastases in all animals.39 In nude rats,
Vogel et al. could induce liver metastases by intraportal injection of HT-29 colon carcinoma 
cells, but not by intraportal inoculation of WiDr colon carcinoma cells.40 Both reports indi­
cated that injection of HT-29 carcinoma cells in the portal vein did result in lung metastases 
in a significant portion of the animals as well. Intrahepatic implantation of HCC cells (unspe­
cified) with metastatic potential has been reported to result in 100 % formation of tumour 
nodules in BALB/c nude mice, although in one study 80 % of the animals also developed 
spleen m etastases.30,41
Next to these heterotopic injection methods, injection of tumour cells into the colonic wall 
has also been used to induce liver metastases. Although it appears likely that such a proce­
dure will mimic the route of dissemination in humans, time for this "primary" tumour to 
grow and metastasize might be too long to be practical, especially when sequential experi­
ments have to be performed. Thereby, although some researchers waited up to more than
100 days after inoculation, liver metastases developed in 0-75 % of the animals.41-46 Fu and --------
co-workers found enhanced formation of liver metastases by inoculation of pieces of HCC in 47  
the colon of SCID and nude mice. This resulted in formation of liver metastases in 80 % and 
60 % of the animals respectively.42 A major improvement of the metastatic rate was observed 
after transplantation of HCC cells derived from liver metastases, resulting in liver metastases 
in all animals already after 10 days. However, 50 % of the animals also developed spleen
m etastases.29,30
In summary, induction of liver metastases in immunodeficient rodents comprises some im­
portant criteria of an animal model very well. Human cancer cells are likely to have a me­
tastatic potential, with ability to invade the liver parenchyma, and subsequently settle and 
grow out into tumour nodules. Lack of an efficient immune system makes these models less 
practical and efficiency seem s to be very dependent on the inoculation method and cell line 
that is used. Intrasplenic as well as intraportal and colonic wall inoculation apparently can 
be quite efficient. Development of lung or spleen metastases is a prominent disadvantage of 
these methods.
L iver m e ta s ta s e s  in  im m u n o c o m p e te n t  r o d e n ts  ( ta b le  2 )
The induction of primary tumours in immunocompetent rodents is generally accomplis­
hed by azoxymethane ingestion or by injections of its metabolite, 1,2-dimethylhydrazine 
(DMH).47,48 DMH-induced colon carcinomas generally do not m etastasize spontaneously to
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Table 1. Animal models for liver metastasis (LM) with immunodeficient rodents (sorted by site and year)
Inoculation
site
Author, year, 
reference
Rodent Cell line no cells 
(x 106)
% Macro­
scopic LM 
(days)
Complications
S u b cu tan e o u s Kyriazis, 1 9 7 8 32 BALB/c n u d e  m ice HCC SW 430 1 a n d  20 0 (62) n r
G iavazzi, 1 9 8 6 33 BALB/c n u d e  m ice HCC (8 k inds) 1-4 0 (3 0 -82) 2 %  p u lm o n a ry  m etas tase s
M orikaw a, 1 9 8 8 34 BALB/c a th y m ic  m ice HCC KM12 1 0 (8 0 -90) n r
C aecal w all M orikaw a, 1 9 8 8 34 BALB/c a th y m ic  m ice HCC KM12 1 20 (8 0 ­
90)
n r
Fu, 1 9 9 1 43 O ut b re d  n u /n u  m ice HCC (2 0  k inds) 8-15  
p iec es  of 
1 m m 3
11 (nr) n r
Fu, 1 9 9 2 42 N u /n u  m ice HCC-CO-3 8-15  
p iec es  of 
1 m m 3
6 0  (nr) n r
SCID HCC 8-15  
p iec es  of
1 m m 3
80 (nr) n r
Furukaw a, 1 9 9 3 44 BALB/c n u d e  m ice HCC COL-2-JCK 50 m g 75 (2 8 ­
42)
n r
Kuo, 1 9 9 5 41 BALB/c n u d e  m ice HCC (8 k inds) 1 piece, 
75 m g
0-75  (84) n r
Sun, 1 9 9 9 29 A thym ic n u /n u  CD-1 
n u d e  m ice
HCC
AC3488UM  1,2
15
p iec es  of 
1 m m 3
100  (10 ) 5 6 %  p e r ito n e a l  see d in g  
1 1 %  m e ta s ta se s  in sp leen
Rashidi, 2 0 0 0 30 BALB/c n u d e  m ice HCC 1 1 o r  2 
p iec es  of 
1 m m 3
100  (10 ) 5 0 %  sp le e n  m etas tase s
F la tm a rk , 2 0 0 4 45 BALB/c n u d e  m ice HCC (12 k inds) tu m o u r  
p iec es  of
2 m m 3
1 (1 2 6 ­
287)
n r
C espedes, 2 0 0 7 46 S w iss N u /N u  m ice HCC HCT-116 2 67 (1 3 0 ) n r
HCC SW -620 0 (130) n r
DLD-1 29 (130) nr
In tra h e p a tic Kuo, 1 9 9 5 41 BALB/c n u d e  m ice M etasta tic  HCC 5 100  (n r)
Non m etas ta tic  
HCC
5 0 (n r) n r
M etasta tic  HCC 1 piece, 
6 m m
100  (n r) n r
Non m etas ta tic  
HCC
1 piece, 
6 m m
0 (n r) nr
Rashidi, 2 0 0 0 30 BALB/c n u d e  m ice HCC 1 1 o r  2 
p iec es  of 
1 m m 3
100  (10 ) 80 %  sp leen  m etas tase s
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Table 1. (cont.)
Inoculation Author, year, Rodent Cell line injected % Macro- Complications
site reference cells (x scopic LM
1 0 6) (days)
In tra sp le n ic  K ozlow ski, 1 9 8 4 36 BALB/c n u d e  m ice HCC HT-29-M 0.5 70 (42 - 1 0 0 %  p u lm o n a ry  m etas tase s
56)
G iavazzi, 1 9 8 6 33 BALB/c n u d e  m ice HCC 2 6 0 -1 0 0  n r
(e .g .P10055 , (90 )
P 8589 , P 4733)
G iavazzi, 1 9 8 6  3 BALB/c n u d e  m ice
HCC1 (e.g.
M 1544,
M 1410)
HCC 1 2
1
0.5
0.1
0.05
100  (4 0 ) n r
100  (3 3 ) n r
83 -1 0 0
(26)
50 (36)
40  (40)
33 (60)
G iavazzi, 1 9 8 6 33 BALB/c n u d e  m ice HCC
(e.g .P10055, 
P 8589 , P 4733)
2 60 -1 0 0
(90)
n r
HCC1 (e.g.
M 1544,
M 1410)
2 100  (40 ) n r
N aito, 1 9 8 7 37 N ude m ice HCC HT-29-M 1 82 (42) n r
Beige n u d e  m ice HCC HT-29-M 1 33 (42) n r
M orikaw a, 1 9 8 8 34 BALB/c a th y m ic  m ice HCC KM12 1 0 (8 0 -90) n r
HCC KM20 1 73 (98) n r
HCC KM 12 2 1 100  (3 5 ­
40)
9%  p u lm o n a ry  m etas tase s
HCC KM20 2 1 100  (50 ) nr
G arofalo, 1 9 9 3 35 N ude m ice HCC HT 29-LM 1 78 (42) 20%  p u lm o n a ry  m etas tase s
B e ig e /n u /x id 100  (42 ) 1 0 0 %  p u lm o n a ry  m etas tase s
SCID m ice 25 (42) 8%  p u lm o n a ry  m etas tase s
In tra p o rta l  Vogel, 1 9 9 8 40 R ow ett H sd :R H -nu / 
nu rats
HCC HT-29 20 Up to  60%  
a t  4-12  
w eeks
Up to  4 0 %  lu n g  m etas tase s  
Up to  5 0 %  p e r ito n e a l 
ca rcinosis
HCC W iD r 20 0%  (120] n r
Cai, 2 0 0 5 39 Crl: N U /N U -nuBR 
n u d e  m ice
HCC HT- 
29LMM
2 100  (7 ­
55)
13%  p u lm o n a ry  m etas tase s
HCC H CT116 2 100  (7 ­
55)
n r
49
1= liver derived
2 = after several passages
nr = none reported
HCC = hum an colon carcinom a
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the liver.20,49 If hepatic metastases develop, it generally takes a long time (20-30 weeks) and 
metastases do not develop synchronously, which renders this model impractical for research 
purposes.20,50 Orthotopic implantation of syngeneic tumour cells is often used as a model for 
primary colorectal carcinoma and has also been used as a model for development of liver 
metastases.
Liver m etastases after orthotopic injection of syngeneic tumour cells
Orthotopic implantation is defined as inoculation of tumour cells in the intestine, e.g. cae­
cum or rectum.51 Bresalier and co-workers studied the development of liver metastases after 
orthotopic implantation of murine colon adenocarcinoma (MCA) cells into the caecal wall of 
conventional BALB/c mice. Injection of the parental cell line resulted in microscopic liver 
metastases in 9 % of the animals after 4 weeks. In order to enhance the metastatic capacity 
of the cell line, tumour cells derived from liver metastases were cultured and again injected 
in the caecal wall, resulting in liver metastases and lung metastases in respectively 100 % 
and 10 % of the animals after 5 weeks.52 Goldrosen and co-workers injected murine co­
lon adenocarcinoma-38 (MCA-38) cells intramurally into the caecal wall of C57Bl/6J mice, 
which led to liver tumours in 65 % of the animals after 8 weeks.53 Inoue and co-workers used 
Fisher rats injected with the RCN-9 cell line. This colon carcinoma cell line, induced by DMH, 
gave rise to hepatic metastases 8 weeks after caecal inoculation in 40 % of the animals.54
--------  Although the above-mentioned results are promising, not all rodent-cell line combinations
50 seem suitable. The models used by Garcia55 and Boni56 did not result in liver metastases 
after intramural injection into the caecum of DHD/K12-PROb cells in BD-IX syngeneic rats. 
Injection into either the mesenteric or antimesenteric site of the colon did not seem to make 
a difference in this respect. Also, the model of Kashtan and co-workers, who injected murine 
colon carcinoma cells CT 26 and MCA-38 into the rectal wall did not result in the develop­
ment of liver metastases in conventional BALB/c and C57Bl/6J mice respectively.57 
In summary, when using an animal model with orthotopic implantation in immunocompe­
tent rodents, certain tumour cell lines seem to have a good metastatic potential and show  
the ability to reach and invade the liver parenchyma. Still, on the whole, this approach suffers 
from a variable tumour incidence, seem s to lack predictability and might not be practical for 
sequential experiments.
Liver m etastases after heterotopic injection of syngeneic tumour cells
Subcutaneous injection of tumour cells does not result in the development of liver metasta­
ses.52,54,58,59 Both intraperitoneal and subcutaneous injection of K12/TR cells in syngeneic 
BD-1X rats induced only peritoneal metastases and no parenchymal lesions, while all ani­
mals developed pulmonary m etastases.55
Liver metastases after heterotopic injection of syngeneic tumour cells into the liver
Subcapsular or intraparenchymal implantation of tumour cells directly into the liver is a
Animal m odels for liver m etastases
widely used method to create liver metastases. Such induction of tumours, either by injec­
tion of a tumour cell suspension or by implantation of a small piece of tumour tissue in 
the liver, has been used by many investigators studying, for example, local therapy of me­
tastases.60-68 Unfortunately, as many studies focus on therapy-related results, exact data on 
efficiency and pitfalls of the procedure are not always reported.61,62,64-67,69,70 Carlsson et al.60 
and Mack et al.71 describe tumour formation five to ten days after intrahepatic injection of 
N-methyl-N-nitrosoguanidine-induced adenocarcinoma cells in Wistar rats, in 83 % and 97 
% respectively.64,68 Intrahepatic inoculation of CC531 tumour cells or tumour fragments in 
WAG/Rij rats results in tumour growth in up to 100 % of the animals after 2 weeks.63,68,72 
Injection of DHDK12/TR cells in BD-IX rats results in hepatic tumour growth in all animals 
after 6 weeks.73 Two studies describe mortality rates of 7 % and 10 % due to anaesthesia, 
but m ost studies do not report if complications occurred using this inoculation method.64,68 
Thus, heterotopic injection of tumour cells or fragments into the liver of an immunocompe­
tent rodent is reproducible and has acceptable complication rates. However, as this method 
does not mimic the generally accepted hypothesis of haematogenous spread of CRC, these 
tumours might not reflect the human situation and therefore react differently to therapeutic 
interventions.
Liver metastases after heterotopic injection of syngeneic tumour cells into the spleen
In 1928 Ewing postulated that tumour cells in the circulation will lodge in the first capillary --------
system they encounter, which thereby constitutes the preferential site of tumour dissemi- 51 
nation.74 Although other factors probably also play a role in the development of metastases,
Ewing's theory is supported by others.75 Intrasplenic injection of tumour cells mimics vas­
cular spread of tumour cells to the liver and has been used by several researchers to create 
liver metastases. Intrasplenic injection of MCA-38 cells with splenectomy after one minute 
in C57Bl/6 mice induced hepatic metastases in 100 % of the animals, although 20 % also de­
veloped pancreatic tumours.76 Casillas et al.77 were able to induce liver metastases after in­
trasplenic injection of poorly differentiated, mucinous colon adenocarcinoma WB-2054-M4 
cells in all involved Wistar/Furth x Brown-Norwegian hybrid rats. Nano and co-workers 
succeeded in tumour growth in a part of the liver of BDIX-rats by clamping one peripheral 
portal vessel before intrasplenic injection of DHDK12/TR tumour cells.78 The latter two did 
not perform a splenectomy after tumour cell injection and do not report growth of tumours 
in the spleen or elsewhere in the abdomen. No liver metastases developed after injection of 
K12-TR cells in the spleen of BD-1X rats, nude rats and nude mice. In these experiments no 
splenectomy was performed and the animals were observed for 9 weeks.58
In summary, intrasplenic injection of tumour cells, with or without splenectomy, appears 
to be a rather consistent method to induce liver metastases, whereas its success is highly 
dependent on the choice of cell line and rodent strain as we described using BD-1X rats and 
K12-TR cells. An advantage of this procedure is that it is relative easy, only requiring a small 
subcostal incision. It has been suggested that subsequent splenectomy might limit periope­
rative mortality and mortality due to tumour growth in the spleen.31
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Table 2. Animal models for liver metastasis (LM) with immunocompetent rodents (sorted by site and year)
Inoculation
site
Author, year, 
reference
Rodent Cell line no cells  
(x 1 0 6)
% M acrosco­
pic LM (days)
Complications
S u b cu tan e o u s B resalier, 1 9 8 7 52 BALB/c m ice MCC 51 B 5 0 (35) 2 0 %  p u lm o n a ry  m etas tase s
MCC 51 B1 5 57  (35) n r
D unn ing ton , 1 9 8 7 58 BDIX ra ts D H D K 12/TR 1 0 (4 1 -1 0 0 ) 1 0 0 %  p u lm o n a ry  m etas tase s
R av ikum ar,198959 W is ta r  ra ts W B-2054-M 1 0 (56) 5 0 %  p u lm o n a ry  m etas tase s
Inoue, 1 9 9 1 54 F isch er ra ts RCN-9 10 0 (56) 6 4 %  p u lm o n a ry  m etas tase s
G arcia-O lm o, 2 0 0 3 55 BDIX ra ts D H D K 12/TR 1 0 (n r) 1 0 0 %  p u lm o n a ry  m etas tase s
C aecal w all G o ldrosen , 1 9 8 0 53 C 57B l/6J m ice MCA-38 1 65-70  (56) n r
B resalier, 1 9 8 7 52 BALB/c m ice MCC 51 B 5 9 (28) n r
MCC 51 B1 5 1 00  (28) 1 0 %  p u lm o n a ry  m etas tase s
Ravikum ar, 1 9 8 9 59 W is ta r  ra ts W B-2054-M 1 2 o u t of 3 rats 
(56 )
n r
Inoue, 1 9 9 1 54 F isch er ra ts RCN-9 10 4 0  (56) n r
K ashtan , 1 9 9 2 57 C 57B l/6J m ice MCA-382 0.1 0 (30) n r
BALB/c m ice CT 26 2 0.1 0 (30) n r
G arcia-O lm o, 2 0 0 3 55 BDIX ra ts D H D K 12/TR 1 0 (n r) 3%  k id n e y  /  s p le n ic /  m e se n te ric  
tu m o u r  fo rm a tio n
Boni, 2 0 0 5 56 BDIX ra ts D H D K 12/TR 1 0 (42) 1 4 %  p e r io p e ra tiv e  m o rta lity
In tra h e p a tic C arlsson , 1 9 8 1 60 W is ta r  ra ts N 1 83 (10) n r
H afström , 1 9 8 4 61 W is ta r  ra ts N 1 n r (nr) n r
M ack,198871 W is ta r  ra ts N 1 > 9 7  (nr) 1 6 %  m o rta lity  d u e  to  e x p e rim e n ­
ta l t r e a tm e n t
R av ikum ar,199162 W is ta r  ra ts W -1756 1 n r (7 ) 100  (35) 1 0 0 %  p u lm o n a ry  m e ta s ta se s  a f te r  
35 days
H illegersberg , 1 9 9 2 63 WAG/Rij ra ts CC531 2 m m 3 87  (22) n r
S tu re s so n ,1 9 9 7 64 W is ta r  ra ts DMH-W 49 0.3 n r (7) 1 1 %  m o rta li ty  d u rin g  an a e s th e s ia
G erm er, 1 9 9 9 65 WAG/Rij ra ts CC531 1 n r  (14 ) n r
R overs, 1 9 9 9 69 WAG/Rij rats CC531 0.5 n r (nr) n r
H agenaars , 2 0 0 0 70 WAG/Rij ra ts CC531 0.05 n r (5) n r
0.1 n r (10 ) n r
Isb e rt ,2 0 0 2 66 WAG/Rij ra ts CC531 1 n r (n r) n r
Lechaux, 2 0 0 2 73 BDIX ra ts D H D K 12/TR 2 100 (43) 1 0 %  m o rta lity  d u e  to  e x p e rim e n ­
ta l t r e a tm e n t
Iv a rsso n , 2 0 0 3 67 W is ta r  ra ts H 1 m m  in 
d ia m e ­
t e r
n r (n r) In tra p e ri to n e a l  tu m o u r  fo rm a tio n  
U nspecified  %.
R o th b a rth , 2 0 0 3 72 WAG/Rij ra ts CC531 0.5 100 (34) n r
D uijnhoven, 2 0 0 5 68 WAG/Rij ra ts CC531 0.05 100 (15) 7%  m o rta lity  d u e  to  a n a e s th e s ia
In tra sp le n ic L afren ie re , 1 9 8 6 76 C 5 7 B l/6  m ice MCA 38 0.1 100 (13) 2 0 %  p a n c re a tic  m e tas tase s  
2%  m o rta lity  d u e  to  su rg e ry
0.3
1
D unn ing ton , 1 9 8 7 58 BDIX ra ts D H D K 12/TR 1 0 (63) n r
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Table 2. (continued)
In ocu lation  A uthor, year, 
s ite  re fe re n c e
R od en t Cell line n o ce lls  
(x  1 0 6)
%  M acro sco ­
p ic  LM (days)
C om p lications
C asillas, 1 9 9 7 77 BD IX rats W B -
2 0 5 4 -M 4
5 1 0 0  (3 5 ) nr
Doi, 2 0 0 2 91 F isch e r RCN -9 3 2 n r (2 1 ) nr
N ano, 2 0 0 4 78 BD IX rats D H D K 12/T R 20 nr (1 0 ) nr
In tra p o rta l B resa lie r , 1 9 8 7 52 B A L B /c  m ice MCC 5 1  B 2.5 0 (3 5 ) nr
MCC 5 1  B 5 7 0 (3 5 ) nr
G old rosen , 1 9 8 6 28 C 5 7 B l/6 R o s
m ice
M CA-38
(liv er
d e r iv e d )4
0 .1 5 9 8  (2 1 ) 6 %  m o rta lity  d u e to  su rg ery
A rcher, 1 9 8 8 89 W is ta r  rats 1 9 2  N Rc5 1 2 - 7 4 1 0 0  (n r) nr
R a v ik u m a r,1 9 8 9 59 W is ta r  rats W B -2 0 5 4 -M 1 5 0  (3 5 ) 0 %  p u lm o n a ry  m e ta s ta s e s
H euff, 1 9 9 3 79 W A G /R ij rats C C 531 1 nr (1 4 ) nr
T h o m a s, 1 9 9 3 81 W A G /R ij rats C C 531 0 .01 8  n o d u les (2 1 ) nr
0 .0 3 2 4  n o du les 
( 2 1 )
nr
0.1 5 0  n o du les 
( 2 1 )
nr
Liu, 1 9 9 5 84 W is ta r  rats L D L X 404 1 0 9 2 .5  (3 0 ) nr
Ku, 1 9 9 9 90 D onryu ra ts A H 1 3 0 3 0.1 1 0 0  (1 0 ) 9 %  m o rta lity
H ag en aars, 2 0 0 0 70 W A G /R ij rats C C 531 1 nr (1 0 ) nr
A lves, 2 0 0 3 85 BD IX rats D H D K 1 2 /T R 20 1 0 0  (1 0 ) nr
M ook, 2 0 0 3 82 W A G /R ij rats C C 531 1,0 0 (2 1 ) nr
2 ,5 2 0  ±  7  n o du les 
( 2 1 )
5 .0 6 7  ±  3 5  no d u ­
les  (2 1 )
7 .5 u n co u n ta b le  
no du les (2 1 )
10
T opal, 2 0 0 3 88 BD IX rats
Q 
D
=c cC 
Q 
H
0 .2 5 -0 .5 >  8 1  (n r ) 1 0 %  m o rta lity
G am b aro ta , 2 0 0 4 80 W is ta r  rats C C 531 5 1 0 0  (2 1 ) nr
Sh in o zak i, 2 0 0 5 “  BD IX ra ts  LMCR- 1 0  9 0 - 1 0 0  ( 1 2 )  nr
R o d e n b a c h ,2 0 0 5 83 W A G /R ij rats  C C 531 4  nr ( 2 8 )  6 %  m o rta lity  d u e to  su rg ery
1 = a fter  several passages
2 = rectal wall
3 = a fter hepatic ischaemia
4 = sm all m esenteric vein/ileocolic vein
5 = bound to spheres
6 = with aggregated cells 
nr = none reported
N  = N -m ethyl-N -nitrosoguanidine induced adenocarcinoma  
H = 1 ,2-dim ethylhydrazine induced
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Liver metastases after injection of syngeneic tumour cells in the portal system
Injection of tumour cell directly in the portal system mimics vascular spread and theoreti­
cally limits the risk of intra-abdominal tumour growth at other places than the liver. Goldro­
sen and co-workers reported that ileocolic vein injection of murine colon adenocarcinoma 
(MCA-38) cells, originated from a liver metastasis, in C57Bl/6R os mice resulted in 98 % 
formation of hepatic foci after 21 days.28 Intraportal injection of W B-2054-M  cells, originated 
from a lung metastasis, yielded only 50 % hepatic m etastases formation in W istar/Furth x 
Brown-Norwegian hybrid rats.59 Several studies reported on the injection of CC531 cells into 
the portal vein of W istar and WAG/Rij rats.70,79,80,80-83 Although not all studies report on exact 
numbers, all available data indicate an almost 100 % success rate in term s of the formation 
of liver m etastases, after a minimum of 10 days and even after inoculation of a small (> 
3x104) number of tumour cells.80-82 Similar success rates have been reported for rat strains 
(W istar and BDIX rats) using the syngeneic tumour cell lines LDLX40 and DHDK12/TR or 
LMCR-, respectively.
Altogether, the data indicate that injection of tumour cells into the portal system reproduci- 
bly results in liver m etastases in almost all animals. Mortality rates due to the operation or 
anaesthesia appear to be limited and vary from 6-10  % .28,83,87,88
Methods to improve of m etastatic rate
5 4  A number of attempts have been made to increase tumour take into the liver. First, several 
authors found that more liver m etastases developed after inoculation of cells from colorectal 
liver m etastases than cells from the primary tumour.28,30,33,35,39,41 Their m etastatic potential 
increased further when cells from these experimental m etastases were inoculated again in 
the spleen and in the colonic wall.29,34,38,52 The m ajor disadvantage of this method is the risk 
of morphological differentiation of the tumour with phenotypical changes, which may influ­
ence both reproducibility and validity of the model. Topal et al. investigated the differences 
in m etastatic potential betw een cells and cell aggregates, using DHD/K12/TRb cells, a tryp­
sin-resistant subtype with a high m etastatic potential. Cell aggregates proved to be more ef­
fective under these conditions.88 Alves e t al. used the same rat strain and cell line but injected 
almost 10 tim es more tumour cells (2 x 1 0 7), which also resulted in liver m etastases in 100 % 
of the animals.85 Hypothesizing that cell-cell interaction plays an im portant role in the m eta­
static capacity of tumours cells implanted in animal models, Sun et al. suggested that the fact 
that tumour fragments are histologically intact, while cell suspensions are not, contributes 
to the success of m etastases formation. After so-called surgical orthotopic implantation of 
small pieces of tumour into the liver, 100 % tumour growth in the liver was indeed reported 
in nude mice.29 Success of tumour fragments was also demonstrated in BALB/c nude mice. 
Both intrahepatic as well as implantation in the colonic wall of tumour fragments of human 
colon cancer, derived from a liver m etastasis of a patient, resulted in 100 % liver m etastases 
after only 10 days.30 However, in a similar model others found hepatic m etastases in only 1 
% of the animals after implantation of pieces of different tumours in the colonic wall.45 It has 
been suggested that only the cell suspension and tumour pieces obtained from colon cancer 
tissue with proven m etastatic capacity will develop into liver m etastases after intrahepatic 
inoculation.41
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Second, to improve m etastatic rates after portal vein injection of tumour cells Archer and 
Gray injected polystyrene micro spheres with surface adherent tumour cells into the portal 
vein. Liver m etastases were found in 100 % of the animals.89 Third, Ku et al. tried to improve 
tumour take in the liver by creating transient ischemia. Adhesion molecules play an essential 
role in tumour cell colonisation and expression of these molecules on epithelial cells is up 
regulated after hepatic ischemia. The researchers postulated that transient ischemia before 
intraportal injection of tumour cells would stimulate the development of liver metastases. 
Indeed, 30 minutes of partial hepatic ischemia resulted in significantly more tumour growth 
in the affected part of the liver.90 Although no exact numbers were given, Doi et al also clai­
med that partial hepatic ischemia before intrasplenic injection of tumour cells increases the 
number of hepatic m etastases in Fischer rats.91
D is c u s s io n
A representative and reproducible animal model for liver m etastases of colorectal origin is 
an essential elem ent for research on this disease. We have evaluated the common animal 
models on efficiency, reproducibility, similarity to the human situation and practical consi­
derations. The actual purpose of the study is the predominant factor deciding which model 
to use. An elem entary distinction for animal experiments is the need for local liver m etasta- 
ses or diffuse m etastases throughout the liver. If one would need a model for resectable he- 55 
patic metastases, one of the m ost important criteria should be the creation of reproducible 
solitary tumours. Subcapsular injection in the liver or intraparenchymal implantation of a 
small tumour piece is reported to result in 100 % hepatic tumours after 15-43 days. This 
method is therefore very efficient and practical, but in return doesn't represent the haemato- 
genous spread of tumour cells in humans. Aiming for diffuse liver metastases, orthotopic in­
jection of tumour cells in the caecal wall provides a model that seems to include all the steps 
of the complex m etastatic pathway, thereby approximating the clinical setting most closely 
This model thus seems interesting for studying the m etastatic pathway of CRC. However, the 
development of liver m etastases is rather unpredictable and inefficient, rendering this ap­
proach less suitable for therapeutic studies. Injection in the spleen or portal system mimics 
haematogenous spread of tumour cells into the liver. These models may achieve induction of 
macroscopic m etastases in up to 100 % of the animals. Most successes have been described 
using C 57B l/6 mice using MCA cells and Wistar, WAG/Rij or BDIX rats with respectively N- 
methyl-N-nitrosoguanidine induced adenocarcinoma cells, CC531 or DHDK12/TR colon car­
cinoma cells. Disadvantages of intrasplenic injection include a reported mortality rate of 10 
% due to operation and the development of splenic, pancreatic and lung m etastases, leaving 
the intraportal injection method as an efficient, reproducible and practical option. Tumour 
growth could, in this model, be limited to a part of the liver by clamping a peripheral portal 
vessel before injection of the tumour cells.
A disturbing factor in the comparison of different models is the use of many different cell 
lines, in some cases selected on their m etastatic potential. Although some strain-cell line 
combinations seem more successful than others, lack of exact information on, for example, 
genotypical and phenotypical characteristics of the m etastases preludes a direct comparison
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of the suitability of the various cell lines. Selection of tumour cells on m etastatic capacity 
seems to result in higher m etastatic rates, however, this might eventually result in strain 
specific resistance to the development and outgrowth of the implanted tumour cells.92 Other 
small variations in technique have been mentioned to improve m etastases rates, but these 
have only been studied in single experiments.
C o n c lu s io n
An ideal animal model for studying liver m etastases of colorectal origin should mimic all 
aspects of the m etastatic development in humans and be practical, predictable and optimal 
in term s of ethical considerations. Based on data available in literature we conclude that 
heterotopic injection of undifferentiated syngeneic tumour cells in immunocompetent ro­
dents covers most of the desired characteristics. Both subcapsular as intraportal injection 
will yield suitable models and the eventual choice will depend on the aim of the study.
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A b s tr a c t
Background
Half of the patients with colorectal cancer develop liver m etastases during the course of 
their disease. The aim of the present study was to assess the efficacy of radioimmunotherapy 
(RIT) with a radiolabelled monoclonal antibody (mAb) to treat experimental colorectal liver 
metastases.
Methods
Male W ag/Rij rats underwent a minilaparotomy with intraportal injection of 1 x 106 CC531 
tumour cells. The biodistribution of m In-labelled MG1, 1 day after intravenous administrati­
on, was determined in vivo and compared with that of an isotype-matched control antibody 
(UPC-10). The maximal tolerated dose (MTD) of 177Lu-labelled MG1 was determined and the 
therapeutic efficacy of 177Lu-MG1 at MTD was compared with that of 177Lu-UPC-10 and saline 
only. RIT was administered either at the day of tumour inoculation or 14 days after tumour 
inoculation. Primary endpoint was survival.
Results
111In-MG1 preferentially accumulated in CC531 liver tumours (9.2 + / -  3.7% ID /g), whereas 
111In-UPC-10 did not (0.8 + /-  0.1% ID /g). The MTD of 177Lu-MG1 was 4 0 0  MBq/kg body 
weight. Both the administration of 177Lu-MG1 and 177Lu-UPC-10 had no side-effects except 
a transient decrease in body weight. The survival curves of the group that received 177Lu- 
UPC-10 and the group that received saline only did not differ (P = 0.407). Administration 
of 177Lu-MG1 RIT immediately after surgery improved survival significantly compared with 
administration of 177Lu-UPC-10 (P = 0 .009) whereas delayed treatm ent did not (P = 0.940).
Conclusion
This study provides proof of principle that RIT can be an effective treatm ent modality for 
microscopic liver m etastases, whereas RIT is not effective in larger tumours.
Radioimmunotherapy and microscopic liver m etastases
C
olorectal cancer (CRC) is the third m ost common cancer affecting both men and wo­
men in the W estern world.1,2 CRC has a worldwide 5-year survival of 4 0 -6 0  % and 
prognosis is mainly determined by the presence of local or distant m etastases.3 The 
liver mostly is the first site of haematogenous dissemination of CRC. Twenty-five % of the 
patients have liver m etastases at the time of presentation and another 25 % of the patients 
with CRC develop liver m etastases within 2 years after surgical resection.45 Development of 
these metachronous liver m etastases is hypothesized to be the result of circulating tumour 
cells or activation of dorm ant microscopic tumours in the liver. A second hypothesis is that 
small liver tumours remain undetected at the time of diagnosis due to the limited sensiti­
vity of imaging techniques.6 For these reasons, patients with stage III colon cancer or high­
risk patients with stage II colon cancer will receive adjuvant treatm ent with 5-fluorouracil 
(5-FU)-based chemotherapy.7 However, pyrimidine-antagonists, such as 5-FU, induce inhe­
rent adverse events and the beneficial effect of adjuvant chemotherapy for stage II patients 
is still subject of debate.8
Radioimmunotherapy (RIT) using radiolabelled monoclonal antibodies (mAbs) directed 
against tumour-associated antigens offers the opportunity to selectively irradiate tumour 
cells, while sparing normal tissues. Several preclinical studies have indicated that RIT can 
be very effective and is at least equivalent to chemotherapy.9-12 Tumour targeting with ra­
diolabelled mAbs has been shown to be particularly efficient in small-volume disease and 
minimal residual disease.11,13 The aim of the present study was to test the hypothesis that 
RIT might be an effective treatm ent modality to treat microscopic and small liver tumours.
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M e th o d s
The in vivo experiments were performed in rats using a MG1 mAb directed against a syngen­
eic colon carcinoma cell line (CC531). Sequential experiments were performed to optimize 
and dem onstrate the feasibility of RIT in this animal model. First, the internalization kinetics 
of the MG1 binding to its antigen were determined. Secondly, the maximum tolerated dose 
(MTD) of 177Lu-MG1 was determined. Next, the biodistribution of 111In-labelled MG1 was 
examined in W ag/Rij rats with CC531 liver tumours and compared with the biodistribution 
of an isotype-matched irrelevant control antibody (UPC10). Subsequently, the therapeutic 
efficacy of RIT using 177Lu-labelled MG1 to treat liver m etastases was tested in two disease 
stages.
Cell line and monoclonal antibody
The syngeneic rat colonic carcinom a cell line CC531 is derived from colonic tumours of W ag/ 
Rij rats exposed to 1,2-dimethylhydrazine.14 CC531 was cultured and suspended as descri­
bed previously.15 MG1 mAb was purchased from Antibodies for Research Applications BV 
(Gouda, the Netherlands). The MG1 mAb is a murine IgG2a antibody, raised by immunization 
of mice with CC531 colon carcinoma cells. It recognizes a cell surface antigen of about 80 
kDa, localizes preferentially in the CC531 tumours when injected in rats, and has minimal
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cross-reactivity with other cell types.16,17 MG1 has a high affinity (Kd = 1.0 nM) for the antigen 
expressed on CC531 tumour cells.18 UPC10 is also a murine IgG2a antibody and is directed 
against p-2-6-linked fructosan (Sigma Life Science, Zwijndrecht, the Netherlands).
Radiolabelling
177Lu is a beta-em itting radionuclide with a maximum beta-energy of 0 .497  MeV and a half­
life of 6.7 days that is commonly used in radioimmunotherapy. 111In has highly similar phy­
sical characteristics to 177Lu but does not em it beta-particles and was therefore used as sur­
rogate radionuclide for 177Lu in in vitro and biodistribution experiments. 111In was purchased 
from Covidien BV (Petten, the Netherlands) and 177Lu from IDB Holland BV (Baarle Nassau, 
the Netherlands). 111In- and 177Lu-labelling of the MG1-DTPA antibody conjugate was per­
formed and radiochemical purity and immunoreactivity were confirmed as described pre­
viously.15 Specific activity of the 111In-MG1 and 111In-UPC10 preparations was 218  kBq/^g 
and 200  kBq/^g, respectively. Specific activity of the 177Lu-UPC10 preparation was 588 kBq/ 
^g. Average specific activity of the 177Lu-MG1 preparations was 49 4  kB q/^g (range 3 9 6 -6 2 9  
kBq/^g). The radiochemical purity of all preparations exceeded 90 %.
Internalization of MG1
64 CC531 cells were cultured to confluency in six-well plates and were incubated with 1.1 kBq 
111In-MG1 for 0.5, 1, 2, 4, 6, and 24 h, in 2 ml binding buffer (RPMI 1640, 0.5 % BSA), at 37 °C 
in a humidified atmosphere with 5 % CO2. After incubation, 1 ml acid wash buffer (0.1 M HAc, 
0.15 M NaCl, pH 2.6) was added for 10 min to remove the membrane-bound fraction of 111In- 
MG1. Subsequently, the cells were harvested from the six-well plates and the amount of acti­
vity was measured in a shielded 3-inch-well-type gamma counter (Wizard, Pharmacia-LKB, 
Sweden). Nonspecific binding and internalization was determined by coincubation with an 
excess of 6.7 nM unlabelled MG1.
Animals
Ten- to 12-week-old male W ag/Rij-rats with a mean weight of 250  g were obtained from 
Charles River Laboratories (Sulzfeld, Germany). Rats were accustomed to laboratory con­
ditions for 1 w eek prior to experimental use and housed under nonsterile, standard labo­
ratory conditions (tem perature 20-24°C ; relative humidity 5 0 -6 0  %; 12 h light/12 h dark) 
on sawdust in filter-topped cages (two or three rats per cage) with free access to animal 
chow (Ssniff Voer, Soest, The Netherlands) and water. All experiments were conducted in 
accordance with the principles laid out by the revised Dutch Act on Animal Experimentation 
(1997 ) and approved by the institutional Animal Welfare Committee of the Radboud Univer­
sity Nijmegen.
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Maximum tolerated dose
Fifteen healthy male W ag/Rij rats were injected intravenously with increasing doses of 
177Lu-MG1 (400 , 600, and 800  MBq/kg, respectively). Five rats were used as controls, recei­
ving an intravenous injection with saline only. Blood samples were collected twice during 
the first week and weekly for the following 7 weeks post injection. White blood cell (WBC) 
counts and platelet counts were analyzed by an ADVIA 120 Hematology System (Siemens 
Medical Solutions Diagnostics, Deerfield, USA). Toxicity was evaluated by monitoring the 
body weight of the animals, general condition, and blood cell counts. When the humane end­
point (>20  % body weight loss, physical inactivity or signs of severe toxicity such as infec­
tions, bleeding, or diarrhea) was reached, rats were killed using O2/CO2 asphyxiation and 
immediately dissected. After 2 months all remaining rats were killed. MTD was defined as 
the highest activity dose (M Bq/kg) at which 100 % of the animals survived without reaching 
the humane endpoint.
Tumour inoculation
The surgical procedures to induce intrahepatic CC531 tumours for the biodistribution and 
therapy studies were carried out under clean conditions. Prior to operation, rats received 
carprofen subcutaneously (5 m g/kg body weight) as analgesic. Immediately after the on­
set of general anaesthesia (isoflurane/O 2/N 2O), the abdomen was shaved and disinfected ---------
with 70 % ethanol. During the operation, rats were placed on a warm m attress to limit heat 65 
loss and chloramphenicol (20 mg/g) eye drops were administered to prevent dehydration of 
the eyes. Rats subsequently underwent a 3-cm midline laparotomy. After the abdomen was 
opened, the intestines were gently lifted out of the abdomen, wrapped in moist gauzes, and 
placed on the left side of the animal, exposing the portal vein. Using a 29-G needle and 1-ml 
syringe, 1 x 106 CC531 tumour cells, suspended in 0.1 ml phosphate-buffered saline (PBS), 
were injected intraportally. To prevent excessive bleeding, the portal vein was punctured 
through m esenteric fat, which served as a tamponade. In addition, the puncture area was 
covered for a few minutes with a cotton stick. The muscular layer of the abdomen was closed 
by continuous absorbable braided 3 /0  sutures and the skin was closed by iron wound clips.
Ten milliliters of warmed saline was injected subcutaneously for rehydration. Rat cages were 
kept on a warmed m attress for the first day. The rats received daily analgesic subcutaneous 
injections for 2 days.
Biodistribution
To determine the uptake of 177Lu-MG1 in normal tissues and liver tumours, the biodistribu­
tion of m In-MG1 was determined after intravenous injection (n = 4). Likewise, the biodis­
tribution of m In-UPC10 was determined in a separate group (n = 4). In this experiment, on 
day 0 eight W ag/Rij rats underwent the surgical procedure to induce intrahepatic tumour 
growth as described above. Twenty days later, rats received a single intravenous injection 
with either 0.4 MBq m In-MG1 (1.7 ^g MG1 mAb per rat) or 0.4 MBq m In-UPC10 (1.9 ^g 
UPC10 mAb per rat), in 0.2 mL PBS, 0.5 % bovine serum albumin (BSA). On day 21 the rats
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were killed using O2/CO2 asphyxiation and dissected. Uptake in normal tissues and liver tu­
mours was measured as described previously.18 The results were expressed as percentage of 
the injected dose per gram tissue (% ID/g).
Radioimmunotherapy
The therapeutic efficacy of RIT with 177Lu-MG1 was determined by the random assignment 
of 56 rats to receive an intravenous injection of either 177Lu-MG1, 177Lu-UPC10 or saline 2 -4  
h after intraportal injection of CC531 cells (n = 14 each). In a separate group, 177Lu-MG1 was 
administered 14 days after tumour cell inoculation (D14-group, n = 14) as shown in Figure 1.
66 Figure 1
Time schedule o f  the radioim m unotherapy experiment.
Figure 2 shows an example of the tumour nodules as present in 
the liver 14 days after inoculation. In all groups, the administe­
red activity was 300  MBq/kg in 0.25 ml PBS in a single dose. The 
primary endpoint was survival. Toxicity was evaluated by moni­
toring body weight and general condition. Rats were monitored 
daily by two experienced and independent animal technicians 
who were blinded to the therapeutic regime. When the humane 
endpoint was reached, rats were euthanized by O2/CO2 asphyxia­
tion and immediately dissected. All remaining rats were euthani­
zed and dissected 120 days after the operation. At dissection, the 
abdominal cavity was carefully inspected, with special attention 
to the liver parenchyma. All macroscopic tumour deposits in the 
liver were resected and weighed. When no macroscopic tumour 
deposits were present, the liver was sliced in 0.5-cm -thick slices 
for routine histopathological hematoxylin and eosin (H&E) stai­
ning. Microscopic tumour growth was scored as either present 
or absent.
Figure 2
Anterior site o f  liver with 
m etastases 14 days a fter in­
traportal injection o f  1x106 
CC531 tumor cells
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Statistical analysis
Statistical analysis was performed using the SPSS software (Chicago, IL) and GraphPad Prism 
version 4 .00 (GraphPad Software, San Diego USA) for Windows. Sample size was determined 
by a power calculation based on an estimated effect of RIT in doubling the survival time of 
the treated animals. Multiple com parisons of dichotomous values were analyzed using the 
one-way analysis of variance (ANOVA)test. Bonferroni correction for multiple testing was 
applied. Survival time was analyzed by Kaplan-M eier method and differences were tested by 
Gehan-Breslow test since no consistent proportional hazard ratio was to be expected. The 
level of statistical significance was set at P < 0.05. Medians, 75 th-, and 25 th survival percen­
tiles and standard error were used to describe continuous data.
R e s u lts
Internalization of MG1
After 6 h, 13 ± 1%  of the incubated m In-MG1 was bound to the target cells. (Fig. 3) MG1 was 
internalized gradually by the target cells: after 6 h, 38 % of the cell-associated m In-MG1 was 
internalized.
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Figure 3
Internalization o f  MG1 in the CC531 
tumour cell. The percen tage a c ­
tivity o f  111In-MG1 present in the 
cell bound fraction  (b lack  squares) 
and in the internalized fraction  
(b lack  circles) is depicted as m ean ± 
standard error on the mean. In ad ­
dition, non-specific binding (white 
squares) and internalization (white 
circles) are given.
time (hours)
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Maximum tolerated dose
Survival of the animals in the MTD study is summarized in figure 4. During the first days 
post injection, all groups receiving 177Lu-MG1 lost weight. After 18 days, 80 % of the animals 
that received either 800  MBq/kg or 600  MBq/kg 177Lu-MG1 had lost more than 20 % of 
their body weight and were euthanized. These rats all showed signs of dehydration and poor 
general condition. There was no diarrhea. At dissection the thymus could not be detected, 
the spleen was small, and the intestines appeared fragile. Moreover, seven of these rats had 
signs of infarction and bleeding in the kidneys, testicles, and around the spleen. The rats that 
received 40 0  MBq/kg lost a maximum of 7 % of their body weight, reaching nadir on day 5, 
and showed signs of clinical discom fort such as inactive behavior during this period. The 
control animals on average gained 3 % of their relative body weight during the correspon­
ding period. After 5 days the animals that had received 40 0  MBq/kg started to gain weight 
again, as the control animals.
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Figure 4
Survival curves o f  the anim als in the MTD study. Lines represent groups receiving escalating doses o f  177Lu- 
MG1; 400 M Bq/kg (white squares), 600 M Bq/kg (b lack  triangles) and 800 M Bq/kg (b lack  circles). Note 
that the control group is not represented in the analyses, since all rats survived the experim ental period.
WBC and platelet counts are shown in Figure 5. All groups showed a similar decrease in 
WBC during the first 14 days post injection, with minimum levels of less than 1 % of the 
initial value. In all remaining rats, WBC started to recover from day 20, reaching a normal 
WBC count after 2 months. Platelets started to decline 4 days after injection and started to 
recover after 2 weeks.
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Figure 5
H aem atological toxicity o f  177Lu-MGl. Both WBC (A) and p latelet counts (B) are given. Lines represent 
groups receiving escalating activities o f  177Lu-MG1; 400 M Bq/kg (white squares), 600 M Bq/kg (b lack  tri­
angles) and 800 M Bq/kg (b lack  circles) and the control group (white circles). Symbols represent mean 
values with standard error. No dose-response pattern was seen in these groups.
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Biodistribution of 111In-MG1
The biodistribution of 111In-MG1 and 111In-UPC10 in rats with intrahepatic CC531 tumours 
is summarized in Figure 6. There was high and specific uptake of 111In-MG1 in the tumour 
of 9.2 ± 3.7 %ID/g, as compared with the tumour uptake of 111In-UPC10 (0.8 ± 0.1 % ID /g) 1 
day post injection. Uptake of MG1 in other organs did not exceed 1.2 %ID/g. The tumour-to- 
blood ratio of m In-MG1 was 7.1 ± 1.3 compared with 0.3 ± 0.01 for m In-UPC10.
Figure 6
Biodistribution. The uptake o f  
IUIn-MGl (b lack  bars) and 111In- 
UPC10 (white bars) on day 20  is 
depicted as m ean ± standard error 
o f  the mean.
Efficacy of radioimmunotherapy using 177Lu-MG1
The relative body weight of the rats during the first 30 days of the study, expressed as the 
percentage of the body weight on the day of surgery, is depicted in Figure 7. Compared with 
administration of the saline only, administration of both 177Lu-MG1 and 177Lu-UPC10 reduced 
body weight, indicating a nonspecific radiation effect. On either time point, 5 days after in­
jection of the radiopharmaceutical, the relative body weight decreased about 4 %. However, 
no other signs of clinical discomfort were observed during the initial posttreatm ent period, 
and body weight recovered quickly in the course of the study. In addition, no signs of wound 
healing disorders were observed.
One rat of the group treated with 177Lu-MG1 on day 14 was euthanized without comple­
tely fulfilling the humane endpoint criteria and was therefore excluded from the survival 
analysis. Altogether 50 rats reached the humane endpoint in the course of the experiment 
and were killed. All of these rats, including all rats in the control group, had developed liver 
tumours at that moment. The mean tumour weight of the group treated with 177Lu-MG1 on 
day 14 was 15 ± 1 g and was significantly higher than the mean tumour weight of each of the 
other groups (P < 0.05 for each comparison). Twenty-seven rats also had tumour nodules
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elsewhere in the abdomen, including at the initial puncture site. One rat of the group treated 
with 177Lu-MG1 on day 0 developed jaundice 90 days after start of the experim ent and was 
found to have an obstructing tumour at the liver hilus. One hundred and twenty days after 
tumour cell inoculation five rats (three in the group that was treated with 177Lu-MG1 on day
0 and one each in the groups treated with 177Lu-UPC10 on day 0 or 177Lu-MG1 on day 14) 
were still alive, without clinical signs of liver tumours. At dissection none of the rats had 
macroscopic tumour growth. Histopathological examination of the livers showed no micro­
scopic tumour nodules either.
0 5 10 15 20 25 30
days after surgery
Figure 7
Course o f  body weight. The mean (± standard error o f  the mean.) relative body weight, with respect to 
preoperative weight, is given f o r  the MG1 D0-group (b lack  squares), MG1 D14-group (b lack  triangles), 
UPC10-group (white circles) and the control group (white squares with interrupted line).
The survival curves are shown in Figure 8. Statistical analysis showed that the survival cur­
ves of the groups receiving 177Lu-UPC10 or the saline only did not differ (P = 0.518). There­
fore, in further analysis, the results were compared with the group receiving 177Lu-UPC10. 
First, Kaplan-M eier survival analysis was performed, which showed that overall survival 
curves of the groups treated with 177Lu-MG1 and 177Lu-UPC10 were significantly different (P 
= 0 .029). Administration of RIT immediately after surgery improved survival significantly 
compared with administration of the control antibody (P = 0 .009) and compared with de­
layed treatm ent (P = 0.027). Administration of RIT 14 days after tumour inoculation did not 
improve survival compared with administration of the control antibody (P = 0.940). The 
median survival of the animals treated with 177Lu-UPC10 was 46  ± 6 days. The 75th and 25 th 
survival percentiles of this group were 34 ± 9 days and 49  ± 3 days, respectively. The median 
survival of the rats treated with 177Lu-MG1 on the day of surgery was 55 ± 24 days and the 
75th and 25 th survival percentile of this group improved to 50 ± 7 days and 97  ± 1 days, res­
pectively
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Figure 8
Survival curves o f  the animals 
in the therapy study. Lines 
represent groups receiving 
300 M Bq/kg 177Lu-MG1 on DO 
(b lack  squares), 300 M Bq/ 
kg 177Lu-MG1 on D14 (black  
triangles), 300 M Bq/kg 177Lu 
-UPC10 (white circles) or the 
saline only (white squares with 
interrupted line).
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D is c u s s io n
---------  The results of the present study show that RIT can increase survival in rats with microsco-
7 2  pic tumours of colorectal origin in the liver. A well-characterized rat model was used in the 
study. The syngeneic rat colon carcinom a cell line CC531 exhibits a reproducible growth 
pattern in W ag/Rij rats.19 We already dem onstrated that MG1 has a high affinity for its an­
tigen on the CC531 cell membrane.18 In addition, the present data dem onstrate that MG1 
is gradually internalized by CC531 cells, which is a favorable characteristic for RIT since it 
increases tumour retention of the radiolabel and consequently enhances the radiation dose 
absorbed by the tumour. The remarkable decrease in cell surface binding of the labelled an­
tibody between 6 and 24  h might indicate either release of the radiolabelled mAb from the 
cell surface or shedding of the antibody-antigen complex after internalization.
Both intrasplenic and intraportal injection of (syngeneic) tumour cells in rodents may re­
sult in liver m etastases with a high reproducibility.20 In the present model, tumour growth 
in the liver occurs in 100 % of the untreated animals, with no mortality or weight loss due 
to the surgical procedure. The in vivo tumour targeting potential of MG1 mAb for CC531 
liver tumour is demonstrated by its specific accumulation in CC531 liver tumours and is in 
concordance with findings in previous animal studies on peritoneal carcinom atosis.15,16,19 In 
addition, the MTD of 177Lu-MG1 for healthy male W ag/Rij rats was found to be approximately 
400  MBq/kg with dose-limiting hematological toxicity. For tumour-bearing rats, the MTD 
is estimated to be lower, but will at least be 300 MBq/kg as shown in previous studies.12,18 
Currently, adjuvant treatm ent strategies after surgery focus on the rate of dissemination at 
the time of diagnosis. For patients with stage III CRC, adjuvant 5-FU-based chemotherapy 
after resection of the primary tumour is most often recommended to improve disease-free 
survival.7 However, pyrimidine antagonists, such as 5-FU, have inherent adverse events. Ad­
juvant systematic or regional therapies after surgery are also hypothesized to decrease re­
lapse rates in patients with stage II colon cancer. However, a recent system atic review by
1.00'
0.75-
0.50-
0.25-
0 .00 '
days after injection
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Figueredo et al. showed that adjuvant systemic 5-FU-based chemotherapy has only small 
benefit for patients with stage II CRC and should therefore only be considered in a carefully 
selected group. Regional adjuvant chemotherapy (by portal vein infusion) has shown similar 
results, but is mostly abandoned because of the technical difficulties of the procedure. As for 
specific immunotherapy, the authors report enhanced recurrence-free survival, but data on 
overall survival are lacking due to the short follow-up period. Moreover, some of these tre ­
atments (for example, active specific immunotherapy with autologous tumour cell vaccines) 
are complicated procedures, requiring a dedicated laboratory to obtain an active vaccine and 
a responsive host. Finally, reports on other adjuvant treatm ents have been limited and did 
not show significant beneficial effects.8
RIT with radiolabelled mAbs directed against tumour-associated antigens has evolved from 
an appealing concept to one of the standard treatm ent options for patients with non-Hodg­
kin's lymphoma.21,22 RIT offers the opportunity to selectively irradiate tumour cells, while 
sparing normal tissues. Another advantage of RIT is the crossfire effect, which means that 
nontargeted cells are irradiated due to radiolabelled antibody uptake by surrounding cells.
Because of the relative radiosensitivity of colorectal carcinoma and the availability of mAbs 
against CRC-associated antigens, the efficacy of RIT using radiolabelled mAbs against CRC 
has been investigated in various preclinical clinical studies. For example, Behr et al. demon­
strated that, in a nude-mouse model for lung m etastases of CRC, RIT (131I-anti-CEA antibo­
dy) cured half of the animals whereas equitoxic chemotherapy only prolonged life for a few 
weeks.23 Aarts et al. demonstrated that adjuvant RIT (177Lu-MG1 mAb) after debulking of 
peritoneal carcinom atosis in a rat model improved survival, whereas adjuvant heated intra­
peritoneal chemotherapy did not and was considered more toxic.12 73 
To date, only a limited number of clinical trials have studied the effect of RIT in CRC patients.
A review of this small number of phase I/II RIT trials in patients with gross m etastatic disease 
precludes any firm conclusion on the potential of RIT in the treatm ent of CRC.24 Most phase 
I/II clinical RIT studies were carried out in pretreated patients with bulky disease, while it 
has been shown that RIT may be more effective in patients with small-volume disease. So far, 
only one study investigated the efficacy of adjuvant RIT in patients with minimal dissemi­
nated disease.25 In this phase II study 21 patients with small-volume m etastatic disease (<3 
cm), all either chem orefractory or chemointolerant, were included. Fourteen patients had li­
ver m etastases; remaining patients had either lung m etastases or peritoneal carcinomatosis.
Patients received a single injection of 131I-MN14 IgG at 2.2 GBq/m 2 (MTD) and follow-up was 
as long as 36 months. The therapeutic infusion was tolerated well by all patients, with mild 
nausea as the only acute side-effect and only mild leuco- and thrombocytopenia. Response 
was measured in 11 out of 21 patients (52 %), which is similar to response rates achieved 
with 5-FU/leucovorin-based chemotherapeutic regimens.
Our results support the suggestion that RIT could be efficacious in CRC patients with small 
liver tumours that cannot be diagnosed at the time of surgery of the primary tumour and 
constitute an enhanced risk of disease recurrence. The survival analysis of this study shows 
that immediate administration of adjuvant RIT will mainly result in an improvement of late 
survival. The data suggest that RIT delays tumour growth in early stages of m etastatic de­
velopment, but does not seem to affect the number of cures and is not effective in animals 
with larger liver tumours, as demonstrated in the group receiving RIT 14 days after tumour 
inoculation. For as yet unknown reasons the tumour weight in this group was found to be 
higher than in the other groups. One rat that was treated with the radiolabelled irrelevant
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antibody (UPC10) did not develop any liver tumours. Most likely, this rat did not receive the 
proper tumour cell inoculation at the start of the experiment.
The marked difference in survival between early and late administration of RIT could very 
well be the result of the inverse correlation betw een uptake and consequent therapeutic ef­
ficacy of radiolabelled antibodies and tumour size.26,27 The growth of minimal disease into 
larger tumours has shown to have a negative effect on the therapeutic efficacy of radiolabel­
led mAbs.28 These conclusions are supported by the outcome of clinical studies dem onstra­
ting that tumour targeting with radiolabelled mAbs is particularly efficient in small-volume 
disease and minimal residual disease.23,25 Moreover, the current study shows that RIT can 
be administered intravenously in a single dose and does not show m ajor side-effects such 
as infections or impaired wound healing. The latter is in line with the findings of Aarts et al., 
who observed that RIT did not impair wound healing.29
If application of RIT is considered in a clinical setting, where surgery-related complications 
could require intensive care for the patient, special care should be taken to ensure minimal 
exposure of medical personnel to radiation. The most promising radionuclides for adjuvant 
RIT in CRC are beta-em itting isotopes such as 131I, 90Y, and 177Lu.30 An important advantage 
of using 177Lu for RIT (as compared with 131I) in a clinical setting is the low abundance of 
gamma radiation (11 %, 208 keV), lowering the radiation burden to the environm ent and 
allowing diagnostic imaging after a therapeutic dose RIT has been administered to a patient.
7 4  C o n c lu s io n
This study provides proof of principle that RIT using 177Lu-labelled MG1 mAb at MTD incre­
ases survival in rats with microscopic liver m etastases and encourages the implementation 
of clinical trials studying the effect of RIT in CRC patients undergoing surgery and at high 
risk for disease recurrence. Further preclinical studies will be performed in this well-defined 
animal model to optimize the use of (adjuvant) RIT in the treatm ent of CRC and to compare 
these effects with the treatm ent of CRC with adjuvant chemotherapy
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A b s tr a c t
Background
During the treatm ent of colorectal liver m etastases evaluation of treatm ent efficacy is of ut­
most importance for decision making. The aim of the present study was to explore the ability 
of preclinical imaging modalities to detect experimental liver metastases.
Methods
Nine male W ag/Rij rats underwent a laparotomy with intraportal injection of one million 
CC531 tumour cells. On day 7, 10 and 14 after tumour induction, sequential PET, CT and MRI 
scans were acquired of each rat. PET and CT scans were acquired with a small-animal PET/ 
CT (Siem ens Inveon) scanner one hour after injection of 10 MBq 18F-FDG. Intraperitoneal 
injections of ioversol and intravenous injections of Fenestra LC® were used to improve alig­
nment of the liver parenchyma on the CT images. MRI was performed on a 7T small-animal 
MRI scanner (Bruker BioSpin ClinScan), using ultrasmall superparamagnetic iron oxide to 
enhance contrast. At each time point, three rats were euthanized and the m etastases in the 
liver were documented histologically. Topographically, the liver was divided in 8  segments 
and the image findings were compared on a segm ent-by-segment basis with the histopatho- 
8 0  logical findings.
Results
64  Liver segments were analyzed, of which 20 contained tumour deposits. The overall sensi­
tivity of PET, CT and MRI was 30% , 25%  and 20% , respectively. For the detection of tumours 
with a histological diameter exceeding 1 mm (n=8), sensitivity of PET, CT and MRI was 63% , 
38%  and 38% , respectively. Overall specificity of PET, CT and MRI was 98% , 100%  and 93% , 
respectively. Although image quality of all three modalities was considered reasonable to 
good, quality-improving factors are suggested for each modality.
Conclusion
This study on small-animal imaging modalities for detection of liver m etastases showed en­
couraging detectability and sensitivity for preclinical imaging of small liver tumours. These 
results indicate that these imaging modalities can be used to monitor growth of liver meta- 
stases in rats.
Detection of liver m etatastases by PET, CT and MRI
Detection and monitoring of colorectal liver m etastases has a major influence on the treatm ent strategy and prognosis of colorectal cancer (CRC) patients. Detailed infor­mation on the presence, localization, size and number of m etastases influences clini­
cal decision making in term s of surgery, adjuvant therapy and palliative therapy regimens.1,2 
Moreover, the use of imaging as an early marker for response is im portant because it allows 
a window of opportunity during which treatm ent regimens can be tailored accordingly, re­
sulting in a decrease in morbidity and undue costs.3 Also, research on the potential effect of 
new therapeutic agents, like antibody-based agents and other biologicals, depend highly on 
response monitoring.4-6 Tumour visualization is traditionally performed using anatomical 
imaging techniques such as ultrasound (US), computed tomography (CT) and magnetic re­
sonance imaging (MRI).7 In daily practice 18F-2-deoxy-2-fluoro-D-glucose-Positron Emission 
Tomography (FDG-PET) is mainly performed when CT or MRI are not decisive. Functional 
imaging by FDG-PET is considered to be of additional value because of high tumour-detec- 
tion rates.
Adequate small-animal imaging of colorectal liver m etastases can be of value for several 
reasons; (1) the efficacy of new therapeutic agents can be studied in preclinical models, in 
which non-invasive response monitoring does not only limit the number of animals needed, 
but also mimics the clinical situation, (2) it allows preclinical studies on the role of different 
imaging modalities on decision making in colorectal cancer patients with liver metastases 
and (3) it could be used in studies on multimodality imaging, which is considered to enhance 
diagnostic information. During the past decade, new animal imaging modalities have been
developed and improved. The aim of the present exploratory study was to determ ine image ---------
quality, sensitivity and specificity of three preclinical imaging modalities to detect small liver 81 
m etastases in a rat model: PET, CT and MRI.
M a te r ia l  a n d  m e th o d s
Animals, cell line and surgical procedure
Twelve 10-12-w eek-old  male W ag/Rij rats, with a mean weight of 254  g, were used (Charles 
River Laboratories, Sulzfeld, Germany). They were accustomed to laboratory conditions for 
one week before use and housed under non-sterile, standard laboratory conditions (tem ­
perature 20-24°C , relative humidity 5 0 -6 0  %, 12-h light-dark cycle), with free access to 
animal chow and water. All experiments were conducted in accordance with the principles 
laid out by the revised Dutch Act on Animal Experimentation (1997 ) and approved by the 
institutional Animal Welfare Committee of the Radboud University Nijmegen.
The syngeneic rat colonic carcinom a cell line CC531 is derived from colonic tumours of W ag/ 
Rij rats exposed to 1,2-dimethylhydrazine.8 CC531 cells were cultured and suspended as des­
cribed previously.9 All surgical procedures were carried out under clean conditions. Tumour 
inoculation was performed via a midline laparotomy and portal vein injection as described 
previously.10 Rat cages were kept on a warm m attress for the first 24  h after operation. Be­
fore surgery and on the first and second day thereafter, analgesia was given in the form of 
subcutaneous carprofen injections (5 ^g per 100 g bodyweight).
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Study design
On day 0 all rats underwent the surgical procedure as described above. On day 7, 10 and 14 
after the operation all rats underwent PET/CT and MRI under general anaesthesia (isoflu- 
rane, oxygen and nitrous oxide). At each time point, 3 rats were euthanized using oxygen/ 
carbon dioxide asphyxiation and immediately dissected. The liver was fixed in formalin and 
embedded in paraffin in the anatomical position and cut in the coronal plane for routine 
histopathological haematoxylin & eosin (H&E) staining (5-^m  thick slices at each 1 mm of 
liver). To determine the localization of each lesion, the liver was topographically divided 
into eight segments (right/left, ventral/dorsal, cranial/caudal). Of each imaging modality, 
the m etastases detection rate in each segment was compared with the histopathological fin­
dings (12 .5x  magnification).
Micro-PET imaging
PET images were acquired with an Inveon small-animal PET/CT scanner (Siemens Pre­
clinical Solutions, Knoxville, TN, USA) with an intrinsic spatial resolution of 1.5 mm.11 All 
rats were fasted 6 hours before an intravenous injection of 10 MBq 18F-FDG (Cyclotron BV, 
Amsterdam, the Netherlands). One hour after injection the animals were placed in a prone 
position in the scanner and body tem perature was maintained at 37 °C by placing the rats
---------  on a warmed mattress. PET emission scans were acquired for 15 minutes. Scans were re-
8 2  constructed using Inveon Acquisition Workplace software version 1.2 (Siemens Preclinical 
Solutions, Knoxville, TN, USA). PET reconstruction was performed using an ordered subset 
expectation maximization-3D/maximum a posteriori (OSEM3D/MAP) algorithm with the 
following param eters: matrix size 256  x 256  x 159, pixel size 0.43 x 0.43 x 0.8 mm3 and a 
uniform variance MAP smoothing param eter of p= 0.05.
Micro-CT imaging
CT was performed in the same imaging session as PET, avoiding the need to reposition the 
animals. CT images were acquired with the same Inveon animal PET/CT scanner. A two- 
bed-positions scan was acquired with 20%  overlap (80 kV, 500  ^A, exposure time 300  ms 
per step, 360° rotation in 180 steps, low magnification, bin by 4, 0.5 mm aluminium filter). 
Two hours prior to scanning rats received 1.5 mL of a reticuloendothelial system -specific 
contrast via the tail vein (glyceryl 2-oleoyl 1, 3-bis [7-(3-am ino-2, 4, 6-triiodophenyl)] alka- 
noate, Fenestra LC; Advanced Research Technologies, Inc, Montreal, Quebec, Canada). Twen­
ty minutes prior to scanning rats were given an intraperitoneal injection of 1.5 mL iover- 
sol (Optiray 320; Covidien, 1:2 dilution). Scans were reconstructed using COBRA software 
version 6 (Exxim Computing Corporation, Pleasanton, USA) using a proprietary algorithm 
(SAMARA) with a Shepp-Logan reconstruction filter, a polynomial based soft tissue beam 
hardening correction and a medium noise-ring artefact reduction. The reconstructed scans 
had the following param eters: matrix size 768 x 768  x 922, pixel size 0.11 x 0.11 x 0.11 mm3.
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Micro-MR imaging
All MRI experiments were performed on a 7T small animal ClinScan 7 0 /3 0  USR (Bruker 
BioSpin, Ettlingen, Germany). The scanner has a B-GA 20S gradient insert with a clear bore 
size of 2 0 0  mm in diameter, maximum gradient strength of 2 9 0  m T/m  and a slew rate of 
1160  T /m /s . The ClinScan is interfaced with the Siemens Magnetom Avanto Syngo user in­
terface (Siemens Medical Solutions, Erlangen, Germany). A dedicated 50x 70  mm homebuilt 
transm it/receive microstrip RF surface coil was used with a customized plastic cradle to 
accommodate the rat in a stable prone position to reduce motion artefacts as described in 
detail by Gamborota et al.12 One day prior to scanning, the rats were given an intravenous 
injection of 0.1 mm ol/kg ultrasmall superparamagnetic iron oxide (Sinerem; Guerbet Group 
Villepinte, France) to increase liver to tumour contrast. During all measurements the body 
temperature and breathing frequency of the rats were monitored using the MR compatible 
model 1025 monitoring and gating system (SA Instruments, Stony Brook, NY, USA). The body 
temperature was kept constant at 37±1  °C with a small rodent heater system (SA Instru­
ments, Stony Brook, NY, USA) and the breathing cycle was kept constant at 4 5 ± 1 0  tim es/m in 
for stable respiratory triggering to further reduce motion artefacts. After initial imaging of 
the liver with a fast Gradient Echo Localizer, 54 contiguous coronal Turbo Spin Echo (TSE) 
images (i.e. parallel to the RF coil) and 64  contiguous TSE sagittal images were acquired fol­
lowed by a FLASH 3D VIBE. The TSE images were used for anatomical localization of the liver 
and detection and m easurem ent of the tumours. The FLASH 3D VIBE was used for additional
anatomical localization of the tumours especially in relation to the vessels in the liver. Ima- ---------
ging param eters were: For the TSE images: Field Of View (FOV) = 120x 120  mm, matrix size 83 
= 2 5 6x 256 , slice thickness = 0.7 mm, Repetition Time (TR) = 1 3 5 0 ± 1 5 0  ms, Echo Time (TE)
= 34 ms, Turbo Factor = 7, Total Acquisition time (TA) « 6 min. To reduce motion artefacts, 
all TSE acquisitions were triggered in real time by the breathing cycle of the rat so that, for 
each image, each set of k lines, was acquired in the same phase of the breathing cycle. This 
caused the small variations in TR. For the FLASH 3D vibe: FOV = 1 2 0 x 1 2 0 x 1 2 0  mm, matrix 
size = 3 8 4 x 3 8 4 x 3 8 4 , TR = 40 ms, TE = 1.2 ms, TA = 19:43  min.
Figure 1
Anterior site o f  liver with m etastases 14 days a fter in­
traportal injection o f  1.106 CC531 tumour cells, showing 
a large confluent (13 mm diam eter) tumour on the right, 
ventral, cranial side and multiple sm all tumours a t other  
sites (arrows).
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Image analysis
The images were arranged randomly and blinded interpretation was done by independent 
experts. MRI and CT images were analyzed by two radiologists (H.D. and R.M., respectively). 
PET images were reviewed by a nuclear medicine physician (M.G.). Experts were asked to 
record the presence of intrahepatic lesions in each liver segment. When lesions were pre­
sent, they were asked to describe the localization (e.g. segment) and estimated size of the
6 largest lesions. FDG uptake was scored semi-quantitatively on a 1-4 scale as well as by 
drawing regions of interests (ROIs) centered over the tumours and the intestines without 
correction for partial volume effects. The mean amount of activity, expressed as the standar­
dized uptake value SUV (body weight), was calculated. The imaging findings were then com­
pared with histopathological findings on a segm ent-by-segment basis.
Data analysis
The sensitivity and specificity of each imaging modality was determined. Regression analysis 
of the detection rate of each modality as a function of the size of the lesions was performed. 
Retrospectively, the chronological detection of growing m etastases was analyzed. In this ex­
ploratory study the number of observations was limited and the data were not independent, 
so no statistical level of significance was determined.
84
R e s u lts
Surgical procedure
One rat died shortly after the operation, probably due to hypothermia. All other surgical 
procedures went uneventfully. Figure 1 shows a typical image of hepatic CC531 tumours, 14 
days after tumour inoculation.
Figure 2
A typical exam ple o f  a 1.3 mm lesion in the left, ventral, cranial segm ent o f  the liver a t  dissection (A), the 
corresponding m icroscopic view (B, 12.5x m agnification), 18F-FDG PET im age (C), CT im age (D) and MRI 
im age (E).
Detection of liver m etatastases by PET, CT and MRI
Image quality
A typical example of a 1.3 mm lesion in the liver at dissection, the corresponding microscopic 
image and the corresponding PET, CT and MRI images are displayed in Fig. 2. Image quality 
of the PET images was judged as reasonable. Interpretation of a few images was impeded 
due to difficult alignment of the liver. Moreover, enhanced uptake in the laparatomy wound 
and physiological uptake of FDG in the intestines complicated correct interpretation of the 
PET images, causing false positive readings in 2 0 /4 4  cases. (See Fig 3A and 3B) The mean 
SUV of the tumours was 2.7 (range 0.7 -  8.4), whereas the mean SUV of the intestines was 1.9 
(range 1.2 - 4.8). The mean ratio of the SUVmean (tumour): SUVmean (intestines) was 1.5.
The animal CT scanner is a conventional scanner, with an average scan time of 15 minutes 
per rat, inevitably causing artifacts by breathing motion. Breathing artefacts appeared as 
blurring of the structural contours and often also as doubling or tripling of these contours.
They can seriously deteriorate image quality and therefore hinder correct image interpreta­
tion. (see Fig. 3C) Moreover, beam hardening influenced image quality of the CT-scans. (Fig.
3D) Image quality for MRI was judged as good. At the post-contrast TSE images the liver 
was dark grey and the m etastatic lesions hyperdense (white), facilitating detection of the 
tumours. However, the quality of the dorsal planes was lower than the quality of the ventral 
planes, since the coil was localized at the anterior side of the animal. Some motion artefacts, 
mainly due to respiration and intestinal motility, were present. However, because image ac­
quisition was triggered by movement in the transverse plane, the artefacts were not present
in the coronal plane and did not disturb the interpretation of the liver region (see Fig. 3E). ---------
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Figure 3
Typical findings and artefacts (indicated with arrow s and lines) on PET, CT and MRI. Misinterpretation on 
PET by enhanced FDG uptake in the laparatom y wound (A) and by physiological uptake o f  FDG in the intes­
tines (B). Breathing artfecats on CT a t  the level o f  the diafragm  (C). Beam  hardening artifacts (D). Motion 
artifacts in the saggital p lane on MRI (E).
Per-segment analysis
Of the 64 segments (8 rats with 8 segments in the liver), twenty segments contained tu­
mours at the time of dissection. The largest tumours in these segments had diam eters of 
<0 .50 mm, 0 .50-1 .00  mm and >1.0 mm in 3, 9 and 8 segments respectively. Forty-four of the 
64  segments did not contain any microscopically detectable tumours. The sensitivity and 
specificity of each imaging modality as determined for different tumour sizes are summari­
zed in Table 1. Overall sensitivity of all modalities was poor (20-30% ). However, the overall
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specificity was high, especially for PET and CT (98%  and 100% , respectively), whereas the 
specificity of MRI was 93% . The sensitivity of the three modalities was similar for tumours 
exceeding 0.50 mm in diameter. The sensitivity for detecting tumours with a diameter lar­
ger than 1.00 mm was 63% , 38%  and 38%  for PET, CT and MRI respectively, without major 
changes in the specificity of the three modalities. This positive correlation betw een tumour 
diameter and sensitivity of each modality was confirmed by regression analysis. The corre­
lation coefficient (R) between PET, CT and MRI and tumour diameter was 0.42, 0 .30 and 0.43 
respectively, indicating a moderate correlation.13
PET CT MRI
«»ver&ll
sensitivity 30% (6/20) 25% (5/20) 20%  (4/20)
specificity 98% (43/44) 100% (44/44) 93%  (41/44)
tu m o u r > 9.SH mm
sensitivity 35% (6/17) 18% (3/17) 24% (4/17)
specificity 98% (46/47) 91% (43/47) 98% (46/47)
tunw uis > 1.00 ra n
sensitivity 63% (5/8) 38% (3/8) 38% (3/8)
specificity 96% (54/56) 93% (52/56) 96% (54/56)
Table 1
Sensitivity and specificity o f  preclinical IBF-FDG PET, CT and MRI f o r  the detection o f  sm all liver m etastases 
-------  in rats.
86
In retrospect, all scans of the rat with the largest tumour at day 14 were analyzed and the 
results are summarized in Figure 4. On day 10 after injection, both PET and MRI detected a 
tumour in the same liver segm ent in this rat. On day 7 after injection MRI also detected a 1 
mm lesion in this segment. At that time point, PET only revealed a lesion with low uptake 
in another segm ent (right, dorsal, caudal side of the liver), m ost likely due to physiological 
uptake in the intestines (not shown). On the CT-scans of the same animal no tumours were 
detected on day 7 or 10 after injection.
D is c u s s io n
The results of this study dem onstrate that small animal imaging can be used to monitor tu­
mour growth in rats. Sensitivity of all modalities correlated with the diam eter of the tumour. 
Small tumours with a diameter of approximately 1 mm can be detected by FDG-PET with 
a sensitivity >60% , whereas the sensitivity of CT and MRI for detecting these lesions was 
38% . Specificity of all three modalities were high, allowing monitoring of therapy-response 
in future studies. Because of the limited number of observations, these results should be 
considered as an indication of the in vivo visualization potential of these three imaging mo­
dalities. Visualization of tumours, or lesion detectability, for all three imaging modalities 
is basically determined by three parameters. (i) The signal level in the lesion versus the 
background level (tumour-to-background ratio), (ii) the lesion size compared to the spatial
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Figure 4
Im age analysis o f  longitudinal scans o f  ra t with a large confluent (13 mm diam eter) tumour on the right, 
ventral, cranial side and multiple sm all tumours a t other locations on day 14 a fter tumour inoculation, 
including estim ated size or uptake o f  lesion. (see Figure 1)
* com m ent by expert: only little uptake a t  dorsal side (not shown), possibly intestinal uptake
** com m ent by expert: multiple tumours
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resolution of the imaging modality, and (iii) the noise level in the image. It is the interplay 
between these param eters that determ ines how well lesions can be detected. Although it 
was beyond the scope of this study to asses all param eters that affect lesion detectability for 
the three modalities, multiple measures have been taken to optimize the settings of all three 
imaging modalities for this particular experiment. For micro-CT we used two contrast agents 
to improve the alignment of the liver and to enhance the intrahepatic tumour-to-background 
contrast. Image quality of micro-PET was optimized by minimizing uptake of FDG in other 
organs by anesthesia, fasting and warming of the animals.14 For micro-MRI, the breathing 
cycle was kept constant allowing respiratory triggering to reduce motion artefacts. However, 
all three small animal imaging modalities suffered from artefacts so that image quality could 
potentially be improved further.
The FDG-PET instrum entation could be further improved. The spatial resolution could pos­
sibly be increased by decreasing the size of the detection crystals in future scanner designs. 
The signal-to-noise ratio can be enhanced by increasing the aspect ratio of the PET scanner 
which increases its sensitivity.11 Moreover, the false-positive rate for FDG PET, due to uptake 
in inflammatory tissue, could be a potential aspect of improvement. If suture material is still 
present in the scar, macrophage accumulation may cause high FDG uptake resembling tu­
mour uptake. This may explain the difficulties localizing the site of FDG uptake to the liver or 
the abdominal scar. Simultaneous CT imaging would help to better localize the site of uptake. 
Also in the case of nonspecific bowel uptake, simultaneous PET/CT scanning will help in 
exactly localizing a potential lesion. Furthermore, gated imaging may help to avoid breathing
---------  artefacts so that on combined PET/CT images the anatomical correlation would be optimi-
8 8  zed in the area of the liver where breathing artefacts are more pronounced due to the close 
proximity to the diaphragm. The disadvantage of gating would be the considerable increase 
in acquisition time, so that there will always be a trade-off betw een anatomical matching, 
imaging quality, and duration of the scan. Improving image quality of CT could be achieved 
by reducing beam hardening. Beam hardening refers to the process of selective removal of 
soft X-rays that are easily attenuated from the X-ray beam. As these X-rays are removed, the 
remaining beam becom es more penetrating (hard X rays). Beam hardening is the result of 
the combination of the initial X-ray spectrum and the composition and thickness of the tissue 
traversed. This results in beam hardening artefacts in CT images. Unfortunately, beam harde­
ning in CT-scans of bony area's is hard to prevent. As for MRI, respiratory gating was already 
conducted in order to reduce motion artefacts. By means of this technique the MRI images in 
the coronal and sagittal plane were of acceptable quality. Because of the rapid breathing rate 
of a rat further optimization of MR images will be difficult to achieve.
This study on preclinical imaging modalities for detection of liver m etastases shows encou­
raging sensitivity and specificity scores for preclinical imaging of small liver tumours. Each 
of these modalities has its particular advantages and disadvantages and could therefore suit 
specific research questions. Multimodality imaging, which is considered to enhance diag­
nostic information, is currently studied in several (pre)clinical studies and faces many chal­
lenges.15-17 The quality of (preclinical) multimodality imaging is likely to benefit from impro­
ved performance of each modality, and does not require the development of multimodality 
probes.18 The results in this study support further studies on detection of liver m etastases 
in an experimental setting and can easily be implemented in studies on multi-modality ima­
ging.
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A b s tr a c t
Background
Although partial hepatectomy can improve 5-year survival of patients with colorectal liver 
m etastases up to 58% , recurrent tumour growth in the liver occurs frequently. RIT using 
radiolabelled monoclonal antibodies directed against tumour-associated antigens, is con­
sidered most suited for treating minimal residual disease and could therefore serve as an 
adjuvant after surgery. The aim of the present study was to test the hypothesis that adjuvant 
radioimmunotherapy (RIT) prevents recurrent liver m etastases and/or results in improved 
survival after tumourectomy in an experimental model.
Methods
Liver m etastases were induced in male W ag/Rij rats by a mini-laparotomy with intrahepatic 
injection of 0.3 x 106 CC531 tumour cells. The biodistribution of the radiolabelled monoclo­
nal antibody MG1, directed against a 80 kDa cell surface antigen on CC531 tumours, in this 
model was determined at 1, 3 and 7 days after intravenous administration. The therapeutic 
efficacy of 177Lu-MG1 was compared with that of a sham antibody (UPC10), labelled with the 
same activity dose of Lu-177, and saline only. RIT was administered either at the day of the 
tumourectomy (day 14 after tumour cell inoculation) or 7 days later. Primary endpoint was 
survival.
Results
Radiolabelled MG1 preferentially accumulated in tumour lesions in the liver reaching a maxi­
mum 3 days post injection (8.7 ± 0.6 %ID/g). Both the administration 177Lu-MG1 and 177Lu- 
UPC10 resulted in a transient decrease in body weight. No other signs of clinical discomfort 
were registered. The survival curves of the group that received 177Lu-UPC10 and the group 
that received saline only did not differ (P =0.886). Administration of RIT immediately after 
surgery improved survival compared to administration of the control antibody (HR 1.54, P= 
0 .051), which was even more pronounced when survival was adjusted for the weight of the 
resected tumour (HR 1.71, P =0.027). A therapeutic efficacy of delayed treatm ent seemed 
likely (HR 2.34, P =0.055). Survival after early administration did not differ from delayed 
administration (HR 1.16, P=0.763).
Conclusion
This study provides proof of principle that radioimmunotherapy can be an effective adjuvant 
treatm ent modality after surgical treatm ent of colorectal liver metastases.
Radioimmunotherapy after resection of liver m etastases
C
olorectal cancer (CRC) is the third most common cancer among both men and women 
in the W estern world.1 25%  of patients with CRC have liver m etastases at the time of 
presentation and another 25%  of the patients with CRC develop liver m etastases w it­
hin 2 years of follow-up after surgical resection of the primary tumour.2 The standard of care 
for these patients is surgical resection of the liver tumours. Currently, studies are ongoing 
to investigate the efficacy of a multimodal treatm ent approach when primary resection is 
not possible.3 Although partial hepatectomy can improve 5-year survival up to 58% 4, recur­
rent tumour growth in the liver develops frequently.5 This relapse is hypothesized to be the 
result of m icro-m etastases in the liver.6-8 In addition, perioperative circulating tumour cells 
could be a potential source of recurrent tumour growth.9 The therapeutic value of adjuvant 
(5-fluorouracil-based) chemotherapy to hepatic resection remains to be assessed.10 
Radioimmunotherapy (RIT) using radiolabelled monoclonal antibodies (mAbs) directed 
against tumour-associated antigens offers the opportunity to selectively irradiate tumour 
cells, while sparing normal tissues. Several preclinical and clinical studies have indicated 
that RIT can be effective for cancer treatm ent.11-13 Because tumour targeting with radiolabel­
led mAbs is more efficient in small tumour lesions, RIT is considered most suited for treating 
minimal or microscopic residual disease.14,15
The aim of the present study was to test the hypothesis that adjuvant RIT might be an ef­
fective way of preventing recurrent liver m etastases after partial hepatectomy. For this 
purpose, an experimental model using MG1, a mAb directed against a tumour-associated
antigen expressed on the syngeneic colonic carcinom a cell line CC531 was used.16 First, a ---------
biodistribution of radiolabelled MG1 was studied in rats with small volume liver m etastases 93 
and subsequently a survival study was performed.
M e th o d s
Cell line and monoclonal antibody
The syngeneic rat colonic carcinom a cell line CC531 is derived from colonic tumours of W ag/ 
Rij rats exposed to 1,2-dimethylhydrazine. CC531 cells were cultured and suspended as des­
cribed previously.17 MG1 mAb was purchased from Antibodies for Research Applications BV 
(Gouda, the Netherlands). It is a murine IgG2a antibody, raised by immunization of mice with 
CC531 colon carcinoma cells. It recognizes a cell surface antigen of about 80 kDa, localizes 
preferentially in the CC531 tumours when injected in rats, and has minimal crossreactivity 
with other cell types.16 Moreover, it has a high affinity (Kd=1.0 nM) for the antigen expressed 
on CC531 tumour cells.18 UPC10 is also a murine IgG2a antibody and is directed against p-2- 
6-linked fructosan which is not present in W ag/Rij rats with CC531 tumours (Sigma Life 
Science, Zwijndrecht, the Netherlands).
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Radiolabelling
m In and 177Lu were purchased from Covidien BV (Petten, the Netherlands) and IDB Holland 
BV (Baarle Nassau, The Netherlands), respectively. The MG1 antibody was labelled with m In 
and 177Lu, and purified as described previously.17 The immunoreactivity of these preparati­
ons exceeded 65% . The specific activity of the 177Lu-labelled diethylenetriamine penta-acetic 
acid (DTPA)-MG1 conjugate (hereafter referred to as 177Lu-MG1) was 548 (range 237-703) 
kBq/^g. The specific activity of the 177Lu-labelled DTPA-UPC10 preparations (177Lu-UPC10) 
was 888  kBq/^g. Radiochemical purity, determined by instant thin-layer chromatography on 
silicagel strips (Gelman Sciences, Ann Arbor, Michigan, USA) using 0.10 m ol/l citrate buffer, 
pH6.0, as the mobile phase, exceeded 95%  for all 177Lu-MG1 and 177Lu-UPC10 preparations.
Animals and surgical procedure
Ten-to-twelve-week-old male W ag/Rij rats, with a mean weight of 230  g, were used (Charles 
River Laboratories, Sulzfeld, Germany). They were accustomed to laboratory conditions for
1 week before use and housed under non-sterile, standard laboratory conditions (tem pera­
ture 20-24°C , relative humidity 5 0 -6 0  %, 12-h light-dark cycle), with free access to animal 
chow and water. All experiments were conducted in accordance with the principles laid out 
by the revised Dutch Act on Animal Experimentation (1 9 9 7 ) and approved by the institutio-
---------  nal Animal Welfare Committee of the Radboud University Nijmegen.
9 4  Immediately after the onset of general anaesthesia (isoflurane, oxygen and nitrous oxide), 
the abdomen was shaved and desinfected with 70%  ethanol. During the operation, rats were 
placed on a warmed m attress to limit heat loss, and eye drops containing 20 m g/g chloramp­
henicol were administered to prevent dehydration of the eyes. The abdomen was opened via 
a 2-cm midline laparotomy. The left lateral lobe of the liver was gently lifted out of the abdo­
men and placed on a gauze. Using a 29-G needle and a 1-ml syringe, 3 x 105 CC531 tumour 
cells, suspended in 0.1 ml phosphate-buffered saline (PBS), were injected subcapsulary. To 
prevent bleeding and leakage of tumour cells the puncture area was covered for a few mi­
nutes with a cotton stick.
For the radioimmunotherapy study, two weeks after inoculation, the abdomen was opened 
again via a 3-cm midline laparotomy. The left lateral lobe of the liver was gently lifted out 
of the abdomen and placed on a gauze in such way that the tumour was clearly visible. To 
mimic irradical resection, a tumourectomy was performed by sharp dissection at the border 
between healthy liver tissue and tumour. To prevent bleeding the resection area was pressed 
with a gauze for a few minutes. After each operation, the muscular layer of the abdomen was 
closed with continuous absorbable braided 4 /0  sutures and the skin was closed with iron 
wound clips. Warmed saline (10  ml) was injected subcutaneously for rehydration. Rat cages 
were placed on a warm m attress for the first 24 h after operation. Before and on the first and 
second postoperative day, analgesia was given daily in the form of subcutaneous injections 
of 5 ^g per 100 g bodyweight of a selective COX-2 inhibitor
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Biodistribution
To determine the uptake of 177Lu-MG1 in different organs and in liver tumours, the biodis­
tribution of m In-DTPA-MG1, as surrogate for 177Lu-MG1, was determined. Twenty W ag/Rij 
rats underwent the surgical procedure and tumour inoculation as described above and five 
rats received a sham operation. On day 13 all rats received a single intravenous injection 
of 4 MBq m In-MG1 (MG1 protein dose 30 ^g per rat) in 0.2 ml PBS, 0 .5%  BSA. At different 
time points after injection of m In-MG1 (1 day, 3 days, 7 days and 14 days) rats were imaged 
with a gamma camera. At each time point one group of 5 rats was euthanized using O2/CO2 
asphyxiation and relevant tissues were dissected. The control group was imaged at every 
time point and was euthanized and dissected at day 14 after injection. Tumour, blood, liver, 
spleen, kidney, lung, muscle, small intestine and large intestine were sampled, blotted dry, 
weighed and radioactivity was measured in a gamma counter. To correct for physical decay 
and to calculate uptake of the radiolabelled antibody in each sample as a fraction of the 
injected dose, aliquots of the injected dose were counted simultaneously. The results were 
expressed as a percentage of the injected dose (ID) per gram of tissue.
Radioimmunotherapy
The therapeutic efficacy of RIT was determined after random assignm ent of 72 rats to re­
ceive an intravenous injection of either 177Lu-MG1, 177Lu-UPC10 or saline only within 3 hours ---------
after resection of the tumour on day 14 (n=18  per group). In a separate group, 177Lu-MG1 was 95 
administered 7 days after tumour resection (n=18), as shown in Figure 1. These groups are 
hereafter referred to as the "MG1-D14", "UPC10-D14", "saline only" and "MG1-D21" group, 
respectively. In all groups, the administered activity dose was 300 MBq/kg in 0.25 ml PBS, 
which had been found to represent the maximum tolerable dose in a previous experim ent.18 
The primary endpoint was survival as calculated from the day of tumourectomy. Toxicity was 
monitored by body weight m easurem ent and assessm ent of general condition. Body weight 
was measured daily during the first w eek and twice weekly thereafter. When the humane 
endpoint (one of the following signs present: > 20%  body weight loss, abdominal distension 
and ascites, signs of physical discom fort like breathing problems) was reached, rats were 
killed using oxygen-carbon dioxide asphyxiation and dissected.
time (days) 0 14 21 180
t t j t
tumour inoculation (n=72) Irradical tumour 
■esection (n= 72) and 
randomization
euthane sia when 
human« endpoint was 
reached
end of study
Intravenous injection Intravenous
of either 177Lu-MG1 injection of
(n=18),177Lu-UPC10 177Lu-MGl 
(n=18) or saline (n=18) (n=18)
Figure 1
Time schedule o f  the radioim m unotherapy experiment.
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All remaining rats were euthanized and dissected 180 days after the operation. The abdo­
minal cavity was carefully inspected, with special attention to the liver parenchyma. The 
peritoneal cancer index (PCI) was scored as described by Koppe et al.17 All macroscopic 
tumour deposits in the liver were resected and weighed. When no macroscopic tumour de­
posits were present, the left lateral lobe of the liver was sliced in 0.5-cm  thick slices for 
routine histopathological haematoxylin & eosin (H&E) staining. Microscopic tumour growth 
was evaluated by an experienced pathologist at two levels in each slice and scored as either 
present or absent.
Statistical analysis
Statistical analysis was performed using the SPSS software (Chicago, IL) and GraphPad Prism 
version 4 .00 for Windows (GraphPad Software, San Diego USA). Sample size was determined 
by a power calculation based on an estimated effect of RIT in doubling the survival time of 
the treated animals. Kaplan-Meier survival curves for overall survival were generated. The 
log-rank test was used to identify the difference betw een the groups for overall survival 
and results were expressed in hazard ratio (HR) and 95%  confidence interval. The level of 
statistical significance was set at a P-value of <0.05. Means and standard deviations were 
used to describe continuous data and differences were calculated using one-way ANOVA and 
independent-samples two-sided T-tests.
Figure 2
Biodistribution. The uptake o f  Inln-MG1 in tumour bearing rats on day 1 (black bar), day 3 (striped bar), 
day 7 (blocked  bar) or day 14 (double striped bar) post injection is depicted as mean ± SD. The white bar 
represents the uptake o f  111In-MG1 in non tumour-bearing animals on day 14 post injection.
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Results
Biodistribution of ^In-labelled  MG1
The biodistribution of m In-MG1 1, 3, 7 and 14 days after injection of the radiolabelled an­
tibody in W ag/Rij rats with intrahepatic CC531 tumours is summarized in Figure 2. There 
was high and specific uptake of m In-MG1 in the tumour reaching a maximum 3 days post 
injection (8.7 ± 0.6 %ID/g). Uptake of MG1 in normal tissues, except in the spleen at day 7, 
did not exceed 1.5 %ID/g. The tumour-to-blood ratio of m In-MG1 increased in time and was 
highest at day 7: 19 ± 4. This ratio decreased to 12 ± 4 at day 14 post-injection. In Figure 3, 
typical gamma camera images are presented. Intrahepatic tumours could be visualized as 
early as one day post injection (Fig 3A, right rat). Three and 7 days post injection tumours 
were visible m ost clearly. At day 7 the spleen was also visualized in some of the rats. At day 
14 the quality of the images was poor and tumours could no longer be detected, mainly due 
to the low activity levels that remained in the body. (images not shown)
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Figure 3
Gamma cam era im ages o f  Male Wag/Rij rats with sm all CC531 liver tumours, 1 day post injection (A), 3 
days post injection (B) and 7 days post injection o f  111ln-MG1 (C). Arrows: CC531 liver tumour, arrow  head: 
spleen.
Efficacy of adjuvant radioimmunotherapy
All rats had developed a small solid m etastasis in the left lateral lobe of the liver at the time 
of tumour resection. In 71 of the 72 rats macroscopic tumourectomy seemed complete, 
whereas in one rat macroscopic tumour was left behind. This rat was included in the ran­
domization and in the analysis. The average weight of the resection specimens was 0.40 g 
± 0.30 g and did not differ between the groups (P =0.803). The relative body weight of the 
rats during the first 35 days of the study, expressed as the percentage of the body weight on 
the day of surgery, is depicted in Figure 4. Compared to administration of saline only, ad-
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Figure 4
Course o f  body weight. The mean (± SD) relative body weight, with respect to preoperative w eight before  
tumour inoculation, is given f o r  the MG1-D14 (white circles), MG1-D21 (white squares), UPC10-D14 (black  
squares) and the saline-only group (b lack  circles). In all groups, tumourectomy was p erform ed a t day 14.
98
days after surgery
Figure 5
Survival a fter tumour resection. Lines represent groups receiving 300 M Bq/kg 177Lu-MG1 on D14 (white 
circles), 300 M Bq/kg 177Lu-MG1 on D21 (white squares), 300 M Bq/kg 177Lu-UPC10 on D14 (blacksquares)  
and saline only on D14 (b lack  circles).
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ministration of both 177Lu-MG1 and 177Lu-UPC10 directly after tumourectomy affected body 
weight. On day 19 the mean relative body weight of the saline-only group was 106.3 ± 2.5 
%. At that time point the mean relative body weight of the MG1-D14 and UPC10-D14 group 
reached a nadir and was 103.6 ± 2.2 % and 102.6 ± 2.0 % respectively (P =0.001 and P<0.001 
as compared to the saline only group). The mean relative body weight five days after delayed 
administration of RIT (MG1-D21) was 106.7  ± 2.7 % as compared to 109.4  ± 2.4 % for the 
saline-only group (P =0.003) at that time point. However, no other signs of clinical discom­
fort were observed during the initial post-treatm ent period and the body weight of the rats 
recovered quickly in the course of the study.
Altogether, 43 rats reached the humane endpoint as a result of tumour growth and were eu­
thanized: 32 displaying extensive tumour in the liver. Mean weight of all tumours detected in 
the liver was 4.9 ± 3.5 g which was the same in all four groups (P =0.092). Seven rats, equally 
distributed over the groups, developed mainly tumours in the lungs and 4 rats developed 
excessive malignant ascites necessitating euthanasia. At dissection 31 rats also had tumour 
nodules elsewhere in the abdomen; 4 rats in the MG1-D14 group (median PCI 9; range 6-11),
7 rats in the MG1-D21 group (median PCI 10; range 7-13), 10 rats in the UPC10-D14 group 
(median PCI 8; range 1-13) and 10 rats in the saline-only group (median PCI 5; range 2-12).
Mean PCI did not differ betw een the groups (P =0.258).
180 Days after tumour cell inoculation 29 rats were still alive, without clinical signs of dis­
comfort. Half-year survival of the MG1-D14, MG1-D21, UPC10-D14 and saline-only group
was therefore 56% , 50% , 28%  and 28% , respectively. Histopathological examination of the ---------
livers showed microscopic tumour nodules in the liver of only one surviving rat from the 99 
UPC10-D14 group. The survival curves are shown in Figure 5. Kaplan-Meier survival analysis 
showed that the survival curves of the groups receiving 177Lu-UPC10 or saline only did not 
differ (HR 1.00; 95%  confidence interval, 0 .46-2 .16 ; P =0.998). Therefore, in further analysis, 
results were compared to the UPC10-D14 group. Administration of RIT immediately after 
surgery (MG1-D14) improved survival as compared to administration of 177Lu-UPC10 (HR 
1.54; 95%  confidence interval, 0 .99-2 .40 ; P= 0 .051). Although there was no difference in 
the mean tumour weight between the groups, within groups the deviance in tumour weight 
was considerable. Since tumour load is known to be negatively correlated to outcome after 
hepatic resection for colorectal liver m etastases in patients19, survival analysis was adjusted 
for the deviance in weight of the tumour at resection. The for tumour weight-adjusted HR 
was addressed with Cox-regression, showing a HR of 1.71 (95%  confidence interval 1 .06­
2.76; P= 0 .027). Analysis of the survival after delayed treatm ent (MG1-D21) as compared 
to administration of 177Lu-UPC10 showed that a therapeutic efficacy seems likely (HR 2.23;
95%  confidence interval 0 .95-5 .24 ; P =0.059), with a for tumour weight-adjusted HR of 2.34 
(95%  confidence interval 0 .98- 5.58; P =0.055). Survival after early administration did not 
differ from survival after delayed administration (HR 1.16; 95%  confidence interval 0 .4 5 ­
3.01; P=0.763).
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D is c u s s io n
The present report shows that adjuvant RIT can increase survival in rats after resection of 
colorectal liver m etastases. A well characterized rat model was used in the present study: 
the syngeneic rat colon carcinoma cell line CC531 exhibits a reproducible growth pattern in 
W ag/Rij rats.20 Subcapsular injection of syngeneic tumour cells in rats results in liver m eta­
stases with a high reproducibility.21 Intrahepatic tumour recurrence is not likely when the 
commonly used partial hepatectom ies, lobectom ies or vessel-orientated resections are ap­
plied in this model.22 In the present study, using narrow tumourectomy, recurrent tumour 
growth in the liver occurred in over 70%  of the untreated animals with no mortality and 
minimal weight loss due to the surgical procedure. Since 30%  of the animals will not deve­
lop recurrences in this model, a certain number of survivors could be expected even in the 
control groups in our study. A few animals (7 /7 2 )  developed macroscopic lung metastases. 
The number of animals is too small to detect an influence of RIT on this m etastatic pattern, 
but it could be an interesting subject of future research. As for the characterization of RIT 
in our model, we already demonstrated that MG1 has a high affinity for its antigen on the 
CC531 cell m em brane23 and that MG1 is gradually internalized by CC531 cells.18 The in vivo 
tumour targeting potential of the MG1 mAb for CC531 liver tumour was demonstrated by 
its accumulation in the CC531 liver tumours and is in concordance with findings in previous 
studies.16,18 A previous study by Koppe et al. in an animal model for peritoneal carcinomato-
---------- sis, using the same rat strain, tumour cell line and antibody, has demonstrated the superio-
10 0  rity of RIT over unlabelled antibody treatm ent.17 The current study dem onstrates clearly the 
specificity of RIT as compared to treatm ent with a radiolabelled sham antibody.
Currently, patients with liver m etastases of CRC need to be evaluated by multi-disciplinary 
oncological team. If necessary, preoperative chemotherapy can be administered to convert 
primarily unresectable m etastases into resectable m etastases. In the past, several authors 
have outlined the factors influencing survival after resection of colorectal liver metastasis. 
Factors like the size and number of the lesions, synchronous presentation of the m etastases 
with the primary tumour and the original staging of the primary tumour have shown impact 
on survival in several studies.19,24,25 However, with improved chemotherapy, the application 
of biologicals and improving results of surgery, more and more patients will be candidates 
for surgery, even if extrahepatic disease is present. Unfortunately, recurrences in the liver 
occur frequently.26,27 When recurrences are diagnosed, repeated hepatectomy can provide 
prolonged survival for the patient, but only specifically selected patients are eligible for this 
treatm ent.28
Two recent studies reported on the possible effect of either adjuvant or perioperative (befo­
re and after hepatic resection) chemotherapy on survival after hepatic resection.29,30 Howe­
ver, it has been pointed out that both studies have their drawbacks.31 The question whether 
or not adjuvant or perioperative chemotherapy can be beneficial might be answered in a 
prospective randomized phase III trial. However, until such a study becomes available, the 
therapeutic value of systemic adjuvant chemotherapy following hepatic resection remains 
unclear and is not routinely advised. The effect of hepatic artery adjuvant chemotherapy has 
been reviewed separately, and does not yield improvement in overall survival.32 
RIT with radiolabelled mAbs directed against tumour-associated antigens has evolved from 
an appealing concept to one of the standard treatm ent options for patients with Non-Hodg-
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kin's Lymphoma.33 RIT offers the opportunity to selectively irradiate tumour cells, while 
sparing normal tissues. Another advantage of RIT as compared to other targeted therapies 
is the crossfire effect, which means that nontargeted cells are irradiated due to radiolabelled 
antibody uptake by surrounding cells. Because of the relative radiosensitivity of CRC and the 
availability of mAbs against CRC-associated antigens, the efficacy of RIT using radiolabelled 
mAbs against CRC has been investigated, and compared to chemotherapy, in various precli- 
nical clinical studies. For example, Behr et al. demonstrated that in a nude mouse model for 
lung m etastases of CRC, RIT with a 131I-anti-CEA antibody cured half of the animals whereas 
equitoxic chemotherapy only prolonged life for a few weeks.34 Aarts et al. dem onstrated that 
adjuvant RIT with 177Lu-MG1 after debulking of peritoneal carcinom atosis in a rat model 
improved survival, whereas adjuvant heated intraperitoneal chemotherapy did not and was 
considered more toxic.13
To date, a few interesting clinical trials have dem onstrated a potential efficacy of postopera­
tive RIT after resection of colorectal liver m etastases.35-38 Recently, the potential therapeutic 
effect of adjuvant RIT after hepatectomy has been demonstrated by Liersch e t al. This first 
phase II trial showed that adjuvant RIT with 1 .48-2.22 GBq/m 2 131I-labelled anti-CEA-antibo- 
dy labetuzumab after resection of liver m etastases of CRC increased median overall survival 
compared to adjuvant chemotherapy. There was a trend to benefit in disease-free survival.36 
This study warrants research on the exact efficacy, advantages, disadvantages and pathways 
of adjuvant RIT for liver metastases. In 1997  Behr et al. already concluded that "Because the 
activity concentration over time determines the radiation absorbed dose, and thus biological 
effects, we postulate that animal models can predict actual clinical scenarios."35 The results in 
our animal model show a hazard ratio of 1.7 comparing the RIT group to the control group, 
indicating a clear increase in overall survival after resection of colorectal liver m etasta­
ses. This study suggests that RIT is also likely to remain effective when treatm ent would 
be delayed with a couple of days after surgery. Moreover, toxicity seems to be the result of 
a non-specific radiation effect and was very limited in either setting. Although significant, 
the absolute decrease in body weight was very small when RIT was postponed for a couple 
of days, making it less relevant. In a clinical setting delay in administration of RIT could 
have the advantage of avoiding the administration of radiolabelled antibodies during the 
first post-operative days in which the patient might need intensive medical care. Therefore, 
delayed administration may reduce radiation exposure to medical personnel. However, care 
must be taken not to postpone RIT too long, since other studies have clearly demonstrated a 
negative correlation betw een tumour load and the efficacy of RIT.18,39 Moreover, the current 
study shows that RIT can be administered intravenously in a single dose and does not show 
major side-effects such as infections or impaired wound healing. The latter is in line with the 
findings of Aarts et al., who found that RIT did not affect wound healing.40 
Tumour size is known to be one of the predicting criteria on long-term outcome after resec­
tion of hepatic m etastases.19 Indeed, in our study the weight of the initial tumour affected the 
therapeutic efficacy of adjuvant RIT. This finding could be of interest for future studies on the 
efficacy of adjuvant RIT after resection of colorectal liver m etastases, indicating a hypotheti­
cal influence of tumour size, more advanced disease or differentiation grade on outcome. For 
example, the influence of extrahepatic disease on survival after liver resection and RIT could 
be studied in a similar animal model, by implementing PET/CT imaging prior to resection. 
Gamma camera imaging could also be implemented after administration RIT, when gamma- 
emitting radionuclides like 177Lu are used, allowing analysis of targeting of intrahepatic and
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extrahepatic lesions. Finally, based on this hypothesis adjuvant RIT after resection could be 
optimized according to disease stage by for example performing multiple resections prior 
to RIT or applying RIT with antibodies with a combination of radionuclides with different 
penetration depths such as Lu-177 and Y-90.
C o n c lu s io n
This study provides proof of principle that adjuvant RIT using 177Lu-labelled MG1 mAb at 
MTD increases survival after resection of colorectal liver m etastases in rats and encourages 
the implementation of clinical trials studying the effect of adjuvant RIT in CRC patients un­
dergoing liver surgery
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Background
Radiofrequency ablation (RFA) has shown to improve survival in patients not eligible for 
surgical resection of colorectal liver m etastases. However, recurrences after RFA are a major 
problem. Adjuvant radioimmunotherapy (RIT) after surgical resection of liver metastases 
has shown to improve survival. The aim of the present study was to test the hypothesis that 
adjuvant RIT might be an effective way to prevent recurrent liver m etastases after RFA in an 
experimental model.
Methods
Tumours in the liver were induced by intrahepatic injection of 3. 105 CC531 cells in male 
W ag/Rij rats (n=60). Ten days later, the intrahepatic tumours were treated with RFA. Adju­
vant RIT (177Lu-labelled monoclonal antibody MG1 at 300 MBq/kg) was administered intra­
venously either at the day of RFA (day 10) or 7 days later. Control rats received no treatment. 
Primary endpoint was survival.
Results
Administration of 177Lu-MG1 resulted in a transient decrease in body weight, compared to 
no adjuvant treatm ent. However, no other signs of clinical discom fort were registered. Log 
rank test showed that the survival curves of the groups treated with RIT, either at day 10 
or day 17, did not differ significantly from the survival curve of the rats that did not receive 
adjuvant treatm ent (P =0.902).
Conclusion
This study shows that adjuvant RIT does not increase survival after RFA of colorectal liver 
m etastases in rats.
Radioimmunotherapy after radiofrequency ablation
W ithout any treatm ent, the 5-year survival of patients with colorectal liver meta- stases is negligible.1 Surgical resection of these liver m etastases has shown to improve 5-year survival of colorectal cancer (CRC) patients to about 30%  (range 
15-67% ), but only 20%  of patients are considered eligible for this surgical procedure.2;3 If 
the m etastases are not resectable, radiofrequency ablation (RFA) is a suitable alternative.3 
RFA induces coagulative necrosis by using high-frequency alternating current applied via 
electrodes placed within the tissue. RFA ablation can be applied percutaneously, laparosco- 
pically or at open surgery. RFA has proven to be a safe procedure with a complication rate lo­
wer than <10% .4 However, a high local recurrence rate is a major problem of RFA. Depending 
on the technique used, the number, the size and the location of the lesions, local recurrences 
are reported in 4 % to 55 % of cases.5;6
Radioimmunotherapy (RIT), using radiolabelled monoclonal antibodies (mAbs) directed 
against tumour-associated antigens, offers the opportunity to selectively irradiate tumour 
cells, while sparing normal tissues. Because tumour targeting with radiolabelled mAbs is 
more efficient in small tumour lesions, RIT is considered suited for minimal or residual 
disease. This concept has been demonstrated in preclinical as well as in clinical trials, sho­
wing an increased survival after resection of colorectal liver tumours when adjuvant treat­
ment with RIT is applied.7;8 Here, we hypothesized that RIT could also treat residual disease 
after RFA. Interestingly, in vitro studies with the human colon adenocarcinoma cell line 
LS174T have indicated that short hyperthermia results in a significant, temporarily, upre- 
gulation of carcinoembryonic antigen membrane expression9, which potentially could result 
in a synergistic combination of RFA and RIT. The aim of the present study was to test the 
hypothesis that adjuvant RIT might be an effective way of preventing recurrent liver m eta­
stases after RFA in an experimental model using the mAb MG1, directed against a tumour- 
associated antigen expressed on the syngeneic colonic carcinoma cell line CC531.
M e th o d s
Cell line and monoclonal antibody
The syngeneic rat colonic carcinom a cell line CC531 is derived from colonic tumours of W ag/ 
Rij rats exposed to 1,2-dimethylhydrazine.10 CC531 was cultured and suspended as descri­
bed previously.11 MG1 mAb was purchased from Antibodies for Research Applications BV 
(Gouda, the Netherlands). It is a murine IgG2a antibody, raised by immunization of mice with 
CC531 colon carcinoma cells. It recognizes a cell surface antigen of about 80 kDa, localizes 
preferentially in the CC531 tumours when injected in rats and has minimal cross-reactivity 
with other cell types.12;13 Moreover, it has a high affinity (1.0 nM) for the antigen expressed 
on CC531 tumour cells and shows high tumour uptake in experimental liver m etastases after 
intravenous injection.14;15
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Radiolabelling
177Lu was purchased from IDB Holland BV (Baarle Nassau, the Netherlands). The MG1 anti­
body was labelled with 177Lu and purified as described previously.11 The specific activity of 
the 177Lu-labelled diethylenetriamine penta-acetic acid (DTPA)-MG1 preperations (hereafter 
referred to as 177Lu-MG1) used in these studies ranged from 169 to 62 7  kBq/^g. Radioche­
mical purity, determined by instant thin-layer chromatography on TEC Control chromato­
graphy strips (Biodex, Shirley, NY), using 0.1 M citrate buffer (pH 6.0) as the mobile phase, 
exceeded 92%  for all 177Lu-MG1 preparations.
Animals and tumour induction
Male W ag/Rij rats, with a mean weight of 230  g, were used (Charles River Laboratories, Sulz­
feld, Germany). They were accustomed to laboratory conditions for one week before use and 
housed under non-sterile, standard laboratory conditions (tem perature 2 0 -2 4  °C, relative 
humidity 5 0 -6 0 % , 12-h light-dark cycle), with free access to animal chow and water. All 
experiments were conducted in accordance with the principles laid out by the revised Dutch 
Act on Animal Experimentation (1 9 9 7 ) and approved by the institutional Animal Welfare 
Committee of the Radboud University Nijmegen.
All surgical procedures were carried out under clean conditions. Tumour induction was per­
---------- formed as described previously15 with the alteration that, via a 2-cm midline laparotomy,
11 0  tumour cells were injected subcapsulary in the left lateral lobe of the liver. Rat cages were 
kept on a warm m attress for the first 24  h after operation. Before surgery and on the first and 
second day thereafter, analgesia was given in the form of subcutaneous carprofen injections 
(5 ^g per 100 g bodyweight).
Radiofrequency ablation
Ten days after inoculation, animals were anaesthetized by isoflurane inhalation and the 
abdomen and back were properly shaved. After supine placem ent onto an electricity-con­
ducting pad (grounding pad), the abdomen was opened via a 3-cm midline laparotomy. The 
left lateral lobe of the liver was lifted out of the abdomen and placed on a gauze to clearly 
visualize the tumour. A radiofrequency ablation needle with active tip of 8 mm (SMK-15, 
Cotop, Amsterdam, the Netherlands) was inserted and placed in the middle of the tumour. 
After placem ent of the radiofrequency ablation needle, impedance could be evaluated on the 
radiofrequency lesion generator system (Model RFG-3B, Radionics, Burlington, MA, USA). 
Next, treatm ent was started by delivering radiofrequency energy. During a treatm ent cycle 
of ~ 1 8 0  s, tem perature could be monitored by means of a therm istor and thermocouple in 
the tip of the probe. Treatm ent was considered successful if a tip tem perature of ~ 7 5 -8 0 °C  
was reached. If the tumour had a size larger than 5 mm in diameter, the treatm ent was re­
peated, repositioning the needle in such a way that the whole tumour would receive one 
treatm ent cycle. After completing the RFA, the abdomen was closed as described before.
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Model validation
To determine the optimal model for recurrences and reproducibility of the model six W ag/ 
Rij rats with a mean weight of 260  g had the tumour inoculation and treatm ent procedure 
as described above. Additionally, in the medial lobe of the liver a second tumour was inocu­
lated, which was treated with 2 cycles of RFA per puncture. Ten days after the treatment, 
three randomly selected rats underwent a FDG-PET/CT scan acquired with an Inveon animal 
PET/CT scanner (Siem ens Preclinical Solutions, Knoxville, TN).16 One hour prior to scanning, 
the rats received an intravenous injection of 10 MBq 18F-2-deoxy-2-fluoro-D-glucose (FDG). 
To enhance liver contrast on the CT scan, two hours prior to scanning, 1.5 mL of glyceryl 
2-oleoyl 1,3-bis [7-(3-am ino-2, 4, 6-triiodophenyl)] alkanoate (Fenestra LC; Advanced Re­
search Technologies, Inc, Montreal,Quebec, Canada) was injected via the tail vein (RES-IV, 
reticuloendothelial system - specific contrast). Twenty minutes prior to scanning an intra­
peritoneal injection of 1.5 mL ioversol (Optiray 320; Mallinckrodt Inc, 1:2 dilution) for in­
traperitoneal contrast was administered. After scanning, all the animals in the experiment 
were killed using oxygen/carbon dioxide asphyxiation and dissected. The liver was resected 
and sliced in 0.5-cm thick slices for routine histopathological haematoxylin & eosin (H&E) 
staining.
Adjuvant radioimmunotherapy
The therapeutic efficacy of RIT was determined after random assignm ent of 60 rats after the 
RFA procedure. One group of rats received an intravenous injection of 177Lu-MG1 a couple of 
hours after the RFA procedure (RIT D10). Since timing is of RIT might be crucial, a second 
group of rats received RIT 7 days after RFA (RIT D17). The administered activity dose in both 
groups was 300  MBq/kg in 0.25 - 0.50 ml PBS, which has been determined as the maximum 
tolerable dose previously.15 The third group did not receive any adjuvant treatm ent after the 
RFA procedure (control).
The primary endpoint was survival calculated from the day of RFA. Toxicity was monito­
red by body weight m easurem ent and assessm ent of general condition. Body weight was 
measured daily during the first week and twice weekly thereafter. The area under the curve 
(AUC) during the first month after RFA was calculated. When the humane endpoint (one of 
the following signs present: >20%  body weight loss, abdominal distension and ascites, signs 
of physical discom fort like breathing problems) was reached, rats were killed using oxygen/ 
carbon dioxide asphyxiation and dissected. Four months after the start of the experiment, 
the median survival was reached in all three groups and the remaining rats were euthani­
zed and dissected. The abdominal cavity was carefully inspected, with special attention to 
the liver parenchyma. To objectify the humane endpoint, at dissection the peritoneal cancer 
index (PCI) was scored as described by Koppe et al.11 Next, the left lateral lobe of the liver 
was sliced in 0.5-cm  thick slices for routine histopathological haematoxylin & eosin (H&E) 
staining. Tumour growth was evaluated by an experienced pathologist at two levels in each 
slice and scored as either present or absent.
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Statistical analysis
Statistical analysis was performed using the SPSS software (Chicago, IL) and GraphPad Prism 
version 4 .00 for Windows (GraphPad Software, San Diego USA). Sample size (n=20) was de­
termined by a power calculation based on observations from a previous animal experiment, 
with an estimated 75-days survival of 50%  and 10%  in the treated groups and in the control 
groups, respectively.15 Alpha was set to 5%  and the power was set to 90% . All analysis were 
performed on a per protocol basis. Kaplan-Meier survival curves for overall survival were 
generated and the log-rank test was used to identify the difference betw een the groups for 
overall survival. The level of statistical significance was set at a P-value of <0.05. Means and 
standard deviations or 95% -coincidence intervals (95% -CI) were used to describe conti­
nuous data and differences were calculated using one-way ANOVA and independent-samples 
two-sided T-tests.
Figure 1
Typical histological specim en 10 days a fter radiofrequency ablation o f  a liver tumour showing a. normal 
liver tissue, b. necrosis, c. inflammation and d. residual tumour cells (haematoxylin and eosin stain, 25x 
original magnification)
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Results
Model validation
Ten days after tumour induction, all rats had a tumour in the medial and left lateral liver lobe 
with an average diam eter of 5 mm. These tumours were all treated with RFA (one or two 
cycles). Ten days after the RFA procedure, central necrosis and a surrounding inflammatory 
zone could be identified microscopically in the RFA-treated areas (Fig 1). All tumours treated 
with one cycle showed, morphologically vital, tumour deposits, mainly present at the border 
of the treated area. Tumours treated with two cycles of RFA showed mainly morphologically 
disturbed tumour cells in the centre of the ablated area (not shown). In Figure 2, typical 
FDG-PET, CT and fused images after RFA are presented. FDG-PET/CT showed no uptake in 
the central parts of the two RFA treated areas of the liver. The FDG-PET scan also showed en­
hanced uptake at the edge of the tumour treated with one cycle only. Based on these results, 
recurrent tumour growth after RFA of liver tumours was expected to have the highest inci­
dence after one RFA cycle and this procedure was selected for the subsequent experim ent in 
which the efficacy of adjuvant RIT was investigated.
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Figure 2
CT-scan (a), FDG-PET scan (b) and fu sed  im age (c) o f  a ra t with liver tumours treated with one cycle (white 
arrow) and two cycles (interrupted arrow) o f  radiofrequency ablation (RFA), respectively. No uptake o f  
FDG w as present in the central parts o f  the RFA treated areas. Irregular enhanced uptake a t  the rim o f  the 
liver a rea  treated with only one cycle was present (arrowheads).
Efficacy of adjuvant radioimmunotherapy
All rats had developed a single m etastasis (mean diameter 5 mm) in the left lateral lobe of 
the liver at the time of RFA. In 59 of the 60 rats RFA could be completed, whereas in one rat 
the location of the tumour prevented adequate RFA. This rat was excluded from the analysis. 
Four randomly selected rats that were assigned to treatm ent 7 days after RFA, were transfer­
red to the control group because the available activity dose on the day of the administration 
was lower than expected. As a consequence, the control group consisted of 23 animals and 
the RIT D10 and RIT D17 groups of 20 and 16 rats, respectively. One rat (of the RIT D10 
group) was censored in the survival analysis 77 days after RFA, since it was euthanized w it­
hout fulfilling the criteria.
The relative body weight of the rats during the first month of the study, expressed as the 
percentage of the body weight on the day of tumour induction, is depicted in Figure 3. The 
mean AUC of the RIT-groups was significantly lower than the mean AUC of the control group
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Figure 3
Course o f body weight. The mean (± SD) relative body weight, with respect to body weight before tumour 
inoculation, is given fo r  the RIT D10-group (white circles), RIT D17-group (black circles) and the control 
group (black squares).
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Figure 4
Survival curves o f the animals in the therapy study. Lines represent groups receiving 3 0 0  M Bq/kg 177Lu- 
MG1 on D10 (white circles), 3 0 0  M Bq/kg 177Lu-MG1 on D 17 (black circles) and the control group (black 
squares).
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(P =0 .007), indicating that RIT significantly reduced the body weight of these rats. However, 
differences in the mean relative body weight per group were small (maximum difference 
between the RIT groups and the control group was 4%  relative bodyweight), no other signs 
of clinical discom fort were observed during the initial post-treatm ent period and the body 
weight of the rats recovered quickly in the course of the study
Thirty-one rats died due to excessive tumour growth. Mean PCI found at dissection was 4.4 
± 4.6, 4.5 ± 5.1 and 3.6 ± 5.3 in the RIT D10, RIT D17 and control group, respectively, and did 
not differ betw een groups (P =0 .902). The survival curves of the groups are shown in Figure 
4. Kaplan-Meier survival analysis showed that the survival curves of the three groups did not 
differ (P =0.902). Median survival time was 119 days, 98 days and 116 days in the RIT D10, 
RIT D17 and control group, respectively. The 75th percentile survival was 74 days (95%-CI:
64  -  84 days), 67  days (95% -CI: 41 -  93 days) and 47  days (95% -CI: 15 -  79 days) in the 
RIT D10, RIT D17 and control group, respectively. 120 Days after tumour cell inoculation, 
the remaining 28 rats (9 in the RIT D10-group, 8 in the RIT D17-group and 11 in the control 
group) were euthanized. Histopathological examination of the livers of these remaining rats 
showed microscopic tumour nodules in 4 of these rats (one in each RIT group and two in the 
control group). Overall, local recurrence after RFA was detected in 45% , 47 %  en 50%  of the 
animals of the RIT D10, RIT D17 and control group, respectively
D is c u s s io n  ----------
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Currently, RFA offers a treatm ent option for patients with colorectal liver m etastases, whom 
are not considered eligible for surgery. One of the major problems of RFA is the high local 
recurrence rate. Depending on the technique used and the number, the size and the loca­
tion of the lesions, local recurrences rates of 4%  to 55%  have been reported.5 Tumour size 
is considered to be one of the m ost im portant prognostic indicators for local recurrence.
In larger lesions, multiple probe insertions are necessary to obtain a treatm ent zone large 
enough to include all tumour tissue. Analysis of recurrence patterns has indicated that the 
efficacy of these overlapping treatm ent zones could be unreliable. Inadequate heating of the 
whole tumour can also be a result of the cooling effect of blood flow through adjacent large 
blood vessels.17 Additionally, lower tem peratures (42 to 46 °C), for example at the borders 
of the ablation area, result in reversible cell damage and could even induce synthesis of heat 
shock proteins, facilitating recovery of tumour cells from heat damage.18 So, after RFA of 
larger tumours and of lesion that are located near large vessels, residual disease might cause 
recurrences. RFA is even thought to accelerate outgrowth of residual or microscopic m eta­
stases in the liver due to hypoxia related pathways.19;20 Interestingly, studies on anti-tumour 
immune responses after tumour ablation by RFA have shown that tumour cell necrosis could 
generate a immunogenic source of tumour antigens.21-23 These antigens can be up taken, 
processed and presented by dendritic cells and induce a potent immune response. However, 
initial cellular immune responses in animal models seem weak.
Clinical trials on RFA are ongoing and US as well as European treatm ent guidelines do not 
contain any recommendations on adjuvant therapy after RFA yet. However, knowledge on 
beneficial effect of adjuvant systemic therapies after resection of colorectal liver m etastases
Chapter 7
can be used as a rationale for a similar approach in RFA. In 2005  Elias et al. performed a stu­
dy to determine the survival rate of patients with technically unresectable liver metastases 
when undergoing liver resection plus RFA, along with optimal systemic chemotherapy. Un­
fortunately, perioperative chemotherapy regimens varied widely, thus the specific therapeu­
tic impact on the median survival of 36 months could not be determined.24 Two studies on 
the safety of hepatic arterial infusion of chemotherapy (six monthly cycles of 5-fluorouracil- 
based chemotherapy) after RFA report high complication and toxicity rates associated either 
to the pumps or to the chemotherapy.25:26 Considering these results, there is an obvious need 
for alternative strategies and adjuvant RIT could be a good candidate. RIT with radiolabelled 
monoclonal antibodies directed against tumour-associated antigens, offers the opportunity 
to selectively irradiate tumour cells, while sparing normal tissues. The results of adjuvant 
RIT after surgical resection of liver m etastases seem promising.7:8
However, the data in the present study show RIT to be ineffective in our model. Therefore, 
we conclude that adjuvant RIT does not influence survival in rats after RFA of colorectal 
liver m etastases. Several biological factors could have contributed to these results. A key 
factor in the efficacy of RIT in solid tumours is the extent of accumulation of the antibody 
in the tumour.27 Accumulation of radiolabelled antibodies has shown to be unfavourable in 
large tumours with limited vascularisation, increased interstitial pressure and a large trans­
port distance in the interstitium .28 In our study, these features could explain the absence of 
therapeutic efficiency of adjuvant RIT after RFA of the liver tumour. First of all, the tumour 
load after RFA could have been too high in this model to show any efficacy of RIT. Another
---------- explanation could be that changes in local tissue structure after RFA affected the antibody
1 1 6  uptake. Vogt et al. studied the morphologic and functional changes in non-tumorous liver 
tissue at several time points after RFA in minipigs.29 The study showed that three different 
zones could be identified on histopathologic evaluation of the ablative site immediately after 
RFA: a central zone demonstrating early signs of tissue necrosis, a transitional zone sho­
wing sinusoids engorged with blood (because the central ablative necrosis was obstructing 
outflow) and a peripheral zone demonstrating mild reactive changes. These findings, also 
present in our histological specimens ten days after RFA (Fig 1), indicate that in the transi­
tional and peripheral zones of the ablated area vascularisation can be disturbed, interstitial 
pressure might be increased and the transport distances are increased due to the inflamma­
tory response. As a result, localisation of systemically administered radiolabelled antibodies 
in the residual tumour cells present at the border of the ablated area might be hampered. 
Therefore, based on the present study, RIT cannot be recommended as an adjuvant therapy 
after RFA of colorectal liver metastases.
C o n c lu s io n
This study shows that adjuvant RIT using 177Lu-labelled MG1 mAbs at MTD does not increase 
survival after RFA of colorectal liver m etastases in rats.
Radioimmunotherapy after radiofrequency ablation
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Chapter 8
A b s tr a c t
Background
Radioimmunotherapy (RIT) is an alternative anti-cancer treatm ent to systemic 5FU-based 
chemotherapy following RO-resection of colorectal cancer liver m etastases (CRC-LM). Pre- 
clinical data clearly advocate administration of RIT early after tumour resection. This study 
examines the potential side effects and safety of RIT in the early postoperative period.
Methods
The clinical courses of 86 patients treated with 131I-labetuzumab after RO-resection of CRC- 
LM were reviewed with respect to wound healing, bile leakage and postoperative bleeding. 
An animal experim ent was performed to study the biliary uptake of 111In-labelled anti-CRC 
antibodies, in an immunocompetent W ag/Rij-rat model of RIT.
Results
---------- Of the 86 patients treated by RIT, 9 patients had surgical complications (wound healing dis-
12 0  orders (n=5), intraabdominal abscess (n=2) or biloma (n=2)) at the time of administration. 
RIT did not aggravate the clinical course of these patients. Whole body scintigrams of the 2 
patients with bilomas showed no increased antibody uptake in the biloma. The biodistribu­
tion study in W ag/Rij-rats showed a low non-specific uptake of 111In-labelled anti-CRC anti­
bodies in bile (mean 0 .04  ± 0.01 %ID/g) 3 days after intravenous injection. 16 of 86 patients 
underwent a reoperation because of recurrent m etastatic disease after RIT. Of these, 4  had 
persistent haematological toxicity at the time of reoperation, without any postoperative ad­
verse events as infection of increased blood loss.
Conclusion
The data presented suggest that RIT neither causes nor aggravates surgical complications 
and therefore should be administered as early after RO-liver resection of CRC-LM as possible.
Radioimmunotherapy and postoperative complications
The only potentially curative treatm ent option for patients with colorectal liver meta- stases (CRC-LM) is histopathologically confirmed complete (RO) resection of all me- tastases. Despite the clearly demonstrated survival benefit of surgical therapy, about 
70%  of these patients experience recurrent disease, probably due to microscopic residual 
disease.1,2 Unfortunately, only 20 -3 0 %  of patients with recurrent disease re-qualify for po­
tentially curative surgical treatm ent, while the m ajority can solely be treated by palliative 
5-fluorouracil (5FU)-based chemotherapy.3 This clinical scenario clearly shows the necessity 
for adjuvant anti-tumour therapy after RO-liver resection. The well-known survival benefit 
of intensified systemic 5FU-based chemotherapy in the adjuvant setting after resection of 
stage III colon cancer has been used as a rationale for a similar approach after resection of 
CRC-LM. Three recent studies reported a possible survival benefit of either "peri-" or posto­
perative systemic 5FU-based chemotherapy.4-6 However, most of these studies lack statistical 
power due to the limited number of patients included.7 Furthermore, results from first-line 
treatm ent of m etastatic colorectal cancer show that intensifying 5FU-based chemotherapy 
protocols can lead to significantly shorter progression-free survival and an inferior quality 
of life.8 Therefore, adjuvant systemic 5FU-based chemotherapy is not routinely advised fol­
lowing R0-liver resection of CRC-LM.
Radioimmunotherapy (RIT) with radiolabelled monoclonal antibodies (mAbs) offers the op­
portunity to selectively irradiate tumour cells, while sparing normal tissues. RIT has shown 
to be mainly effective in minimal or microscopic residual disease9,10 and is therefore believed 
to be a promising alternative to systemic 5FU-based chemotherapy in adjuvant treatm ent 
after R0-liver resection for CRC-LM.11-13 Preclinical studies on the detailed mechanisms of 
successful adjuvant RIT, emphasize the need to administer RIT within a couple of days after 
surgery.14-16 However, concerns exist about the potential side effects and safety of RIT in 
the early postoperative period. Based on a collaboration betw een the interdisciplinary RIT- 
research groups of Gottingen, Germany (clinical studies on anti-CEA-RIT after liver resection 
for CRC-LM) and Nijmegen, the Netherlands (animal model of RIT in CRC-LM bearing W ag/ 
Rij-rats) we tried to deal with this important clinical issue by reviewing the courses of pa­
tients treated with RIT with 131I-labetuzumab after R0-resection of CRC-LM and by perfor­
ming an animal experim ent to specifically study the biodistribution of RIT. The safety of RIT 
is discussed in relation to wound healing disorders, surgical site infections, bile leakage and 
postoperative bleeding.
M e th o d s
Clinical experience
Two phase II trials on anti-CEA-RIT after RO-resection of CRC-LM were performed using 
131I-labetuzumab, a CDR-grafted (humanized) anti-CEA (CEACAM5) immunoglobulin G1- 
subclass mAb (Immunomedics, Inc. Morris Planes, NJ). In the first trial, 23 patients received 
a single dose of 1.11 to 1.48 GBq/m 2 of 131I-labetuzumab at least 4  weeks after RO-liver resec­
tion for CRC-LM. Two of these patients received an equivalent second dose 5 and 31 months 
later for recurrent disease.11,12 The aim of the second trial was to evaluate the efficacy of
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repeated anti-CEA-RIT with 131I-labetuzumab. Sixty three patients with completed treatm ent 
protocols were included in this study.13 For the current analysis, the charts of all 86 patients 
were reviewed focusing on the following surgical complications: wound healing disorders, 
biliary leakage/bilom a, intraabdominal abscess formation, persistent abdominal drainage 
and anastom otic leakage (in case of simultaneous bowel and hepatic resection). In addition, 
patients with repeated surgery for m etastatic recurrence after RIT were identified. In these 
patients we analyzed whether RIT-related toxicity (according to the Common Toxicity Cri­
teria version 2 .017) was present at the time of the diagnosis of m etastatic recurrence and 
w hether this influenced the treatm ent algorithm.
Experim ental model
To determ ine the uptake of radiolabelled antibodies in different tissues and especially in 
bile, a biodistribution study was performed in immunocompetent rats. MG1 (Antibodies 
for Research Applications BV, Gouda, the Netherlands) is a murine IgG2a antibody, directed 
against a 80 kDa cell surface antigen.18 It localizes preferentially in the thymus and CC531 
tumours when injected intravenously in rats and has been used in a series of preclinical RIT 
studies.14-16 UPC10 (Sigma Life Science, Zwijndrecht, the Netherlands) is also a murine IgG2a 
antibody and can therefore serve as an isotype matched control antibody to determine the 
specificity of the localization of MG1. Fifteen rats with an average weight of 315 g (Charles
---------- River Laboratories, Sulzfeld, Germany) were housed under non-sterile, standard laboratory
12 2  conditions (tem perature 20-24°C , relative humidity 5 0 -6 0  %, 12-h light-dark cycle). The 
animals had free access to animal chow and water. The experim ent was conducted in ac­
cordance with the principles laid out by the revised Dutch Act on Animal Experimentation 
(1997 ) and approved by the institutional Animal Welfare Committee of the Radboud Univer­
sity Nijmegen.
The biodistribution of 111In-DTPA-MG1 (hereafter referred to as 111In-MG1), as surrogate ra­
dionuclide for 177Lu-MG1, was determined. The 111In-MG1 (n=8) or the 111In-UPC10 (n=7) 
was administered intravenously (0 .37  M Bq/rat). Three days later, the bile duct of the rats 
was cannulated under general anesthesia and bile was collected. After the bile was collected, 
the animals were killed. Blood, liver, spleen, kidney, lung, thymus, muscle and intestine were 
sampled, blotted dry and weighed. Activity was measured in a y-counter. The results were 
expressed as a percentage of the injected dose (ID) per gram of tissue.
R e s u lts
Clinical exp erien ce
Within the 2 phase-II trials, post-operative complications after the R0-resection of CRC-LM 
persisted at the time of RIT in 9 out of 86 patients (10% ); wound infection (n=5), intraab­
dominal abscess with abdominal drains still in place (n=2) and bile leakage (n=2) (Table 1). 
None of the described complications required further surgical reintervention.
Radioimmunotherapy and postoperative complications
Patient
number Arc Sex
Surgical
complication
Lymphocytosis 
Fever f> 1 0 .0 0 0 /n il
Elevated C- 
reactive protein Progress 
under RIT
Surgical
treatm ent
1 81 m WHD[*c5cm) -  - - Conventional wound treatment
2 65 m WHD[<5cm) -  - + - Conventional wound treatment
3 SO w WHD[<5cm) -  - - - Conventional wound treatment
4 57 m WUÜ [<5cm) -  - - - Conventional wound treatment
5 51 m WHD [<5cm) -  - - - Conventional wound treatment
6 69 m I ntraabdominalabscess -  - + - Prolonged intraabdominal drains
7 63 w
lntrAihdomin.il
abscess -  - + - Prolonged intraabdominal drains
Table 1
Wound healing disorders and intraabdominal abscess formation at the time o f RIT. 
WHD = wound healing disorder.
N °o f RTT
cycles
Toxicity
grades
Localisation 
o f first
Interval RTT
Interval diagnosis 
of recurrence Surgical therapy
before
recurrence WBC PLT
recurrence 
after liver resection
to reoperation 
(months)
to reoperation 
(months]
o f recurrence
1 1 0 0 Local 3 0.5 Tumour resection
2 2 0 0 Local 22 0.5 Tumour resection
3 1 1 1 Lung 3 0.5 N on-anatomic lung resection
4 1 0 2 Lung 4 0.5 N on-anatomic lung resection
5 2 0 0 Lung 4 0.5 Non anatomic lung resection
6 2 1 1 Lung 7 4 Non anatomic lung resection
7 1 0 0 Liver 3 0.5 N on-anatomic liver resection
8 1 1 0 Liver 3 0.5 N on-anatomic liver resection
9 1 0 0 Liver 3 0.5 Anatomic liver resection
10 1 0 1 Liver 4 0.5 N on anatomic liver resection
11 2 0 2 Liver 4 1 N on-anatomic liver resection
12 2 2 3 Liver 5 1.5 Extended right hemihepalectomy
13 2 0 0 Liver 6 3 N on-anatomic liver resection
14 2 0 2 Liver 16 1 5 Non anatomic liver resection
15 1 0 1 Lung+ Liver 3 1 N on-anatomic lung resection+  
systemic 5FU-basedCTx
16 2 0 0 Lung +  Liver 15 6
Non anatomic liver resection + 
non anatomic lung resection
Table 2
Surgical treatm ent o f tumour recurrences.
RIT = radioimmunotherapy
WBC = white body counts
PLT = platelets
5FU = 5-fluorouracil
CTx = chemotherapy
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Figure 1
Antibody-distribution in patients with postoperative biloma. Whole body scintigraphic images (a+c, ven­
tral and dorsal view) in 2  patients 4 days after injection o f the l-131-labelled antibody showing no incre­
ased antibody-uptake at the resection planes after resection o f colorectal liver metastases. In contrast, the 
corresponding coronal thin-section (3m m ) helical CT-scans o f the abdomen (b+d) display the postoperative 
biloma at the resection plane o f the remnan t liver after righ t trisegmen tectomy SIV-VIII in patien 11 (b) and 
after non-anatomical resection S IVa/VIII in patient 2  (d).
Radioimmunotherapy and postoperative complications
No adverse effects of administration of RIT on wound healing were observed. All wounds 
showed healing by secondary intention and epithelised as expected. In the 2 patients with 
intraabdominal abscess the abdominal drains were removed once the secretions stopped, 
without further complications. Due to the good clinical condition of the two patients that 
had a biloma at the resection plane (verified by computed tomography) RIT was administe­
red according to the study protocol. Whole body scintigraphic images 4 days after injection 
of the I-131-labelled mAb showed no increased antibody uptake in the bilomas. (Figure 1) 
Sixteen of the 63 patients treated within the second phase-II trial underwent reoperati­
on with curative intent because of recurrent m etastatic disease after a median period of
4 months after RIT administration (range 3-22) (Table 2). Of these 16 patients, three had 
grade 2 toxicity and one had grade 3 toxicity following RIT, being persistent at the time of 
reoperation. Two patients with platelet counts < 6 0 x 1 0 9/ l  received preoperative platelets 
transfusions, but surgery was not postponed in any of the patient because of hematologic 
parameters. No abnormal perioperative tendency of bleeding occurred in these 4 patients. 
In particular, none of the patients needed to be packed because of coagulopathy. One patient 
suffered from transient liver failure after extended right hemihepatectomy.
Experim ental model
The biodistribution of m In-MG1 three days after intravenous injection is summarized in Fi­
gure 2. There was specific uptake of m In-MG1 in the thymus (mean 0.63 ± 0.15 % ID /g m In- 
MG1 versus 0.20 ± 0 .07 % ID /g m In-UPC10). Uptake of radiolabelled antibodies in other 
organs was not antibody-specific. The mean uptake of m In-MG1 and m In-UPC10 in bile was 
0 .038 ± 0.01 and 0 .042 ± 0.01 %ID/g, respectively).
1.00-
G)
Q
0 .25-
0 .00-1- * ! 1
✓ ^  ^  J f  *  J?
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Figure 2
Biodistribution o f 111In-MGl and ln ln-UPC10 (isotype-matched control antibody) in rats, 3  days after in­
travenous injection.
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D is c u s s io n
Wound healing d isord ers, surgical site infections and RIT
The m ajor side effect of RIT in clinical studies in solid cancers, using 177Lu-, 90Y- or 131I-la- 
belled mAbs at MTD, consistently is a transient grade 3 to 4 haematological toxicity (white 
blood cells, platelets and hemoglobin) in the first 10 weeks after RIT, followed by a recovery 
phase. Immunosupression may increase the risk of wound healing disorders and surgical 
site infections. Within the 2 phase-II- trials with 131I-labetuzumab and also in the study of 
Ychou et al. RIT was administered not earlier than 4-6  weeks after liver resection.11,12,19 This 
delay was chosen to avoid interactions with severe surgical complications such as surgical 
site infections, wound dehiscence, liver insufficiency or cardiopulmonary failure that might 
occur after major liver resection. Moreover, managing these complications in patients who 
are hospitalized in a protected nuclear medicine ward, would be very difficult. As displayed 
in Table 1, five of the 86 patients treated within our RIT-trials suffered from wound healing 
disorders at the time of RIT administration and 2 additional patients still had their abdomi­
nal drains in place. In our limited experience, RIT does not negatively influence secondary 
wound healing in patients treated with RIT after liver resection. Many preclinical studies on 
the efficacy of adjuvant RIT after major surgery for CRC support the clinical observation that 
RIT does not influence wound healing or increase the risk on surgical site infections.14-16,20,21
---------- Aarts e t al. specifically studied the effect of adjuvant intraperitoneal RIT after cytoreductive
1 2 6  surgery (CS) on abdominal and anastom otic strength.22 RIT was applied immediately after 
surgery and three or five days later wound strength remained unaffected in both the abdo­
minal wound and the anastom oses in colon and ileum.
Bile leakage and RIT
Bile leakage after hepatic resection occurs in 8%  of the patients treated in specialized cen­
ters.23,24 In about 30%  of cases the bile leakage lasts longer than 2 weeks and may result in 
peritonitis or sepsis. IgG molecules catabolize in the liver and radioactive compounds might 
therefore leak into the bile and worsen biliary-related complications. Fortunately, the bio­
distribution study in rats clearly shows that there is hardly any uptake of In-111 in bile after 
intravenous administration of radiolabelled mAbs. In addition, our scintigraphic images in 
two patients with bile leakage showed that postoperative bilomas are not associated with an 
increased antibody uptake. (Figure 1) Therefore, it seems likely postoperative bile leakage is 
not a contra-indication for RIT administration.
Bleeding risk  and RIT
As mentioned before, transient myelosuppression with consecutive neutropenia and/or 
thrombocytopenia is the major adverse event in patients treated with high activity doses of 
radiolabelled antibodies, increasing the risk of spontaneous or surgical bleeding. Liersch et 
al. (2 0 0 5 ) reported a 52%  rate (12 out of 23 patients) of grade 3 or 4 hematologic toxicities
Radioimmunotherapy and postoperative complications
after single dose RIT with 131I-labetuzumab but complete bone marrow recovery occurred 
in all patients.11 Recently, Liersch e t al. presented the interim analysis of the phase II trial 
on repeated RIT with 131I-labetuzumab showing that no cumulative toxicity occurred after 
the second cycle.13 The current analysis of the follow-up of these patients showed that none 
of them experienced an episode of spontaneous bleeding. In a study by Ychou et al. (2008) 
patients were administered a diagnostic dose of 131I-labelled F (ab ')2 fragments [131I-F (ab ')2] 
of the anti-CEA mAb F6 (2 9 6 -4 4 4  M Bq/5 mg) 5 to 7 days before surgery.25 Patients were 
eligible to receive a second therapeutic injection (7.4 GBq 131I/5 0  mg) 4 to 8 weeks after sur­
gery only if the tumour-to-normal liver uptake ratio of 131I-F (ab ')2 was superior to 5, based 
on analysis of tissues obtained during surgery. Thirteen of the 22 patients were treated with 
the therapeutic injection [6.7-7.4 GBq 131I/5 0  mg F (ab ')2] 4 -9  weeks after surgery. Twelve of 
these 13 patients experienced a WHO grade 3 /4  hematologic toxicity, but no spontaneous 
haemorrhages have been observed. Patients with thrombocytopenia are at risk for bleeding 
complications during and after surgery. In our own series no bleeding complications were 
observed, even in patients with thrombocytopenia, when thrombocyte transfusions were 
given. (Table 2)
The results described above show that RIT neither seems to cause nor aggravate surgical 
complications after liver resection. However, when the preclinically demonstrated benefit 
of early postoperative RIT will be transferred into clinical routine, the aspect of medical 
personnel safety has to be addressed. The safety of the medical and nursing staff must be 
guaranteed on the intensive care, the ward and in the operation theatre when patients must 
be re-operated for complications. No studies have been performed to investigate the radia­
tion dose of medical personnel working close to a patient for several hours a day, e.g. at the 
intensive care or in the operating room, after injection of high activity doses of radiolabelled 
antibodies. A promising method to reduce the risk for the medical personnel but also the 
bone marrow toxicity is "pretargeted” RIT In pretargeting RIT, in a first step the unlabelled 
anti-tumour antibody is administered and allowed to accumulate in the tumour. In a later 
phase, when the antibody has cleared from the circulation, the radionuclide is administered 
as a rapidly clearing agent with high affinity for the unlabelled molecule that was adminis­
tered in the first phase.26 Although the initial radiation dose administered to the patient will 
be higher than in conventional RIT, dosimetry studies on pretargeted RIT have indicated that 
the radiation dose to the personnel will be limited from the second day after injection on.27 
Pretargeting is currently under investigation in phase I studies in advanced cancer patients 
and could potentially also be implemented in studies on adjuvant RIT.28
Conclusion
Preclinical data clearly advocate early postoperative RIT after tumour resection. The data 
from the clinical studies on postoperative RIT after R0-liver resection for CRC-LM as well as 
the study with radiolabelled antibodies in rats suggest that RIT neither causes nor deterio­
rates surgical complications even when administered shortly after the operation. However, 
treatm ent of surgical complications, especially when reoperation is indicated, might be dif­
ficult in the phase of high radioactivity. The authors suggest that RIT should be administered 
as early after R0-liver resection of CRC-LM as clinically possible.
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Surgery is the cornerstone in the treatm ent of a patient diagnosed with colorectal can­cer (CRC). After successful surgical removal of the tumour the survival rate of patients with a primary tumour and/or liver m etastases improves significantly.1,2 Obviously, 
the diagnosis of local recurrences after potentially curative surgery is devastating and has 
major impact on the prognosis. Local recurrences are defined as recurrences of tumour near 
the surgical wound after resection of the initial tumour. It is hypothesized that these recur­
rences are the result of residual disease after surgical removal of the bulky tumour. The 
remaining tumour cells can be present in tissue near the surgical resection site or could 
be a result of tumour spill during surgery. The surgical wound plays a key role in the etio­
logy of local recurrences. Several preclinical studies have shown that surgical trauma and 
subsequent angiogenesis during wound healing lead to enhanced tumour cell adhesion and 
promote tumour growth.3-7 In addition, it has been hypothesized that occult tumours might 
even be activated due to removal of the primary tumour.8,9 Adjuvant therapy refers to an 
additional therapy in a situation where all detectable disease has been removed, but where 
there remains a statistical risk of (local) recurrence due to occult disease. The aim of adju­
vant treatm ent is to improve disease-specific and overall survival. The experimental studies 
described in this thesis show that radioimmunotherapy (RIT) can be an effective adjuvant 
treatm ent modality after CRC surgery to prevent local recurrences.
Loco-regional recurrences, or anastom otic recurrences, after surgical removal of a primary 
colorectal tumour have a 5-year incidence that varies betw een 4 and 28% , mainly depending 
on tumour stage.10-13 The studies with the animal model for anastom otic recurrences, sho­
wed that adjuvant RIT after colon resection prevents tumour growth in the peri-anastom otic 
area. RIT remained effective even when it was administered a couple of days after surgery 
Moreover side-effects from RIT were negligible. In term s of survival, adjuvant RIT was at 
least as effective as adjuvant chemotherapy for improvement of survival after CRC surgery 
in rats. Hence, these results should be discussed in the context of other available adjuvant 
strategies. Although several adjuvant therapies have been studied over the past decades, 
only adjuvant chemotherapy has shown benefit in stage III CRC patients.14 However, this sys­
temic treatm ent with multiple cycles is a burden for patients and has some important side 
effects. Moreover, the individual responses to chemotherapy are difficult to predict.15 More 
localised treatm ent strategies in this patient category, such as intra-abdominal lavage with 
water or cytotoxic agents, have not shown a clear effect so far.16-18 As for stage II CRC patients, 
Figueredo et al. conclude in their review in the Cochrane Library that adjuvant chem othe­
rapy will improve disease-free survival in those stage II patients who have high risk fea­
tures, including obstruction, perforation, inadequate lymph node sampling or T4 disease.19 
These features indicate a higher risk on disease dissemination, but do not account for pos­
sible tumour spill during surgery. This potential threat is present in all patients, reflected 
in the (occasional) occurrence of local recurrences in low grade CRC patients.10,11 However, 
the excellent prognosis of stage I and stage II patients without currently available adjuvant 
treatm ent strategies (75%  to 80%  survival at 5 years) justifies only interventions with high 
effectiveness, low toxicity and short duration.20
Our results in the rat model show a similar therapeutic benefit of the adjuvant use of radio­
labelled mAbs as compared to chemotherapy in a model for anastom otic recurrence. Howe­
ver, RIT reached the same effectiveness with a single dose, without showing signs of major 
toxicity. Moreover, because of the bystander effect of RIT, the therapeutic response of RIT is
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less dependent on individual cell interactions with the product. These potential benefits of 
RIT over chemotherapy, w arrant more preclinical research on the potential of RIT to prevent 
anastom otic recurrences.
Recurrent tumour growth is the major cause of death in patients that go through resection 
of colorectal liver m etastases.21 In a majority of cases, the liver is involved.2,21 High local re­
currence rates require adjuvant treatm ent strategies in these patients as well. However, no 
consensus has been reached yet on the ideal strategy.22 In our preclinical studies the poten­
tial therapeutic effect of RIT has been demonstrated in several settings. In our first studies 
we showed that RIT improved survival of rats with microscopic liver m etastases as well 
as survival of rats with residual disease after resection of liver tumours. RIT could be ad­
ministered in a single dose with limited toxicity. Because the target of adjuvant treatm ent 
strategies after hepatectomy is limited to tumour cells in the liver, several other researchers 
have focused on adjuvant hepatic arterial infusion of chemotherapy.23 Although the results 
seem promising, the complexity of delivering regional therapy has hampered its widespread 
use. Consequently, the m ajority of these patients are usually treated with systemic therapies 
based on data extrapolated from adjuvant trials for primary colorectal cancer. A few recent 
studies reported on the possible effect of either adjuvant or perioperative (before and af­
ter hepatic resection) chemotherapy on survival after hepatic resection.24-27 However, it has 
been pointed out that most of these studies lack statistical power due to the limited number 
of patients included.28 Therefore, the efficacy of adjuvant RIT should be compared to the ef-
---------- ficacy of adjuvant chemotherapy after surgical resection of liver m etastases in a preclinical
1 3 4  study. Performing such a study in a well characterized rat model, such as ours, could give an 
indication on the efficacy of both therapies in proportion to their side-effects.
As known from the literature and also shown in our study, the size of the liver m etastases is 
an important prognostic factor.31 So, early detection of liver m etastases is essential. Unfortu­
nately, small tumours will remain undetected due to the limited sensitivity of pre-operative 
imaging techniques.6 Therefore, more studies on non-invasive detection of small liver m eta­
stases are warranted. We demonstrated the feasibility of preclinical imaging of experimental 
liver m etastases. These results will be the basis for further studies focusing on for example 
the use of multimodality imaging, the use of new contrast agents, monitoring therapy res­
ponse of small liver m etastases and follow-up to detect recurrences after surgery.
Eighty percent of patients with colorectal liver m etastases are not eligible for surgical rem o­
val of the tumour and radiofrequency ablation (RFA) can then become an interesting alter­
native. However, local recurrences are reported in 4%  to 55 % of cases, and again adjuvant 
treatm ent strategies are warranted.32,33 Theoretically, adjuvant RIT could reduce recurrence 
rates since hyperthermia may favourably alter the pharmacokinetics of the antibody resul­
ting in a more homogenous intratumoural distribution of the antibody and hyperthermic 
treatm ent may also increase the radiosensitivity of tumour cells.34 Unfortunately, our survi­
val study showed no therapeutic effect of adjuvant RIT after RFA of liver m etastases in the 
rat that could be due to the local morphologic and functional changes after RFA. The ablative 
site after RFA contains areas with compromised vascularisation and increased interstitial 
pressure.35 These factors could have had a negative impact on the transport of radiolabel­
led antibodies to the residual tumour cells present in this area. Therefore, focus in future 
studies should be on other adjuvant strategies after RFA, like for example modulation of the
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anti-tumour immune response that is initiated by RFA.36
Experiments in animal models can provide valuable proof of principle, but differences in 
outcome in preclinical and clinical research may occur due to differences betw een rodents 
and men. However, preclinical studies on RIT may be special in this respect, which would 
make this comparison a little easier. This phenomenon is described by Behr et al., in an ele­
gant article entitled: "Radioimmunotherapy of solid tumours: a review "of mice and men”".37 
The authors state that: "Despite dramatic differences in size, weight and percent-of-injected- 
dose-per-gram uptake values, only small differences between animal models and the actual 
patient situation exist with respect to activity concentrations (in microCi/gram) in the tumors 
and tissues. Because the activity concentration over time determines the radiation absorbed 
dose, and thus biological effects, we postulate that animal models should be able to predict 
actual clinical scenarios fa irly  well. These findings could be used as guidelines in the design of 
future preclinical, as well as clinical, trials."
Thus, based on the results of the experimental studies on RIT after surgery for colorectal 
cancer and liver m etastases described in the present thesis, RIT might be a valuable adjuvant 
treatm ent modality in patients with primary colon cancer or colorectal liver metastases. 
Apart from further preclinical studies such as suggested above, clinical trials on adjuvant 
RIT in colorectal cancer patients are warranted. First of all, studies on the effect of adjuvant 
RIT in patients that underwent a partial colectomy for CRC would be very interesting. Ho­
wever, since local recurrences in these patients develop "only” in a small number of patients 
and the prognosis of low stage colorectal cancer patients is very good, demonstrating benefit 
of a new strategy will require long follow-up and large groups of participants. Although such 
studies should certainly be performed, a clinical trial in patients undergoing surgery for 
colorectal liver m etastases might be more feasible. Several other clinical trials support this 
point of view: the promising results published by Liersch et al. supply an elegant scientific 
basis for further studies on RIT in these patients.38-40 This first phase I/II trial showed that 
adjuvant RIT with 1.48-2.22 GBq/m 2 131I-labelled anti-CEA-antibody labetuzumab after re­
section of liver m etastases of CRC, increased median overall survival compared to adjuvant 
chemotherapy. Moreover, the analysis of the (possible) postoperative complications after 
RIT in these patients, such as described in this thesis, showed that surgery and RIT are not 
mutually exclusive.
For future studies, two elem ents of post-operative administration of RIT are crucial. First, 
timing of RIT has to be adequate. As described in the analysis of the implications of posto­
perative RIT, the radiation dose to medical personnel will increase when intensive care is 
needed after surgery. While the preclinical studies described in this thesis suggest that the 
efficacy of RIT can be negatively influenced by delay of the treatm ent, postponing RIT for a 
few days only after surgery will result in an optimal therapeutic response. Secondly, clinical 
studies on RIT in cancer patients have always emphasized that the radiation dose to the red 
marrow is the dose limiting factor. Combining RIT with a bone marrow transplantation has, 
in a mouse model with subcutaneous CRC tumours, shown to decrease the toxicity.41 Myelo­
toxicity after RIT could also be tackled by pretargeted RIT (PRIT). In PRIT, in a first step the 
unlabelled anti-tumour antibody is administered and allowed to accumulate in the tumour. 
In a later phase, when the antibody has cleared from the circulation, the radionuclide is ad­
ministered as a rapidly clearing agent with high affinity for the unlabelled molecule that was
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administered in the first phase. PRIT therefore aims to optimize the radiation dose to the tu­
mour, while minimizing exposure to the non-target organs. In a currently performed phase I 
study, an anti-CEA bispecific antibody and a Lu-177-labelled peptide are administered to pa­
tients with advanced colorectal cancer (PR IT2008) [www.clinicaltrials.gov; N CT00860860]. 
This study, in which the radionuclide is administered separately from the antibody, will test 
the feasibility of PRIT and provide data on toxicity, pharmacokinetics, biodistribution and 
tumour response. The results of this study will therefore be valuable for future RIT studies. 
So, when the initial safety of PRIT has been confirmed, the author suggests initiating a phase 
II trial to assess the efficacy of PRIT in patients who had salvage surgery for colorectal liver 
tumours.
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Colorectal cancer (CRC) has a high incidence and mortality rate in W estern Europe and the United States of America. 5-Year survival of patients with CRC is 4 0 -6 0 %  and sur­gical removal of the tumour and/or its m etastases play(s) an important role in the 
treatm ent protocol. Survival after surgery depends on disease stage at diagnosis and deve­
lopment of loco-regional recurrences or liver m etastases. The estimated risk on recurrences 
and distant m etastases determ ines the choice of adjuvant therapies, of which (5-fluoroura- 
cil based) chemotherapy has been studied the most. However, using the current treatm ent 
protocols 4 -2 8 %  of patients develop loco-regional recurrence after resection of the primary 
tumour and 75%  of patients develop recurrent tumour growth in the liver after surgical tre ­
atm ent of liver m etastases. These recurrences are believed to originate from microscopic or 
minimal residual disease or from tumour spill during the operation.
Radioimmunotherapy (RIT) using radiolabelled monoclonal antibodies (mAbs) directed 
against tumour-associated antigens has shown promising results is several preclinical and 
clinical studies on CRC. In particular, remarkable results have been achieved in animal stu­
dies where RIT is applied in an adjuvant setting after surgical debulking of peritoneal m eta­
stases. In these studies a clear beneficial effect of RIT was demonstrated for the treatm ent 
of minimal residual disease after surgery. The success of RIT in this setting is the result of a 
more favourable tumour physiology, like tumour perfusion and interstitial pressure, of smal­
ler tumours as compared to larger tumours. These results, combined with the alleged aetio­
logy of recurrences after colectomy or partial hepatectomy in CRC, led us to hypothesize that 
adjuvant RIT could also be beneficial in these situations. The experimental studies described 
in the present thesis therefore aimed to investigate the therapeutic efficacy of adjuvant RIT 
on local-regional recurrences and liver m etastases of colorectal origin.
In our studies we used male W ag/Rij rats inoculated with syngeneic CC531 colon carcino­
ma cells. For targeting these tumours, the specific and high affinity murine IgG2a mAb MG1, 
directed against an 80 kDa cell surface antigen, was used which was labelled with Lute- 
tium -177, using DTPA as a chelator (hereafter referred to as 177Lu-MG1). 177Lu belongs to 
the group of rare earth isotopes. It is a low energy beta emitting radiometal (Pmax= 4 9 7  keV), 
providing a maximal penetration range of 2.5 mm in tissue that renders it effective for trea­
ting smaller tumours. 177Lu has a half-life of 6.65 days, which matches the pharmacokinetics 
of antibodies in patients. Moreover, 177Lu also emits gamma-radiation that allows diagnostic 
imaging of tissue. The maximal tolerated dose (MTD) of 177Lu-labelled MG1 in rats has been 
determined at 300 MBq/kg. m In has highly similar physical characteristics to 177Lu but does 
not em it beta-particles and was therefore used as surrogate radionuclide for 177Lu in in vitro 
and biodistribution experiments.
Several patient and tumour characteristics predict an increased risk on local-regional re­
currences after surgical removal of the primary tumour. These include stage III patients, 
and stage II patients with T4-tumours, highly differentiated and/or perforated tumours, 
obstruction, angioinvasion and the situation where less than 10 regional lymph nodes are 
studied from the resection specimen. Local-regional recurrences or anastom otic recurren­
ces are defined as tumour recurrences in the initial tumour bed, operative field, anastomosis 
or in peritoneal structures contiguous or adherent to the primary tumour. A rat model to 
mimic this clinical situation has been developed. In male W ag/Rij rats an anastom osis was 
constructed after intraluminal injection of 2 x 106 CC531 tumour cells, which resulted in high
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incidences of peri-anastomotic tumour growth. Chapter 1 and 2 describe the studies with 
this animal model for anastomotic recurrences. The biodistribution after intraperitoneal ad­
ministration showed that 111In-MG1 preferentially accumulated in peri-anastomotic CC531 
tumours. The first therapy study showed that adjuvant RIT using 177Lu-MG1 (single MTD, 
ip) prevented tumour growth in the peri-anastomotic area, even when administered 5 days 
after the intestinal operation. RIT resulted in transiently lower body weight compared to the 
control group. However, no other signs of clinical discomfort were registered. Encouraged 
by these results, a second experiment was performed to study the effect of adjuvant RIT 
on survival and compare it to the effect of adjuvant chemotherapy (6 cycles, 5-fluorouracil, 
leucovorin and oxaliplatin, ip). The results of this study are described in Chapter 2, showing 
that adjuvant RIT seems at least as effective as adjuvant chemotherapy. The median survival 
of both treatm ent groups did not differ significantly (1 5 7  and 170 days for the RIT and che­
motherapy group, respectively), while the median survival of the control group was only 97  
days. However, toxicity of RIT at MTD was lower than toxicity of this chemotherapy regime. 
Moreover, the efficacy of RIT could be achieved with one single injection, while chemothe­
rapy is generally administered in multiple cycles. These promising results suggest that RIT 
might be an interesting adjuvant after colectomy in CRC patients, to prevent local-regional 
recurrences and to increase disease-free and overall survival.
The metastatic pattern of CRC has an exceptionally high degree of predictability, the liver 
almost invariably being the first site of distant metastases. In order to improve survival of
---------- these patients there is an urgent need for new treatm ent strategies which need to be deve-
1 4 4  loped and tested in a preclinical model. An ideal animal model for studying liver metastases 
of colorectal origin should mimic all aspects of the metastatic development in humans and 
should also be practical, predictable and optimal in terms of ethical considerations. So far, 
no model has been developed which meets all these criteria. Chapter 3 reviews the pros and 
cons of different animal models used for research on experimental liver metastases of colo­
rectal origin. Based on data available in the literature it was concluded that heterotopic in­
jection of undifferentiated syngeneic tumour cells in immunocompetent rodents meets most 
of the desired characteristics. Both subcapsular as intraportal injection will yield suitable 
models and the eventual choice will depend on the aim of the study.
The therapeutic potential of RIT in patients with various stages of liver metastatic develop­
ment has been investigated in animal models in this thesis. Patients without visible liver 
metastases at initial presentation could benefit from adjuvant RIT after colonic surgery, in 
order to limit the risk for metachronous liver metastases due to the presence of micrometa- 
stases. Chapter 4  describes a study in male Wag/Rij rats that underwent a laparotomy with 
intraportal injection of 1 x 106 CC531 tumour cells. The biodistribution after intravenous ad­
ministration of 111In-MG1, showed that 111In-MG1 preferentially accumulated in CC531 liver 
tumours, whereas an 111In-labelled control antibody did not. In a survival study in rats with 
microscopic liver metastases, RIT using 177Lu-MG1 (single MTD, iv) did improve survival sig­
nificantly as compared to treatm ent with a radiolabelled nonspecific control-antibody. Ho­
wever, the results in this study also clearly showed that the effectiveness of RIT disappears 
when administration of RIT is delayed with 14 days. This observation might be the result of 
the tumour load in the liver at that moment. Indeed, other studies have suggested a negative 
correlation between tumour size and efficacy of RIT. For future studies and clinical appli-
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cation this finding leaves clinicians with a challenging problem. Can one select the patients 
with very small colorectal liver m etastases? One option would be to improve imaging tech­
niques for small liver metastases. Current protocols mainly include computed tomography 
(CT) as the diagnostic tool for the detection of liver m etastases. Because each modality has 
its own favourable characteristics, the use of magnetic resonance imaging (MRI) or positron 
emission tomography (PET) for detection of liver m etastases is currently a subject of several 
trials. In this respect, preclinical studies might yield valuable data. Morever, adequate small- 
animal imaging of colorectal liver m etastases can be of value for several reasons; (1) the ef­
ficacy of new therapeutic agents can be studied in preclinical models, in which non-invasive 
response monitoring does not only limit the number of animals needed, but mimics the cli­
nical situation and (2) it allows preclinical studies on the role of different imaging modalities 
on decision making in colorectal cancer patients with liver m etastases. Chapter 5 describes 
one of the first studies conducted to compare the detectability of small liver m etastases of 
the most advanced imaging modalities currently available for small animals. Based on these 
exploratory results, future studies on the optimization of detection of liver m etastases can 
be initiated.
Many CRC patients are diagnosed with liver m etastases at their initial presentation. Alt­
hough partial hepatectomy can improve 5-year survival up to 35-40% , a significant num­
ber of these patients develop recurrent tumour growth in the liver. In Chapter 6 an animal 
model to study the efficacy of RIT to prevent recurrent liver m etastases after partial hepa­
tectomy is used. Liver m etastases were induced in male W ag/Rij rats by a laparotomy with 
intrahepatic injection of 0.3 x 106 CC531 tumour cells. The biodistribution one day after 
intravenous administration showed that 111In-MG1 preferentially accumulated in these tu­
mour lesions in the liver and reached a maximum 3 days post injection. In a survival study, 
the liver m etastasis was intentionally resected in an irradical way and subsequently the the­
rapeutic efficacy of adjuvant RIT was studied. The therapeutic efficacy of 177Lu-MG1 (single 
MTD, iv) was compared with that of a control antibody, labelled with the same activity dose 
of Lu-177, and with that of saline only. The survival analysis showed a significant and spe­
cific improvement of survival in rats treated with adjuvant RIT. Moreover, the results of this 
experimental study indicated that RIT administration could be delayed 7 days after surgery, 
without a major change in the therapeutic efficacy. Delayed administration also showed less 
side effects than immediate post-operative administration. This delay has the advantage of 
avoiding the administration of radiolabelled antibodies during the first post-operative days 
in which the patient might need intensive medical care. Therefore, delayed administration 
may reduce radiation exposure to medical personnel. Finally, this study indicated that the 
efficacy of adjuvant RIT is depended on the size of the resected tumour, showing a higher 
survival benefit of adjuvant RIT after resection of smaller metastases.
Unfortunately, only 20%  of patients are considered eligible for partial hepatectomy. Alterna­
tively, ablation of the liver m etastases by radiofrequent energy or freezing is a treatm ent op­
tion for some of these patients. Radiofrequency ablation (RFA) reportedly improves survival 
rates but also shows high recurrence rates. In Chapter 7 the efficacy of adjuvant RIT in this 
setting is investigated. In this study the animal model with intrahepatic injection of CC531 
cells was used and after 10 days the liver m etastases were treated with RFA (180  s , tip tem ­
perature of the probe ~ 7 5 -8 0  °C). Analysis of the survival data showed no beneficial effect of
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adjuvant RIT after RFA as compared to RFA alone. Most likely, changes in tumour physiology 
and microstructure of the surrounding tissue (disturbed perfusion, inflammation and incre­
ased interstitial pressure) after RFA affected the therapeutic efficacy of RIT
The positive data generated in the preclinical studies described in the previous chapters, 
together with the promising results of the early clinical studies reported in the literature, 
raise legitimate questions concerning the efficacy, safety and potential side-effects of early 
post-operative administration of RIT. For example, bile leakage is a severe complication after 
hepatic resection with an incidence of 8%  in specialized centres. In about 30%  of cases the 
bile leakage continues longer than 2 weeks and may result in peritonitis or sepsis which 
may require surgical reintervention. A high uptake of the radionuclide in bile would w or­
sen this complication. In Chapter 8, we therefore tried to deal with this important aspect 
by reviewing the clinical courses of patients treated by adjuvant RIT with 131I-labetuzumab 
after salvage resection of colorectal liver metastases, by performing animal experiments on 
bile leakage and RIT and by a literature review focusing on surgical complications and their 
impact on treatm ent decisions concerning adjuvant RIT. The results described in this chap­
ter suggest that adjuvant RIT after surgery might result in an increased incidence of wound 
infection. However, it has already been demonstrated previously in animal studies that RIT 
does not influence (anastomotic) wound strength. Moreover, no uptake of radionuclides 
could be detected in bile of rats after intravenous administration of RIT. In the post-opera­
tive patient receiving RIT, extensive medical care might be necessary at the intensive care
---------- during the first days after surgery, especially when a complication warrants a re-operation.
1 4 6  Factors influencing the radiation dose to personnel are discussed in the final paragraph of 
this chapter.
In Chapter 9 the experimental results are discussed and future perspectives are outlined.
Summary
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H
et colorectaal carcinoom (CRC) heeft een hoge incidentie en een hoge m ortaliteit in 
West-Europa en in de Verenigde Staten. De 5-jaarsoverleving van patiënten m et een 
CRC is 40 -6 0 %  en is in belangrijke mate afhankelijk van een succesvolle operatieve 
verwijdering van de tumor. De prognose na de operatie wordt grotendeels bepaald door het 
stadium van tumor op het moment van de diagnose, het ontstaan van locale recidieven en 
het ontstaan van m etastasen op afstand. Op basis van het ingeschatte risico op deze locale 
recidieven en m etastasen wordt bepaald of een patiënt in aanmerking komt voor een adju­
vante therapie. Van de beschikbare adjuvante therapieën is adjuvante chemotherapie (op ba­
sis van 5-fluorouracil) de m eest bekende. Met de huidige behandelingen ontwikkelt helaas 
toch nog 4 -28%  van de patiënten een locoregionaal recidief na chirurgische verwijdering 
van de primaire tumor. Daarnaast ontwikkelt 50%  van de patiënten m et een CRC ergens in 
het beloop van de ziekte leverm etastasen. Hoewel deze leverm etastasen in sommige geval­
len in opzet curatief geresecteerd kunnen worden, komen locale recidieven in de lever zeer 
frequent voor. Een aantal studies suggereren dat adjuvante chemotherapie ook voor deze 
patiënten nuttig kan zijn, maar er is to t op heden onvoldoende bewijs om dit beleid te stan­
daardiseren. Voor zowel locale recidieven na verwijdering van de primaire tumor, als locale 
recidieven na leverchirurgie, lijkt de oorzaak te liggen in de aanwezigheid van m icroscopi­
sche of residuele ziekte na de verwijdering van de tumor of kan er sprake zijn van contami­
natie met tumorcellen tijdens de operatie.
Bij radioimmunotherapie (RIT) wordt gebruik gemaakt van monoclonale antilichamen die 
zijn gelabeld m et een radionuclide. Deze radioactief gelabelde antilichamen zijn gericht te ­
gen tum orgeassocieerde antigenen. Diverse preklinische en klinische studies met RIT bij de 
behandeling van CRC hebben reeds veelbelovende resultaten getoond. Met name de resul­
taten van studies waar RIT is toegepast als adjuvans na chirurgische verwijdering van peri­
toneale m etastasen van CRC zijn opvallend. In deze situatie zijn alleen nog microscopische 
resten van de tumor in de buikholte aanwezig. Al eerder werd aangetoond dat RIT m et name 
effectief is in kleine tumoren omdat de fysiologie van kleine tumoren, zoals de perfusie en 
interstitiële druk in de tumoren, een gunstig effect heeft op de opname van antilichamen. De 
resultaten van adjuvante RIT bij peritoneale m etastasen vormen het uitgangspunt van onze 
hypothese dat RIT ook werkzaam zou kunnen zijn ter voorkoming van locale recidieven na 
colectomie en lever chirurgie. In dit proefschrift worden diverse dierexperimentele studies 
beschreven waarin de effectiviteit van adjuvante RIT op darmnaadrecidieven en leverm eta­
stasen wordt onderzocht.
In onze experimenten maakten wij gebruik van W ag/Rij ratten die werden geïnoculeerd met 
syngene CC531 colon carcinoomcellen. Voor RIT maakten wij gebruik van het muizen IgG2a 
antilichaam MG1, dat een hoge affiniteit heeft voor een 80 kDa-groot antigen op de celmem- 
braan van de CC531 cel. Het MG1 antilichaam werd gelabeld m et Lutetium -177 (afgekort 
als 177Lu-MG1). 177Lu is een radionuclide dat sinds enige jaren beschikbaar is voor klinische 
toepassing. Dit radionuclide geeft laag energetische bètastralen af m et een maximale pe- 
netratiediepte van 2.5 mm in weefsels. Hierdoor is dit radionuclide zeer effectief voor de 
behandeling van kleine tumoren. Daarnaast komt de halfwaardetijd van dit radionuclide 
(6.65 dagen) overeen m et de verblijfstijd van antilichamen in tumoren en geeft 177Lu ook 
gammastraling af die gebruikt kan worden voor beeldvorming. De maximaal getolereerde 
dosis (MTD) van 177Lu-MG1 voor ratten is vastgesteld op 300  MBq/kg. Indium-111 heeft ver­
gelijkbare fysische eigenschappen als 177Lu, maar zendt daarbij geen bètastralen uit. Daarom
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maakte wij bij de in vitro- en biodistributie studies, als alternatief voor 177Lu, gebruik van 
111In gelabeld MG1.
Bepaalde patiënt- en tumorkenmerken voorspellen een hoger risico op het ontstaan van lo­
cale recidieven na verwijdering van de primaire tum or Dit geldt voor stadium III patiënten, 
maar ook voor de stadium II patiënten m et T4 tumoren e n /o f een slechte differentiatiegraad 
en /o f een perforatie of een obstructie bij presentatie en /o f angioinvasie en /o f een situatie 
waarin minder dan 10 regionale klieren van het resectiepreparaat zijn onderzocht. Een adju­
vante therapie lijkt dan ook gerechtvaardigd in deze twee patiënten groepen. Locoregionale 
recidieven (c.q. darmnaadrecidieven) worden gedefinieerd als recidiverende tumor op de 
plaats van de initiële tumor, in het operatiegebied, op de anastom ose of op het nabij gelegen 
peritoneum. Wij ontwikkelden een diermodel om deze klinische situatie na bootsen en de 
effectiviteit van adjuvante therapieën te kunnen toetsen. Hiervoor werd een anastom ose ge­
creëerd in het colon descendens van mannelijke W ag/Rij ratten nadat intraluminaal 2 x 106 
CC531 tumorcellen waren geïnjecteerd. Deze techniek resulteerde in peri-anastom otische 
tumorgroei in meer dan 80%  van de proefdieren. In hoofdstuk 1 en 2 worden de studies in 
dit diermodel beschreven. Een biodistributie studie m et intraperitoneaal geïnjecteerd 111In- 
MG1 toonde aan dat er sprake was van specifieke opname in de peri-anastom otische CC531 
tumoren. Een eerste therapiestudie liet zien dat adjuvante RIT m et 177Lu-MG1 (enkele gift, 
MTD, ip) na de operatie de groei van de locale recidieven kon voorkomen. Dit effect kon ook 
bereikt worden wanneer adjuvante RIT 5 dagen na de operatie werd toegediend. Hoewel
---------- het lichaamsgewicht van de dieren die RIT toegediend kregen tijdelijk  lager was dan dat
15 2  van de dieren in de controle groep, werden er geen andere klinische verschijnselen van toxi­
citeit waargenomen. Vervolgens werd een tweede studie uitgevoerd waarin het effect van 
adjuvante RIT werd vergeleken m et het effect van adjuvante chemotherapie (6 cycli, 5-flu- 
orouracil, leucovorin en oxaliplatin, ip). In dit experim ent was de overleving van de dieren 
de primaire uitkomstmaat. Het resultaat van deze studie is beschreven in hoofd stuk  2. Ad­
juvante RIT bleek tenm inste net zo effectief te zijn als adjuvante chemotherapie. De mediane 
overleving van beide groepen was gelijk (157  en 170 dagen respectievelijk voor de RIT en 
chemotherapiegroep), terwijl de mediane overleving van de onbehandelde groep slechts 97 
dagen was. Echter, de toxiciteit van adjuvante RIT was lager dan de toxiciteit van dit chem o­
therapieschem a en bovendien werd het overlevingsvoordeel bij RIT bereikt m et een lager 
aantal injecties. De gezamenlijke resultaten uit de bovenstaande studies ondersteunen de 
hypothese dat adjuvante RIT na resectie van een primair CRC, locale recidieven kan voorko­
men en de prognose van deze patiënten kan verbeteren.
Het disseminatiepatroon van het CRC is uitgebreid bekend en opvallend voorspelbaar: de 
lever is nagenoeg altijd de eerste plaats voor m etastasering op afstand. Nieuwe behandel- 
strategieën zouden de overleving van patiënten m et leverm etastasen aanzienlijk kunnen 
verbeteren. Preklinische modellen waarin deze nieuwe strategieën getoetst kunnen worden 
zijn daarom essentieel. Het ideale diermodel voor colorectale leverm etastasen zou alle fa­
cetten van het proces van m etastasering van CRC in de mens na moeten bootsen. Daarnaast 
moet het model praktisch en reproduceerbaar zijn en voldoen aan de ethische normen. Tot 
op heden bestaan er geen diermodellen die aan al deze criteria voldoen. In hoofdstuk 3 
worden de voor- en nadelen van diverse diermodellen die beschikbaar zijn voor het verrich­
ten van onderzoek naar colorectale leverm etastasen besproken. Uit deze literatuurstudie
Samenvatting
werd geconcludeerd dat heterotope injectie van ongedifferentieerde syngene tumorcellen 
in immunocompetente dieren leidt to t het diermodel m et de m eest optimale experimentele 
eigenschappen. Afhankelijk van het doel van de studie, kan gekozen worden voor subcapsu- 
laire of intraportale injectie van de cellen.
De mogelijke therapeutische toepassingen van RIT bij colorectale leverm etastasen werd on­
derzocht in diermodellen, waarbij diverse dissem inatiefases en locale behandelingen w er­
den nagebootst. In de eerste plaats werd gefocusseerd op de patiënt die op het moment 
van de diagnose CRC reeds occulte microscopische leverm etastasen zou kunnen hebben. In 
hoofdstuk 4  werd deze situatie nagebootst door in mannelijke W ag/Rij ratten, na een la­
parotomie, intraportaal 1 x 106 CC531 tumorcellen te injecteren. Een biodistributie studie 
in dit model toonde aan dat 111In-MG1 (iv) specifiek accumuleerde in de ontstane CC531 
levertumoren. Uit een overlevingsstudie m et dit diermodel, bleek dat RIT de overleving van 
dieren m et microscopische leverm etastasen significant kon verbeteren ten opzichte van be­
handeling m et een radioactief gelabeld controle antilichaam. Deze studie toonde echter ook 
aan dat RIT niet meer effectief was wanneer 14 dagen m et de toediening werd gewacht. 
W aarschijnlijk ligt de grootte van de tumoren ten grondslag aan deze bevinding. Uit andere 
studies is inderdaad bekend dat er een negatieve correlatie bestaat tussen de effectiviteit 
van RIT en de tumorgrootte. Voor de klinische praktijk blijkt het dus essentieel om lever­
m etastasen in een vroeg stadium te detecteren. In de huidige protocollen wordt gebruik ge­
maakt van "computed tomography" (CT) om leverm etastasen te diagnosticeren. Onderzoek 
naar het gebruik van andere beeldvormende modaliteiten, bijvoorbeeld "magnetic resonan­
ce imaging" (MRI) of positron emissie tomografie (PET), is relevant omdat elke modaliteit 
andere eigenschappen heeft. Beeldvormende studies in diermodellen zouden een belang­
rijke bijdrage kunnen leveren aan optimalisatie van de opsporing van levermetatastasen. 
Bovendien kan goede preklinische beeldvorming een belangrijke rol spelen in onderzoek 
naar (1) de effectiviteit van nieuwe therapeutica waarbij niet-invasieve beeldvorming het 
aantal benodigde proefdieren kan verminderen en bovendien een betere afspiegeling geeft 
van de klinische gang van zaken (2) de rol van verschillende beeldvormende technieken op 
het maken het therapeutische beslissingen tijdens de behandeling van patiënten met lever 
metastasen. In hoofdstuk 5 wordt één van de eerste studies beschreven waarin de sensiti­
viteit en specificiteit van de momenteel beschikbare, geavanceerde preklinische beeldvor­
mende technieken voor de detectie van kleine leverm etastasen worden vergeleken.
W anneer de diagnose CRC wordt gesteld blijken bij veel patiënten reeds m etastasen in de 
lever aanwezig te zijn. Hoewel een partiële hepatectom ie de 5-jaarsoverleving voor deze 
patiënten m et 35-40%  kan verbeteren, ontwikkelt meer dan de helft van deze patiënten uit­
eindelijk recidiverende tumoren in de lever. In hoofdstuk 6 wordt een diermodel gebruikt 
om de effectiviteit van adjuvante RIT voor de preventie van recidiverende leverm etastasen 
te onderzoeken. In deze studies werden leverm etastasen bij mannelijke W ag/Rij ratten ge- 
induceerd door, na een laparotomie, intrahepatisch 0.3 x 106 CC531 tumorcellen te in jecte­
ren. Uit een biodistributie studie bleek dat 111In-MG1 (iv) specifiek accumuleerde in de ont­
stane CC531 levertumoren, waarbij de accumulatie het hoogst was op dag 3 na injectie van 
het antilichaam. In een overlevingsstudie werd deze levertumor irradicaal geresecteerd en 
werd vervolgens het therapeutische effect van adjuvante RIT onderzocht. Het effect van RIT 
m et 177Lu-MG1 (op de MTD, iv) werd vergeleken met het effect van een radioactief gelabeld
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controle antilichaam (identieke dosis). De overleving van de ratten die adjuvant behandeld 
waren met RIT na de irradicale verwijdering van de levertumor verbeterde ten opzichte van 
de controle groepen. Daarbij bleek dat dit effect nauwelijks veranderde wanneer RIT pas 7 
dagen na de operatie werd toegediend. Deze "uitgestelde" behandeling had als belangrijk 
voordeel dat de bijwerkingen van RIT minder invloed hadden op het postoperatieve beloop 
van de ratten. Ook zou deze "uitgestelde" adjuvante behandeling een voordeel kunnen heb­
ben in het kader van de stralenbelasting voor het medische personeel dat de patiënten in 
de eerste postoperatieve dagen intensief verzorgt. Als laatste bleek uit deze studie dat de 
grootte van de initieel operatief verwijderde tumor van invloed lijkt te zijn op de effectiviteit 
van RIT. Adjuvante RIT bleek effectiever te zijn na resectie van kleine tumoren dan na resec- 
tie van grote tumoren.
In de klinische praktijk komt helaas slechts 20%  van de patiënten met colorectale leverme­
tastasen in aanmerking voor in opzet curatieve resectie van de tumoren. Locale ablatieve 
technieken, zoals cryo- of radiofrequente ablatie, zijn een mogelijk alternatief voor de be­
handeling van colorectale levermetastasen. Hoewel radiofrequente ablatie (RFA) de overle­
ving van deze patiënten kan verbeteren, vormen locale recidieven een groot probleem van 
deze behandeling. Een studie naar de mogelijke therapeutische waarde van adjuvante RIT 
na RFA van levermetastasen wordt beschreven in hoofdstuk 7. In deze overlevingsstudie 
werd gebruik gemaakt van hetzelfde diermodel als beschreven in hoofdstuk 6, maar werd de 
levertumor behandeld met RFA (180  s, tip temperatuur van de probe ~ 7 5 -8 0  °C) in plaats
---------- van chirurgisch verwijderd. Uit de analyse van de overlevingsresultaten bleek dat adjuvante
1 5 4  RIT in deze situatie geen verbetering laat zien ten opzichte van RFA alleen. Waarschijnlijk 
beïnvloedden de veranderingen in de fysiologie van de tumor en het omliggende weefsel 
(verstoorde perfusie en verhoogde interstitiële druk door inflammatie) het effect van de 
systemisch toegediende RIT nadelig.
De positieve resultaten uit dit proefschrift en de eerste klinische resultaten van adjuvante 
RIT na resectie van colorectale levermetastasen, maken de potentiële rol van adjuvante RIT 
bij het CRC duidelijk. In dit kader is het relevant om stil te staan bij de veiligheid en de bij­
werkingen van RIT bij een patiënt met postoperatieve complicaties. Een gevreesde compli­
catie na leverchirurgie is bijvoorbeeld gallekkage. Gallekkage komt in ongeveer 8%  van deze 
patiënten voor en zal in 30%  van de gevallen meer dan 2 weken aanhouden. Uiteindelijk kan 
gallekkage resulteren in een peritonitis en /of sepsis en kan een chirurgische reïnterventie 
nodig zijn. Een hoge opname van het radionuclide in gal na toediening van RIT zou het be­
loop van deze complicatie ernstig kunnen beïnvloeden. In hoofdstuk 8 werden de gevolgen 
van het postoperatief toedienen van RIT onderzocht door het klinisch beloop van patiënten 
die na curatieve resectie van levermetastasen behandeld werden met RIT (131I-labetuzumab) 
retrospectief te onderzoeken. Daarnaast werd een biodistributie studie verricht in een dier­
model om de opname van radionucliden in gal te onderzoeken en werd in de literatuur ge­
zocht naar studies met betrekking tot chirurgische- en stralingsgerelateerde complicaties. 
De resultaten die staan beschreven in dit hoofdstuk toonden aan dat adjuvante RIT na een 
operatie kan leiden tot een verhoogde incidentie van wondgenezingsproblemen van de huid. 
Uit eerder gepubliceerde studies naar het effect van straling op wondgenezing blijkt echter 
dat RIT waarschijnlijk geen invloed zal hebben op de wondsterkte van de darmnaden. Uit 
het dierexperiment bleek verder dat er nauwelijks activiteit te detecteren was in gal na in-
Samenvatting
traveneuze toediening van RIT. Als laatste wordt in dit hoofdstuk de stralingsbelasting van 
medisch personeel bij postoperatieve toediening van RIT bij een patiënt besproken.
In hoofdstuk 9 worden de bovengenoemde resultaten bediscussieerd en wordt een per­
spectief geschetst voor toekomstig onderzoek naar de waarde van RIT voor de behandeling 
van locale recidieven bij patiënten m et het CRC.
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even "mijn" stagiair Ik vond het een mooie deal. Rafke, Alexander en Maarten, lang zaten 
we als 4  promovendi aan hetzelfde bureau en in hetzelfde schuitje. Bedankt dat ik altijd bij 
jullie terecht kon voor de "W eet iemand hoe...?"-vragen. Sandra, je was mijn eerste student- 
stagiaire en ik w eet niet wie het m eest heeft geleerd van wie. Ik w eet wel dat je  inmiddels 
een leuke collega bent en dat je  m et glans zal promoveren. In het Aquarium ben je  nooit 
alleen; Peter, Ingrid, Karolina, Jonathan, Cheng, Lieke, Cathelijne en Janneke, ik ben heel blij 
dat ik (een tijd je) "one of the guys" mocht zijn!
Het centrale dieren laboratorium, m et name de Radionucliden Unit (RNU). Beste Bianca en 
Kitty, het succes van dierexperim enteel onderzoek staat of valt m et overleg, samenwerking, 
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gebrek! Jullie inzet en betrokkenheid bij het onderzoek w erkt als een stimulans voor iedere 
onderzoeker op de afdeling. Bedankt dat jullie het werken op de RNU zo leuk maakten.
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het gebied van chirurgisch (dierexperim enteel) onderzoek. Bedankt dat ik zo onbaatzuchtig 
gebruik mocht maken van jullie kennis, kunde, tijd en gezelligheid.
Collega's van de afdeling Nucleaire Geneeskunde en de afdeling Heelkunde, bedankt dat ik 
me altijd welkom heb gevoeld. Manuel en Frits, als voorvaders van het project kon ik altijd 
rekenen op jullie enthousiasme voor mijn bevindingen.
De afdeling Pathologie en in het bijzonder Iris Nagtegaal en Arie Maat, meer dan eens kwam 
ik m et een grote hoeveelheid preparaten of rare histopathologische verzoeken bij jullie aan 
en altijd was er hulp. Bedankt daarvoor.
Ich möchte mich bei Kia Homayounfar und Torsten Liersch vom Klinik für Allgemein- und 
Viszeral Chirurgie, Georg-August-Universität in Göttingen recht herzlich bedanken. Vielen 
Dank für Eure Gastfreundschaft als ich Euch damals im Klinikum besucht hatte. Hoffentlich 
können wir in der Zukunft weiterhin zusammen arbeiten.
De Clinical PhD Council en de promovendi-introductiedag werkgroep, er zijn vreselijk  veel 
promovendi die zullen profiteren van het werk dat jullie verrichten. Ik vond het leuk om dit 
m et jullie op te mogen zetten.
---------- Paranimfen Lana en Eva, de drie zusjes zijn onlosmakelijk met elkaar verbonden, dus jullie
1 6 4  promoveren ook een beetje. Met jullie aan mijn zijde komt het dadelijk helemaal goed!
Hoewel een proefschrift een wetenschappelijke verhandeling is, mogen de volgende men­
sen niet op deze pagina ontbreken. Ik ben er nam elijk van overtuigd dat het promoveren is 
gelukt omdat jullie op de achtergrond aanwezig waren. Pap en mam, jullie staan altijd voor 
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